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7Abstract
The peroxisome proliferator activated receptor alpha (PPARα) is a ligand activated tran-
scription factor involved in the regulation of a variety of processes, ranging from inflam-
mation and immunity to nutrient metabolism and energy homeostasis. PPARα serves as a 
molecular target for hypolipidemic fibrates drugs which bind the receptor with high affinity. 
Furthermore, PPARα binds and is activated by numerous fatty acids and fatty acid derived 
compounds. PPARα governs biological processes by altering the expression of large number 
of target genes. Although the role of PPARα as a gene regulator in liver has been well estab-
lished, a comprehensive overview of its target genes has been missing so far. Additionally, 
it is not very clear whether PPARα has a similar role in mice and humans and to what extent 
target genes are shared between the two species.
The aim of the research presented in this thesis was to identify PPARα-regulated genes in 
mouse and human liver and thereby further elucidate hepatic PPARα function. The applied 
nutrigenomics approaches are mainly expression microarrays combined with knockout 
mouse models and in vitro cell culture systems.
By combining several independent nutrigenomics studies, we generated a comprehensive 
overview of PPARα-regulated genes in liver with the focus on lipid metabolism. We identi-
fied a large number of PPARα target genes involved in different aspects of lipid metabolism. 
Furthermore, a major role of PPARα in lipogenesis was detected. Our data pointed to several 
novel putative PPARα target genes. Next, we compared PPARα-regulated genes in primary 
mouse and human hepatocytes treated with the PPARα agonist Wy14643 and generated an 
overview of overlapping and species specific PPARα target genes. A large number of genes 
were found to be regulated by PPARα activation in human primary hepatocytes, which iden-
tified a major role for PPARα in human liver. Interestingly, we could characterize mannose 
binding lectin 2 (Mbl2) as a novel human specific PPARα target gene. Plasma Mbl2 levels 
were found to be changed in subjects receiving fenofibrate treatment or upon fasting. Regula-
tion of Mbl2 by PPARα suggests that it may play a role in regulation of energy metabolism, 
although additional research is needed. 
We also compared the PPARα-induced transcriptome in HepG2 cells versus primary human 
hepatocytes to investigate the suitability of HepG2 cells in PPARα research. The results re-
vealed that the HepG2 cell line poorly reflects the established PPARα target genes and func-
tion, specifically with respect to lipid metabolism. Finally, we characterized the transcription 
factors Klf10 and Klf11 as novel PPARα target genes. Our preliminary findings using in 
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8vitro transfection assays and in vivo tail vein injection of plasmid DNA suggested a potential 
metabolic role of Klf10 and Klf11 in liver. 
In conclusion, this thesis has extended our understanding of PPARα-regulated genes and 
function in liver, and has specifically highlightened a major role of PPARα in human hepa-
tocytes. This research has also given birth to a possible biomarker of hepatic PPARα activity 
which is of great interest for future studies. Considering the need for proper biomarkers in the 
field of nutrigenomics and beyond, the properties of Mbl2 as a biomarker should be further 
investigated. The identification of other novel putative PPARα target genes offers ample op-
portunities for continued research. 
Abstract
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Chapter 1
Nutrition
Nutritional science has been through a major evolution in recent decades. Starting out as 
a scientific discipline focused on establishing nutrient requirements and the prevention of 
nutrient deficiencies, in modern times nutritional science has gradually placed increasing 
emphasis on the prevention of chronic diseases. Chronic diseases that are presently in the 
spotlight are obesity and the related metabolic syndrome, both of which have experienced a 
major surge in prevalence in the past decades. Metabolic syndrome is defined by a number of 
characteristics including visceral obesity, insulin resistance, hypertension and dyslipidemia 
and is associated longitudinally with increased risk for cardiovascular disease and diabetes 
[1-3]. As a consequence, obesity and the metabolic syndrome predispose individuals towards 
a reduced quality of life and increased healthcare associated costs. 
Although the first specific guidelines on the identification, evaluation and treatment of over-
weight and obesity were released in 1998, since then the trend towards increased global 
obesity rates has continued unabated [4, 5]. In the meantime, the realization has grown that 
traditional nutritional science focused mainly on physiological and epidemiological aspects 
of nutrition may fall short of providing all the answers necessary for an effective strategy 
towards combating obesity and its complications. In response, interest has grown into un-
derstanding the molecular mechanisms underlying the beneficial or adverse effects of food 
components, which became a basis for the introduction of the science of nutrigenomics.
Nutrigenomics
Nutritional genomics or nutrigenomics investigates the interaction between nutrients and 
genes at the molecular level by using genomics tools [6, 7]. As is the case for nutritional sci-
ence in general, nutrigenomics research is mainly focused on disease prevention rather than 
to yield a specific cure. The main objective of nutrigenomics is to provide a solid mecha-
nistic framework for evidence based nutrition aimed at reducing risk for chronic diseases 
such as cardiovascular disease, diabetes and cancer. Within this field of research, dietary 
nutrients and their metabolites are considered as signaling molecules that target cellular sens-
ing systems, leading to changes in cellular and tissue function. The growing interest in un-
derstanding how nutrition acts at the molecular level has been accompanied by impressive 
technological advancements, leading to the emergence of a novel field generally referred 
to as genomics, which include transcriptomics, proteomics and metabolomics. Large scale 
gene expression profiling or transcriptomics is extensively used to measure global changes 
in mRNA level (the transcriptome) of a cell or tissue in response to external stimuli such as 
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nutrients or pharmacological reagents, or in response to certain types of diets and diseases. 
Application of these genomics tools in nutritional research gave rise to the birth of the field 
of nutrigenomics. 
One of the main goals of nutrigenomics is to try to distinguish healthy individuals from 
individuals that are in a pre-diseased or diseased state by utilizing large scale gene expres-
sion profiling. In this way, by establishing biomarker profiles, nutritional interventions in 
the early diseased state may be guided towards restoring health, thereby preventing the need 
for intensive pharmacological therapy. Changes at the level of the transcriptome form the 
basis for changes at the level of corresponding proteome and metabolome, which thus are 
the linkage between the gene expression profile and a specific phenotype. Although the most 
extensive phenotypical characterization would be achieved by combining several genomics 
techniques, at the moment transcriptomics is the most developed and feasible tool applied in 
nutrigenomics. 
In the recent years, microarray technology has emerged as a powerful tool to study whole 
genome gene expression. High density oligonucleotide arrays, such as the Affymetrix 
GeneChip® Arrays, are able to measure the expression of the entire genome of an organism 
in a single hybridization assay [8, 9]. Microarrays utilize gene specific probes representing 
individual genes which are attached to a glass surface. The experimental process starts with 
RNA isolation from the biological samples, labeling with a detectable marker followed by 
hybridization to the array. After subsequent washing, an image of the array is acquired by 
determining the extent of hybridization to each gene-specific probe. The data then need to be 
normalized to facilitate the comparison between the experimental samples [10, 11]. A good 
quality control of the arrays and proper statistical tests are critical for precise and reliable 
outcomes measurements.                     
Liver, the central player in metabolic homeostasis 
                                                                     
The liver is the major site for the metabolism of nutrients including fatty acids, cholesterol, 
glucose, and amino acids, and plays a key role in the biotransformation of xenobiotics. The 
liver also has an immunologic function via the expression of specific pro- and anti-inflamma-
tory cytokines acting either locally or systemically, and via production of an array of acute 
phase proteins. This variety of functions is due to the fact that the liver contains numerous 
cell types including paranchymal cells, stellate cells, sinusoidal endothelial cells, cholangi-
ocytes and Kupffer cells. While paranchymal cells are the principal site for metabolic regu-
latory pathways, Kupffer cells are mainly responsible for the generation of inflammatory 
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reagents which can further influence the phenotypes of neighboring cells [12]. The liver can 
thus be considered to function at the crossroads of metabolic and inflammatory signaling.
The liver plays a central role in metabolic handling of lipids. Depending on nutritional status, 
fatty acids predominantly enter the liver as free fatty acids, as triglycerides within remnant 
lipoprotein particles, or are generated via de novo lipogenesis. Incoming fatty acids can be 
metabolized by the liver as fuel or can be stored in the from of triglycerides within lipid 
droplets. Additionally, fatty acids can be exported as triglycerides within very low density li-
poproteins. Impaired balance between these pathways might promote hepatic triglyceride ac-
cumulation and lead to the development of hepatic steatosis, which may progress to chronic 
hepatic inflammation, insulin resistance and liver damage [13]. 
As a central metabolic organ, liver has the capacity to respond to numerous nutritional and 
hormonal signals [14]. In the fed state, dietary glucose stimulates insulin secretion from the 
pancreas, which travels directly to the liver via the portal vein and activates lipogenesis. In 
contrast, in the fasted state release of glucagon and adrenal cortisol, in combination with high 
plasma free fatty acid levels, leads to enhanced fatty acid oxidation. Liver can also contribute 
to the regulation of energy metabolism by secreting proteins that have systematic effects, 
thus acting as a part of the endocrine system [15, 16]. The capacity of the liver to coordinate 
metabolism is coupled to a very dynamic transcriptional regulatory network. Key transcrip-
tion factors include the farnesoid X receptor (FXR), liver X receptor (LXR) and, peroxisome 
proliferator activated receptor alpha (PPARα). 
PPARα, pharmacological, physiological and nutritional sensor
PPARα is a ligand activated transcription factor that belongs to the superfamily of nuclear 
hormone receptors and plays a major role in nutrient homeostasis [17-20]. Other known 
PPAR isoforms are PPARβ/δ and PPARγ. PPARα and PPARβ/δ are ubiquitously expressed, 
whereas PPARγ is mainly expressed in adipose tissue, macrophages and colon [21, 22]. En-
dogenous PPAR ligands are comprised of fatty acids and their derivatives such as acyl-CoAs, 
oxidized fatty acids, eicosanoids, endocannabinoids, and phytanic acid [20, 23-29]. Upon 
ligand binding PPARs form a heterodimer with the nuclear hormone receptor RXR and bind 
to specific DNA response elements (PPRE) in target genes to initiate gene transcription [20, 
30]. 
At the functional level, PPARα is known as the master regulator of lipid metabolism in liver. 
Clinically, PPARα has been the target of fibrate class of drugs and is prescribed to improve 
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dyslipidemia by lowering fasting plasma triglycerides (TG) and raising plasma HDL levels 
[31-34]. With respect to its role in physiology, PPARα is needed for the adaptive response 
to fasting. The absence of PPARα elicits a complex phenotype characterized by fatty liver, 
hypoketonemia, hypoglycemia, and elevated plasma free fatty acids levels [35-37]. While 
the initial belief was that plasma free fatty acids can ligand-activate PPARα in liver, more 
recently it was demonstrated that hepatic PPARα can not become activated by plasma free 
fatty acids [38, 39]. Instead, PPARα serves as sensor for dietary fatty acids [40-42] and fatty 
acids generated via de novo lipogenesis [39]. It has been recently shown that the effects of 
dietary unsaturated fatty acids on hepatic gene expression are almost exclusively mediated by 
PPARα and mimic the effect of synthetic PPARα agonists [43]. The target genes and function 
of PPARα are described in more detail in chapter 2.
Outline of this thesis 
The aim of the research presented in this thesis is to identify PPARα-regulated genes in 
mouse and human liver and thereby further elucidate hepatic PPARα function. The applied 
nutrigenomics approaches are mainly expression microarrays combined with knockout 
mouse models and in vitro cell culture systems.
In chapter 2, we provide a review of current knowledge on PPARα-regulated genes related to 
different biological processes in liver. In chapter 3, using microarray technology we generate 
a comprehensive overview of PPARα-regulated genes in liver with the focus on lipid me-
tabolism. We identify a large number of PPARα target genes involved in different aspects of 
lipid metabolism. Furthermore, a major role of PPARα in lipogenesis was detected. Our data 
pointed to several novel putative PPARα target genes. Chapter 4 compares PPARα-regulated 
genes in primary mouse and human hepatocytes treated with PPARα agonist Wy14643 
and generates an overview of overlapping and species specific PPARα target genes. In this 
chapter, a large number of genes was found to be regulated by PPARα activation in human 
primary hepatocytes, identifying a major role for PPARα in human liver. In chapter 5, we 
characterize mannose binding lectin 2 (Mbl2) as a novel human specific PPARα target gene 
and demonstrate changes in plasma Mbl2 levels in subjects receiving fenofibrate treatment 
or upon fasting. Regulation of Mbl2 by PPARα suggests that it may play a role in regulation 
of energy metabolism, although additional research is needed. Chapter 6 compares PPARα-
induced transcriptome in HepG2 cells versus primary human hepatocytes to investigate the 
suitability of HepG2 cells in PPARα research. The results reveal that the HepG2 cell line 
poorly reflects the established PPARα target genes and function, specifically with respect to 
lipid metabolism. In chapter 7, we characterize transcription factors Klf10 and Klf11 as novel 
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PPARα target genes and perform preliminary experiments to identify their physiological role 
in liver using in vitro transfection assays and in vivo tail vein injection of plasmid DNA. 
Finally, general discussion and conclusions are presented in chapter 8.
19
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Abstract
The peroxisome proliferator activated receptor alpha (PPARα) is a ligand activated transcrip-
tion factor involved in the regulation of a variety of processes, ranging from inflammation 
and immunity to nutrient metabolism and energy homeostasis. PPARα serves as a molecular 
target for hypolipidemic fibrates drugs which bind the receptor with high affinity. Further-
more, PPARα binds and is activated by numerous fatty acids and fatty acid derived com-
pounds. PPARα governs biological processes by altering the expression of a large number 
of target genes. Accordingly, the specific role of PPARα is directly related to the biological 
function of its target genes. Here, we present an overview of the involvement of PPARα in 
lipid metabolism and other pathways through a detailed analysis of the different known or 
putative PPARα target genes. The emphasis is on gene regulation by PPARα in liver although 
many of the results likely apply to other organs and tissues as well.
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Introduction 
Nutrient metabolism and energy homeostasis are tightly controlled by numerous regulatory 
systems involving specific transcription factors. The peroxisome proliferator activated recep-
tors (PPARs) are ligand activated transcription factors that belong to the superfamily of nu-
clear hormone receptors and play an important role in nutrient homeostasis [1-3]. Three dif-
ferent PPAR subtypes are known: PPARα, PPARß/δ and PPARγ. All PPARs share the same 
molecular mode of action via formation of heterodimers with the nuclear receptor RXR, 
followed by binding to specific DNA-response elements in target genes known as peroxi-
some proliferator response elements (PPREs). PPREs are characterized by a common core 
sequence consisting of a direct repeat of the consensus sequence AGGTCA interspaced by a 
single nucleotide [1, 4]. Expression of PPARα and PPARß/δ is found ubiquitously, whereas 
PPARγ is mainly expressed in adipose tissue, macrophages and colon [5, 6]. Activation of 
transcription by PPARs is dependent on a number of different steps including ligand binding 
to PPAR, binding of PPAR to the target gene, removal of co-repressors and recruitment of co-
activators, remodeling of the chromatin structure, and finally facilitation of gene transcrip-
tion [7]. This review will focus exclusively on PPARα.
PPARα was first discovered in the early 1990s, and since then has been identified as the mas-
ter regulator of hepatic lipid metabolism [8]. In addition, PPARα has been shown to govern 
glucose metabolism, lipoprotein metabolism, liver inflammation, amino acid metabolism and 
hepatocyte proliferation (specifically in rodents). Synthetic agonists of PPARα lower plasma 
triglycerides and raise plasma high-density lipoprotein (HDL) levels and are thus used clini-
cally in the treatment of dyslipidemia [2, 9-11].
In recent years, the advent of microarray technology has allowed the study of whole genome 
expression profiles. Accordingly, a wealth of new information has become available about 
the role of specific transcription factors in regulation of gene expression. Combined with data 
collected using more established methods, microarray has permitted the generation of a com-
prehensive picture of the impact of PPARα on gene expression, thereby providing key insight 
into the functional role of PPARα. The present review is aimed at providing a detailed and 
updated overview of PPARα target genes in different biological processes and to highlight 
possible differences between mouse and human. 
Although the presence of a functional PPRE is often used as a criteria for designating direct 
PPARα target genes, we did not apply this criteria very stringently in our analysis as the in 
vivo functionality of most of the identified PPREs remains uncertain. Recent studies indicate 
that the standard approach to screen for PPREs in the 1-2 kb region upstream of the tran-
Peroxisome Proliferator Activated Receptor alpha target genes
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scriptional start site (TSS) is at odds with accumulating evidence that PPARs often bind quite 
distant from the TSS [12-14]. In those cases, contact with the basal transcription machinery 
is expected to be established via DNA looping. Thus, the absence of a PPRE in the 1-2 kb 
region upstream of the TSS cannot be used as a criteria to disqualify target genes. Other as-
pects that need to be taken into account include correspondence in gene function with better 
established PPAR targets and the timing of gene induction following PPARα activation.
PPARα tissue expression profile in mouse and human
High expression levels of PPARα expression are found in liver and specifically in the paren-
chymal cell population. Expression of PPARα in non-parenchymal liver cells such as Kupffer 
cells is much lower [15, 16]. Other tissues with high PPARα mRNA levels are heart, kidney, 
intestine, and brown adipose tissue, all of which are characterized by an elevated rate of fatty 
acid catabolism [17]. PPARα expression has also been detected in immune cells such as the 
peripheral blood mononuclear cell population, and specifically in T-cells and macrophages 
[18-22]. Evidence suggests that mice and humans share similar PPARα tissue expression pro-
files [6, 17] (Figure 1). In the past, the importance of PPARα in human liver was questioned 
based on data showing an approximately 10-fold lower PPARα mRNA levels in human liver 
compared with mouse liver [23]. A recent study using more advanced methodology revealed 
similar PPARα expression in mouse and human liver and in mouse and human hepatocytes, 
thus strongly arguing against this notion [24]. Given that PPARα has been most extensively 
studied in liver, most of the information on PPARα target genes presented here relates to 
hepatic gene regulation.
29
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PPARα structure in mouse and human
Analogous to other nuclear receptor superfamily members, PPARα has a domain structure 
consisting of a N-terminal activating function-1 (AF-1) domain, a central DNA binding do-
main (DBD) and a C-terminal ligand binding domain (LBD) [25, 26]. The N-terminal do-
main can be phosphorylated leading to changes in transcriptional activity and even ligand 
binding of the receptor [27]. The DBD is responsible for physical interaction with DNA and 
allows PPARα to bind to specific PPREs as a heterodimer with RXR [28]. The LBD harbors 
the ligand binding pocket, is crucial for dimerization with RXR, and contains the activating 
function-2 involved in physical interactions with co-regulatory proteins [7, 29, 30]. Com-
parison of human and murine PPARα shows 85% identity at the nucleotide level and 91% 
identity at the amino acid level. Data have indicated that there is some genetic heterogeneity 
in the functional coding sequence of human PPARα that translate into functional differences 
in receptor activity. One identified variant of the human PPARα gene produces a protein 
that is mutated within the PPARα DNA binding domain. This L162V gene variant exhibits 
greater ligand-induced activity compared to the wild type receptor [31, 32]. While there is 
some evidence for a link between the L162V polymorphism and metabolic parameters such 
as plasma lipid levels, these correlations are not always found [32-37]. Interestingly, the ef-
Figure 1. Expression profile of PPARα in human tissues. The FirstChoice Human Total 
RNA Survey Panel (Ambion) was reverse transcribed and used for qPCR using primers specific for 
human PPARα. Expression levels are expressed relative to small intestine, which showed the highest 
expression level (100%).
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fect of L162V polymorphism has been suggested to be modulated via gene-drug and gene-
nutrient interactions [38-40]. The V227A polymorphism was found in Japanese population 
and has been associated with altered serum lipid levels and non-alcoholic fatty liver disease 
[41-44]. In addition to polymorphic variants, a truncated splice variant of human PPARα has 
been described that negatively interferes with wild type PPARα activity [45].
PPARα ligands
PPARα  serves as a receptor for a structurally diverse set of compounds. The most important 
class of synthetic PPARα ligands are the fibrates, including gemfibrozil, bezafibrate, clofi-
brate, fenofibrate and Wy14643 [2, 9-11, 46]. This class of drugs is used in the treatment 
of dyslipidemia primarily associated with type 2 diabetes mellitus. In addition, PPARα is 
activated by plasticizers, insecticides, and other rodent hepatic carcinogens. Natural ligands 
of PPARα include a variety of fatty acids as well as numerous fatty acid-derivatives and 
compounds showing structural resemblance to fatty acids, including acyl-CoAs, oxidized 
fatty acids, eicosanoids, endocannabinoids, and phytanic acid [47-53]. Endogenous ligand 
activation of PPARα in liver was initially suggested to occur primarily during fasting as large 
amounts of free fatty acids are released into the bloodstream and enter the liver [54, 55]. 
However, compelling evidence indicates that hepatic PPARα is not activated by plasma free 
fatty acids, whereas it can be activated by dietary fatty acids and fatty acids generated via de 
novo lipogenesis [56-60]. Recently, it was shown that the effects of dietary unsaturated fatty 
acids on hepatic gene expression are almost exclusively mediated by PPARα and mimic the 
effect of synthetic PPARα agonists [61]. 
PPARα and hepatic lipid metabolism
Regulation of lipid metabolism is mainly coordinated by liver, which actively metabolizes 
fatty acids as fuel and continuously produces very low density lipoproteins (VLDL) particles 
to provide a constant supply of fatty acids to peripheral tissues. Disturbances in these path-
ways are the basis for hepatic steatosis and alterations in plasma lipoprotein levels. Many 
aspects of hepatic lipid metabolism are under control of PPARα, including fatty acid uptake 
through membranes, fatty acid activation, intracellular fatty acid trafficking, fatty acid oxida-
tion and ketogenesis, and triglyceride storage and lipolysis (Figure 2). It has been suggested 
that part of the effect of PPARα on hepatic ketogenesis may be mediated by induction of the 
PPARα target fibroblast growth factor 21 [62-64]. A detailed discussion of the specific genes 
within the various lipid metabolic pathways that are targeted by PPARα is provided on the 
right page (Table 1).
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Table 1. List of PPARα target genes in different biological processes in liver. Genes 
regulated by PPARα in mouse are shown in black. Genes regulated in human and mouse are shown in 
red. Genes regulated only in human are shown in bold font, and genes with detected functional PPRE 
are shown in italic font.
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Peroxisomal fatty acid β-oxidation
The first link between PPARα and fatty acid catabolism was established by the identification 
of the Acyl-CoA oxidase gene, encoding the rate-limiting enzyme in peroxisomal long-chain 
fatty acid oxidation, as a direct PPARα target gene [65, 66]. Peroxisomes are known to be 
involved in many aspects of lipid metabolism, including synthesis of bile acids and plas-
malogens, synthesis of cholesterol and isoprenoids, alpha-oxidation, glyoxylate and H2O2 
metabolism, and beta-oxidation of very-long-straight-chain or branched-chain acyl-CoAs. 
The beta-oxidation of straight-chain acyl-CoAs starts with a reaction catalyzed by acyl-CoA 
oxidase 1 (Acox1) followed by one of two enzymes carrying both enoyl-CoA-hydratase and 
3-hydroxyacyl-CoA dehydrogenase activity (L-bifunctional enzyme, Ehhadh; D-bifunction-
al enzyme, Hsd17b4) and finally peroxisomal 3-ketoacyl-CoA thiolase (Acaa1a, Acaa1b). 
All genes mentioned above represent PPARα targets [24, 55, 66-75]. Additionally, genes 
involved in peroxisomal fatty acid uptake (Abcd2 and Abcd3), conversion of fatty acid to 
acyl-CoA (Crot), and numerous thioesterases (Acots) that convert acyl-CoAs back to fatty 
acids have been reported to be regulated by PPARα [24, 69, 76-78]. Activation of PPARα 
using synthetic agonists is known to cause massive proliferation of peroxisomes in rodents 
via induction of a large set of genes encoding peroxisomal fatty acid oxidation enzymes, as 
well as genes involved in peroxisomal biogenesis (Pex genes). Chronic exposure to these so 
called peroxisome proliferators can also induce liver cancer in rodents [79]. In contrast, acti-
Figure 2. Schematic representation of PPARα target genes in different aspects of 
hepatic lipid metabolism.
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vation of PPARα in humans does not seem to induce hepatocellular carcinomas, suggesting 
a species specific response to PPARα activation. Initially it was believed that the differential 
response was due to the lack activation of Acox1 and other peroxisomal genes by PPARα 
in humans [80-82]. However, recent data indicate that PPARα is able to induce a significant 
number of genes involved in peroxisomal fatty acid oxidation in human primary hepatocytes, 
including Acox1 [24]. Also, PPARα-mediated induction of the Pex11a gene involved in per-
oxisome proliferation is observed in both species [24].
Mitochondrial fatty acid β-oxidation
The crucial role of PPARα in mitochondrial fatty acid oxidation is illustrated by the pheno-
type of fasted PPARα-/- mice, which exhibit hypoketonemia, hepatic steatosis, and elevated 
plasma free fatty acid levels [54, 55, 83]. It is now evident that virtually every enzymatic 
step along the fatty acid oxidative pathway is under control of PPARα. Specifically, PPARα 
induces genes controlling fatty acid import into the mitochondria (Cpt1, Cpt2, Slc25a20, 
Slc22a5), as well as the major enzymes within the β-oxidation pathway, including various 
acyl-CoA dehydrogenases (Acad, step 1), mitochondrial trifunctional enzyme (Hadh, step 
2-4), and genes involved in β-oxidation of unsaturated fatty acid (Dci, Decr) [24, 54, 55, 67, 
69, 70, 75, 77, 84-95].
Additionally, synthesis of ketone bodies via mitochondrial HMG-CoA synthase (Hmgcs2) 
and HMG-CoA lyase (Hmgcl) is governed by PPARα [24, 69, 96-98], as is the expression 
of genes encoding electron transferring flavoprotein and the corresponding dehydrogenase 
(Etfa, Etfb, Etfdh) [24, 69]. The latter proteins mediate the transfer of electrons from Acyl-
CoA dehydrogenases to the membrane-bound electron transfer flavoprotein ubiquinone oxi-
doreductase, allowing further entry into the oxidative phosphorylation pathway [99, 100]. 
Finally, PPARα induces uncoupling proteins Ucp2 and Ucp3, which have been proposed to 
function as an outward transporter of non-esterified fatty acid anions from the mitochondrial 
matrix [24, 69, 101-103].
Microsomal fatty acid ω-hydroxylation
Cyp4A enzymes are members of the cytochrome P450 monoxygenase superfamily and cata-
lyze microsomal ω-hydroxylation of fatty acids [104, 105]. Studies using PPARα-/- mice have 
shown that hepatic expression of Cyp4a genes is almost completely dependent on PPARα 
(Cyp4a10 , Cyp4a12, Cyp4a14 in mice, Cyp4a1, Cyp4a3 in rat, Cyp4a11 in human) [55, 
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69, 77, 88, 104, 106-110]. Furthermore, expression is extremely sensitive to PPARα ligand-
activation, indicating Cyp4a genes may serve as PPARα marker genes. Although previous 
studies performed in human primary hepatocytes could not show regulation of Cyp4a by hu-
man PPARα, our microarray data revealed significant induction of Cyp4a11 by Wy14643 in 
primary human hepatocytes [24, 70, 111, 112]. ω-hydroxylation of saturated and unsaturated 
fatty acids may lead to the generation of high affinity PPARα ligands, including hydroxyei-
cosatetraenoic acids (HETEs), thus creating a positive feedback loop [113]. Alternatively, 
induction of ω-oxidation by PPARα has been suggested to promote the degradation of the 
PPARα agonist leukotriene B4 as part of a feedback mechanism aimed at controlling the 
duration of the inflammatory response [53]. 
Hepatic lipogenesis
Whereas PPARα is mostly known for its ability to induce fatty acid oxidation, growing evi-
dence points to a role of PPARα in regulation of lipogenesis.  A functional PPRE was identi-
fied in the promoter of a limited number of lipogenic genes including Δ6 desaturase (Fads2), 
malic enzyme (Mod1), Phosphatidate phosphatase (Lpin2) and Δ9 desaturase (Scd1) [56, 
114-116]. Gene expression profiling showed that chronic in vivo treatment of mice with 
PPARα agonist causes the upregulation of a large set of lipid biosynthetic genes [69]. How-
ever, regulation is much less pronounced in primary hepatocytes, suggesting an indirect 
mechanism. Consistent with this notion, induction of lipogenic genes by chronic PPARα 
activation was completely abolished in SREBP1-/- mice [117]. The effect of PPARα agonists 
on SREBP targets has been attributed to increased activation of SREBP1c via enhanced pro-
teolytic cleavage [118]. Such a mechanism may also lead to increased SREBP1 mRNA via 
an autoloop regulatory circuit [119]. Alternatively, it is possible that PPARα is recruited to 
promoters of SREBP targets and stimulates SREBP activity [12]. Interestingly, in rat FAO 
hepatoma cells it was found that PPARα activation reduced expression of lipogenic genes, in-
cluding Fasn, Gpam and SREBP1c, while Insig1 expression was increased by PPARα [120]. 
The reason for the discrepancy is not clear.
In contrast to de novo fatty acid and cholesterol synthesis, synthesis of triglycerides may be 
directly targeted by PPARα. Several genes within this pathways are upregulated by PPARα 
activation, including Gpam, various Agpat genes, Mogat1, Dgat1, and Lpin2 [24, 69, 94, 
118]. Induction of genes involved in triglyceride synthesis from fatty acids may reflect a 
broader role of PPARα in the hepatic response to fasting aimed at neutralizing large amounts 
of incoming adipose tissue-derived free fatty acids. 
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Fatty acid uptake and binding
Before they can be metabolized in the liver, fatty acids have to be transferred across the cell 
membrane. Several proteins are involved in fatty acid transport across the plasma membrane, 
a number of which carry both fatty acid transporter and acyl-CoA synthetase activity. Studies 
have shown that the fatty acid transport proteins Slc27a1, Slc27a2, and Slc27a4 are upregu-
lated by PPARα in liver [24, 69, 70, 71, 94, 121-123]. 
Slc27a1 is not expressed and not regulated by PPARα in isolated primary hepatocytes, sug-
gesting regulation occurs in liver macrophages (Kupffer cells). So far the only fatty acid 
transporter for which a PPAR response element has been identified is Slc27a1. PPARα ago-
nists also markedly induce hepatic expression of the fatty acid transporter/scavenger receptor 
Cd36, which is expressed in various liver cell types [24, 69, 91, 122].  Additionally, expres-
sion of numerous acyl-CoA synthetases is induced by PPARα [24, 67, 69, 81, 91, 124, 125]. 
Currently, limited information is available about the cellular localization and the structure/
function relationship of Acyl-CoA synthetase enzyme [126]. 
The Fabp gene family comprise a group of high affinity intracellular fatty acid binding pro-
teins. Interestingly, Fabp1 was one of the first PPARα target genes identified [77, 127-129]. 
Recent studies indicate that Fabp1 may be involved in partitioning of FA to specific lipid 
metabolic pathways [130]. Other Fabp genes induced by PPARα activation in mouse liver in-
clude Fabp2, Fabp3, Fabp4, and Fabp5 [24, 69, 91]. Induction of Fabp4 (A-FABP, aP2) upon 
PPARα activation is likely occurring via its expression in Kupffer cells. Fabp4 expression in 
hepatocytes is correlated with acquisition of a steatotic phenotype concurrent with upregula-
tion of PPARγ mRNA [131].
Lipases and lipid droplet proteins
PPARα-/- mice exhibit elevated hepatic TG accumulation, especially under fasting condi-
tions [54, 132, 133]. Conversely, treatment with PPARα agonists lowers hepatic triglyceride 
levels in models of hepatic steatosis and can prevent the fasting-induced increase in liver TG 
[134, 135]. The anti-steatotic effect of PPARα has mainly been attributed to stimulation of 
fatty acid oxidation, which would decrease the availability of fatty acids for TG storage. 
Recently, hepatic lipid droplets were shown to be targeted by autophagy, which ultimately 
leads to TG hydrolysis via lysosomal acid hydrolase (Lipa). Which other lipases importantly 
contribute to intracellular lipolysis of hepatic TG stores remains unclear but lipases active in 
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adipocytes likely play a role, including Ces3, Lipe, Pnpla2, Mgll, and perhaps Pnpla3 [136-
141].  With the exception of Pnpla3, all of the above genes are induced by short term treat-
ment with PPARα agonist in mouse hepatocytes. Regulation of Pnpla2 was also observed 
in human hepatocytes. Pnpla2 and Lipe were previously classified as direct target genes of 
PPARγ in adipose tissue, suggesting the genes are direct target of PPARα as well [142, 143]. 
Thus, apart from induction of fatty acid oxidation, PPARα activation may also decrease he-
patic TG storage by stimulating the TG hydrolysis pathway.
Lipid droplets are coated with one or more members of the perilipin family of proteins: 
perilipin (Plin1), Adrp/adipophilin (Plin2), Tip47 (Plin3), S3-12 (Plin4), and Oxpat/Lsdp5 
(Plin5). Adrp and Lsdp5 have been identified as target genes of PPARα in liver [144, 145]. A 
recent study suggests that Adrp could serve as potential mediator of the effect of PPARα on 
VLDL production. Adrp induction by PPARα may diminish VLDL production by favoring 
fatty acids storage in cytosolic lipid droplets rather than directing through VLDL assembly 
[146]. Besides Adrp, expression of S3-12 and perilipin, which are known as PPARγ target 
genes in adipose tissue, is induced by PPARα agonist in human hepatocytes [24, 147]. Per-
ilipin expression in human liver is correlated with development of steatotic liver [148]. 
Two recently identified lipid droplet-associated proteins that are not part of the perilipin fam-
ily are Cidec (FSp27) and Cidea [149, 150]. Both proteins promote TG accumulation and 
are targets of PPARγ in adipocytes [151, 152]. In addition, they are regulated by PPARα in 
mouse liver, although the kinetics of induction of the two genes seems to be quite different 
[153]. Cidec but not Cidea upregulation by PPARα agonist could be confirmed in human 
primary hepatocytes [24]. 
Interestingly, the G(0)/G(1) switch gene 2 (G0s2) was recently identified as an inhibitor of 
Pnpla2 activity and located to lipid droplets in adipocytes stimulated with β-adrenergic re-
ceptor agonist [154]. Previously, G0s2 was shown to be a direct PPARα target gene in mouse 
liver and PPARγ target in adipocytes [155]. Whether G0s2 associates with lipid droplets 
in hepatocytes remains to be further investigated. Similar to the induction of triglyceride 
synthesis, regulation of numerous lipid droplet proteins by PPARα reflect a broader role of 
PPARα in the hepatic response to fasting aimed at deflecting large amounts of incoming adi-
pose tissue-derived free fatty acids towards storage in lipid droplets.
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PPARα and lipoprotein metabolism
Clinical studies in humans have provided ample evidence that fibrate drugs effectively lower 
fasting plasma triglycerides (TG) and raise plasma HDL [156-159]. At the molecular level, 
fibrates act as synthetic agonist for PPARα, indicating an important role of PPARα in the con-
trol of lipoprotein metabolism. PPARα lowers plasma TG in part by reducing very low den-
sity lipoprotein (VLDL) production [135]. Traditionally, this effect of PPARα was ascribed 
to induction of genes involved in fatty acid oxidation and the concomitant reduction in lipid 
availability for VLDL production. However, this review has made it evident that in addition 
to its role in fatty acid catabolism, PPARα influences multiple aspects of intracellular lipid 
trafficking and metabolism, some of which may oppose hepatic TG lowering. Furthermore, 
expression of Mttp, which is involved in the lipidation of apoB100 to form a nascent VLDL 
particle, is positively regulated by PPARα [160]. Thus the precise target genes underlying 
the suppressive effect of PPARα agonist on hepatic VLDL production remain to be fully 
elucidated.
In addition to suppressing VLDL production, PPARα agonists are known to stimulate clear-
ance of TG-rich lipoproteins [135]. Clearance of TG-rich lipoproteins VLDL and chylomi-
crons is mediated by the enzyme lipoprotein lipase (LPL), which is attached to the capil-
lary endothelium in of muscle and adipose tissue. Expression of Lpl in liver is restricted 
to Kupffer cells and upregulated by PPARα agonists [161, 162]. In contrast, no evidence is 
available indicating a stimulatory effect of PPARα on Lpl expression in heart and skeletal 
muscle, which account for the major share of plasma TG clearance [162, 163]. LPL activity 
is mostly regulated post-translationally via altered secretion from liver of LPL-modulating 
factors, including apolipoprotein C-III (Apoc3), apolipoprotein A-V (Apoa4), Angiopoietin-
like protein 3 (Angptl3) and Angiopoietin-like protein 4 (Angptl4). Firstly, PPARα agonists 
down-regulate the expression of LPL inhibitor APOC3, supposedly via mechanisms involv-
ing the transcription factors REV-ERBα, HNF4α, or FOXO1 [164-167]. Secondly, PPARα 
agonists increase hepatic expression and plasma levels of APOA5, which is a positive regu-
lator of LPL [168]. A functional PPAR responsive element has been identified in the pro-
moter of the human Apoa5 gene, classifying Apoa5 as a direct PPARα target gene [169, 170]. 
Thirdly, PPARα upregulates hepatic expression and plasma levels of Angptl4, which acts as 
inhibitor of LPL activity by converting active LPL dimers to inactive monomers [171]. The 
DNA response element conferring PPAR regulation was located to intron 3 of the Angptl4 
gene [172]. Finally, PPARα stimulates hepatic expression of the VLDL receptor (Vldlr) [24, 
69]. The functional significance of Vldlr regulation in liver is unclear, as Vldlr is most highly 
expressed in adipose tissue, heart and skeletal muscle, where it plays an auxiliary role in 
plasma TG hydrolysis by LPL. Recently, Vldlr was shown to be under control of PPARγ in 
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adipocytes [173]. Thus, it appears that both pro- and anti-lipolytic pathways are activated by 
PPARα. Under conditions of pharmacological PPARα activation, the pro-lipolytic actions of 
PPARα dominate, as illustrated by the stimulation of plasma TG clearance.
PPARα agonists raise plasma HDL levels in humans, which is most likely achieved via spe-
cies specific mRNA induction of apolipoprotein A-I (Apoa1) and A-II (Apoa2) [82,174-
177]. Apoa1 gene expression is not induced by PPARα in rodents due to the presence of 
disabling mutations within the PPAR-response element [178]. In fact, PPARα activation in 
mouse downregulates Apoa1 mRNA expression and plasma concentrations through an indi-
rect pathway involving the PPARα-dependent induction of the nuclear receptor REV-ERBα, 
a negative regulator of transcription [178-180]. 
The impact of PPARα in HDL metabolism likely extends beyond regulation of apolipopro-
teins. Evidence suggests that both PPARα and PPARß/δ stimulate expression of endothelial 
lipase (Lipg) in liver [69, 181]. Endothelial lipase mainly carries phospholipase activity and 
its overexpression was shown to significantly reduce plasma HDL cholesterol levels [182-
184]. Since Lipg is expressed in endothelial cells, macrophages and hepatocytes, regulation 
of hepatic Lipg by PPARα and PPARß/δ may be mediated by different cell types. In as much 
as PPARα agonists raise plasma HDL levels, the physiological relevance of Lipg induction 
by PPARα remains to be established. 
In our recent publication the PPARα agonist Wy14643 modestly induced hepatic lipase 
(Lipc) expression in primary human hepatocytes [24]. Hepatic lipase exhibits both phospho-
lipase and triglyceride hydrolase activity and hydrolyzes triglycerides and phospholipids of 
chylomicron remnants, IDL, and HDL [185]. Whether Lipc represents a direct target gene 
of PPARα in human remains unclear. Other genes involved in lipoprotein metabolism that 
are regulated by PPARα include phosphatidylcholine transfer protein (Pctp). Induction of 
Pctp mRNA by PPARα is conserved in primary human hepatocytes [24]. Pctp encodes a 
steroidogenic acute regulatory related transfer domain protein that binds with high density 
to phosphatidylcholines. In a recent publication, a role for Pctp in the metabolic response to 
PPARα was proposed [186]. Overall, it is evident that PPARα governs multiple aspects of 
plasma lipoprotein metabolism. 
PPARα and glucose/glycerol metabolism
Although PPARα has mostly been linked to fatty acid metabolism, studies in mice have 
yielded considerable evidence for a role of PPARα in hepatic glucose metabolism. Indeed, 
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fasted PPARα-/- mice display severe hypoglycemia [54, 55, 83]. Several mechanisms may 
account for the hypoglycemia, including decreased hepatic glucose production and increased 
peripheral glucose utilization. Genes involved in gluconeogenesis that have been identified 
as PPARα targets include phosphoenolpyruvate carboxykinase (Pck1), pyruvate carboxylase 
(Pcx), lactate dehydrogenase A [69]. Interestingly, regulation of Pck1 by PPARα was only 
observed in human hepatocytes [24]. Pyruvate carboxylase was identified as direct target of 
PPARγ in adipocytes [187].
PPARα was shown to have a specific role in the metabolic conversion of glycerol in liver 
by directly upregulating the expression of genes such as Gpd1, Gpd2, Gyk, Aqp3 and Aqp9 
[188]. Besides governing glucose production, PPARα may also alter glucose utilization in 
numerous tissues via induction of pyruvate dehydrogenase kinase isoform 4 (Pdk4) [189-
194]. Pdk4 phosphorylates and inactivates pyruvate dehydrogenase, thereby limiting carbon 
flux through glycolysis. Synthesis of glycogen is also affected in PPARα-/- mice, which may 
be mediated in part via defective regulation of Gys2 [195]. It is noteworthy that in contrast 
to studies in mice, human trials generally do not support an effect of PPARα activation on 
plasma glucose levels. Consistent with these data, it was found that upregulation of genes 
involved in the glycolysis/gluconeogenesis pathway by Wy14643 was uniquely observed in 
mouse hepatocytes and not human hepatocytes [24]. 
PPARα and hepatic cholesterol/bile metabolism
It has been demonstrated that PPARα activation increases efflux of cholesterol to HDL. For-
mation of nascent HDL is mediated by Abca1-dependent lipidation of newly-secreted Apoa1. 
Expression of Abca1 is upregulated by PPARα agonists in both human and mouse hepato-
cytes, as well as in mouse intestine [24, 196]. Presently, it is not clear if this effect of PPARα 
activation is mediated via LXRα, as was shown previously in macrophages [21]. Other genes 
involved in cholesterol uptake and transport that were shown to be under control of PPARα 
include Abcg5, Abcg8, Cav1, Npc1, and Rab9 [24, 69, 197].
While PPARα is known to govern specific genes involved in bile acid synthesis, the over-
all impact on bile acid homeostasis remains somewhat ambiguous. Expression of Cyp7a1, 
which represents the rate limiting enzyme in bile acid synthesis, is markedly downregulated 
in PPARα-/- mice in fasting condition [69]. Paradoxically, synthetic PPARα agonists reduce 
Cyp7a1 expression in both mice and human [198-201]. In agreement with the latter obser-
vation, fibrate treatment led to decreased bile acid synthesis. To what extent the changes in 
Cyp7a1 expression reflect direct regulation by PPARα is unclear as PPARα also influences 
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the expression of other nuclear hormone receptors involved in the regulation of Cyp7a1 such 
as FXR and LXR. It has also been suggested that PPARα can antagonize LXR signaling and 
LXR-dependent activation of Cyp7a1 gene promoter [202-204].
Other genes involved in bile acid synthesis that are regulated by PPARα include Cyp27a1 
which is downregulated by PPARα agonists in PPARα dependent manner [201], and Cyp8b1 
which is upregulated by PPARα [69, 205]. Recently, CYP7b1 expression was shown to be 
suppressed by PPARα in a sex-specific manner, which was shown to occur via sumoylation 
of the LBD of PPARα [206]. Finally, PPARα stimulates expression of the hepatobiliary phos-
pholipid transporter Abcb4 [24, 69, 97, 197]. 
PPARα and amino acid metabolism
 Accumulating evidence supports a role for PPARα in regulation of amino acid and urea 
metabolism [207-210]. Studies in mice have shown that PPARα governs metabolism of ami-
no acids by suppressing expression of genes involved in transamination (Aspartate amino 
transferase (Got1), Alanine amino transferase (Gpt), Alanine glyoxylate aminotransferase 
(Agtx2)) and deamination (Glutaminase (Gls)), as well as numerous genes that are part of 
the urea cycle (Cps1, Otc, Ass1 and Asl) [207, 210, 211]. In agreement with these data, 
PPARα-/- mice exhibit increased plasma urea levels [207]. Several of the above genes were 
also downregulated by PPARα agonist in primary human hepatocytes, suggesting that regu-
lation of nitrogen metabolism by PPARα is at least partially conserved between mice and 
human [24]. 
At the present time, the mechanism behind downregulation of nitrogen metabolism by 
PPARα remains elusive. It has been proposed that PPARα may modulate the activity of other 
transcription factors that are directly involved in amino acid homeostasis, including HNF4α 
and C/EBPα [207]. However, concrete evidence supporting such a mechanism is lacking.
Whereas PPARα activation decreases hepatic aminotransferase expression in mice, PPARα 
agonists were shown to increase expression of Gpt in human hepatocytes and HepG2 cells, 
which occurred via direct regulation of the gene promoter [211, 212]. The observed increase 
in plasma alanine amino transferase activity in patients treated with fibrates may thus be re-
lated to direct regulation of Gpt transcription, rather than drug-induced liver injury. 
41
Peroxisome Proliferator Activated Receptor alpha target genes
PPARα and inflammation
Besides regulating numerous metabolic pathways, PPARα also governs inflammatory process-
es, which is mainly achieved by downregulating gene expression via a mechanism generally 
referred to as transrepression. The first clue towards an anti-inflammatory effects of PPARα 
came from the observation that PPARα-/- mice exhibit a prolonged inflammatory response 
in the ear swelling test [53]. The anti-inflammatory effects of PPARα are likely explained 
by interference of PPARα with the activity of many pro-inflammatory transcription factors 
including signal transducer and activator of transcription (Stat), Activator protein-1 (AP-1), 
and NF-κB [213]. Specifically, it has been shown that activated PPARα binds to c-Jun and 
to the p65 subunit of NF-κB, thereby inhibiting AP-1 and NF-κB mediated signaling [214]. 
Additionally, PPARα induces the inhibitory protein IκBα, which normally retains NF-κB in a 
non-active form, leading to suppression of NF-κB DNA binding activity [215]. Suppression 
of fibrinogen gene expression by PPARα activation is likely mediated by interference with 
the transcription factor CAATT/enhancer binding protein (C/EBP) via sequestration of the 
coactivator glucocorticoid receptor-interacting protein 1/transcriptional intermediary factor 
2 (GRIP1/TIF2) [216]. Finally, recent data indicate that activated PPARα may downregulate 
gene expression by causing the loss of STAT1 and STAT3 binding to DNA [12]. 
Specific genes downregulated by PPARα include a number of acute phase genes such as 
fibrinogen, serum amyloid P-component, lipocalin 2, metallothioneins, and serum amyloid 
A2, which were shown to be suppressed by the PPARα agonist Wy14643 in wild type mice 
but not PPARα-/- mice [217]. Similarly, in humans fenofibrate treatment has been shown 
to decrease plasma levels of several acute phase proteins including C-reactive protein, 
fibrinogen-α and –β and interleukin 6 [216, 218, 219]. With the exception of the sIl-1 recep-
tor antagonist and Vanin-1, to our knowledge no inflammatory genes have been identified as 
direct positive targets of PPARα [217].
The Vanin-1 (Vnn1) gene encodes a glycosylphosphatidylinositol–linked membrane-as-
sociated pantetheinase that generates cysteamine from pantothenic acid. Studies suggest 
that Vanin1 may promote inflammation. Mice lacking Vnn1 showed decreased NSAID- or 
Schistosoma-induced intestinal inflammation, which was associated with higher glutathione 
levels [220]. Other evidence indicates that Vanin-1 stimulates production of inflammatory 
mediators by intestinal epithelial cells and thereby controls the innate immune response, pos-
sibly by antagonizing PPARγ activity [221]. Epithelial Vanin-1 was also found to regulate 
inflammation-driven cancer development in a colitis-associated colon cancer model [222]. 
Evidence presented in Figure 3 demonstrates that Vnn1 likely represents a direct target gene 
of PPARα. Expression of Vnn1 in mouse liver was markedly increased by fasting in wildtype 
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but not PPARα-/- mice (Figure 3A). Negligible Vnn1 expression was detected in PPARα-/- 
mouse liver. Moreover, hepatic Vnn1 expression was significantly induced by 6h treatment 
with dietary fatty acids and by the synthetic PPARα agonists Wy14643 and fenofibrate (Fig-
ure 3B). Additional data lend strong support to the importance of PPARα in Vnn1 gene regu-
lation in small and large intestine (Figure 3C, D), although the results are not quite as striking 
as in liver. Finally, it was shown that two adjacent and partially overlapping PPREs located 
around 4 kb down-stream of the transcription start site of the mouse Vnn1 gene were func-
tional in a luciferase reporter assay in HepG2 cells (Figure 3E). PPARα transfection and 
Wy14643 markedly increased luciferase activity, although for reasons that remain unclear no 
synergism between the two treatments was observed. Overall, these data suggest that Vnn1 
represents a direct PPARα target gene.
The ability of PPARα to stimulate fatty acid oxidation and suppress hepatic inflammation has 
led to the exploration of PPARα agonists as a therapeutic option for non-alcohol fatty liver 
disease and specifically non-alcoholic steatohepatitis (NASH). Several studies in mice have 
shown that PPARα activation can reduce or even reverse the progression of steatohepatitis 
[134, 223-228]. The inhibitory effect of PPARα on progression of steatosis to steatohepati-
tis may be mediated in part by COX2 (Ptgs2), a candidate gene involved in steatohepatitis 
development that is suppressed by PPARα [229]. In the absence of PPARα, liver steatosis 
and inflammation are enhanced in mice chronically fed a HFD [230]. Whether the effects of 
PPARα on NASH are primarily related to changes in hepatic TG content or occur via direct 
suppression of inflammatory genes and markers remains unclear.  
PPARα and biotransformation
The detoxification of endogenous and exogenous molecules is generally divided into three 
distinct biotransformation phases. The phase I reaction involves the introduction of a polar 
group into the xenobiotic molecule and is catalyzed by members of the cytochrome P450 
(CYP) superfamily [105, 111, 231]. Phase II enzymes are responsible for covalent linkage 
of the absorbed chemicals or products of the phase I reactions with compounds such as 
glutathione, glucuronic acid, or amino-acids and is carried out by sulfotransferases, UDP-
glucuronosyltransferases (UGT), glutathione- S-transferases (GST) and N-acetyltransferases 
[231]. The third phase corresponds to elimination of  the conjugated molecule from cells and 
their excretion into bile or urine via specific transporters, mainly members of the superfamily 
ATP-binding cassette transporter proteins [232, 233]. Studies have shown that peroxisome 
proliferators modulate exclusively Cyp4a class of monooxygenases (involved in the me-
tabolism of biologically important compounds such as fatty acids, see Microsomal fatty acid 
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ω-hydroxylation) in mouse while regulating various other Cyp genes in human hepatocytes, 
including members of the Cyp1a, Cyp2a, Cyp2c and Cyp2e subfamilies [24]. Our recent 
microarray data confirmed the human specific regulation of Cyp genes belonging to classes 
1-3 by PPARα in primary human hepatocytes. Interestingly, we also observed a significant 
induction of another subfamily member of Cyp4 enzymes, Cyp4x1, by PPARα in human 
primary hepatocytes which was not conserved in mouse [24]. Cyp4x1 has been shown to be 
involved in oxidation of anandamide, which represents one of the endocannabinoids. Besides 
upregulation of gene expression, a number of genes involved in phase I biotransformation 
are downregulated by PPARα in mice, including Cyp2a5, Cyp2c11, Cup2c12 and Cyp2c29 
[106, 234]. 
With respect to phase II biotransformation, PPARα has been shown to downregulate Gluta-
thione-S-transferase A [GSTA], possibly leading to decreased biliary excretion of glutathione 
conjugates [235-237]. In contrast, expression of UDP-glucuronosyltransferase 1A (Ugt1a9), 
which participates with other UGT enzymes in glucuronidation of bilirubin, arachidonic and 
linoleic acid metabolites, is under direct stimulatory control of PPARα [238]. Overall, it is 
evident that PPARα is a major regulator of biotransformation enzymes and governs the ex-
pression of numerous cytochrome P-450 and conjugating enzymes. However, only a small 
portion of the regulation seems to be conserved between rodents and human.
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Figure 3.  Vanin-1 likely represents a direct PPARα target gene. A) Vnn1 expression in 
livers of ad libitum fed and 24h fasted wildtype and PPARα-/- mice. B) Vnn1 expression in liver (B), 
small intestine (C) and large intestine (D) of wildtype and PPARα-/- mice 6h after administration of a 
single oral dose of Wy14643 (4mg), fenofibrate (4 mg), and synthetic triglycerides triolein, trilinolein, 
trilinolenin, trieicosapentaenoin or tridocosahexaenoin (400 mL). E) HepG2 cells were transiently 
transfected with reporters (PPRE)3-TK-LUC or PPRE-Vnn1-LUC (PPRE present in intron 3-4 of the 
Vnn1 gene cloned into pGL3-promoter) and PPARα expression plasmid (pSG5). After transfection, 
cells were treated with WY14643 (50 μM) for 24 h followed by determination of luciferase and 
β-galactosidase activities in the cell lysates. Luciferase activities were normalized to β-galactosidase, 
and the relative luciferase activity of the cells treated with DMSO was set to 1. Error bars represent 
SEM.
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Conclusion  
In 2010 we are celebrating the 20th anniversary of the discovery of PPARα by Isseman and 
Green. PPARα was initially isolated as a novel nuclear hormone receptor that serves as mo-
lecular target of a diverse class of rodent hepatocarcinogens. Since then it has become clear 
that PPARα can be activated by a large variety of endogenous and synthetic agonists includ-
ing fibrate drugs. In fact, PPARα is nowadays considered as a crucial fatty acids sensor that 
mediates the effects of numerous fatty acids and fatty acid derivatives on gene expression. 
Furthermore, over the years PPARα has emerged as a crucial transcriptional regulator of nu-
merous metabolic and inflammatory processes. Although PPARα has mostly been connected 
with stimulation of fatty acid oxidation, it is now evident that the effects of PPARα are much 
more widespread and cover numerous aspects of nutrient metabolism and energy homeosta-
sis, including metabolism of lipoproteins, glucose/glycerol, cholesterol and bile acids, xeno-
biotics and amino acids. Certainly, PPARα merits the classification as a master regulator of 
hepatic intermediary metabolism. Until recently, much confusion surrounded the effects of 
PPARα activation in human liver. Recent studies indicate that at least in terms of lipid metab-
olism the function and specific target genes of PPARα are generally well-conserved between 
mouse and human. One of the major challenges lying ahead is to gain better understanding of 
the molecular mechanism underlying down-regulation of gene expression by PPARα, to im-
prove insight into the specific mechanisms and pathways of endogenous PPARα activation, 
and to better link the functional consequences of PPARα activation to induction of specific 
PPARα target genes.
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Abstract
PPARα is a ligand-activated transcription factor involved in the regulation of nutrient me-
tabolism and inflammation. Although much is already known about the function of PPARα 
in hepatic lipid metabolism, many PPARα-dependent pathways and genes have yet to be dis-
covered.  In order to obtain an overview of PPARα-regulated genes relevant to lipid metabo-
lism, and to probe for novel candidate PPARα target genes, livers from several animal studies 
in which PPARα was activated and/or disabled were analyzed by Affymetrix GeneChips. 
Numerous novel PPARα-regulated genes relevant to lipid metabolism were identified. Out 
of this set of genes, eight genes were singled out for study of PPARα-dependent regulation 
in mouse liver and in mouse, rat, and human primary hepatocytes, including thioredoxin 
interacting protein (Txnip), electron-transferring-flavoprotein ß polypeptide (Etfb), electron-
transferring-flavoprotein dehydrogenase (Etfdh), phosphatidylcholine transfer protein (Pctp), 
endothelial lipase (EL, Lipg), adipose triglyceride lipase (Pnpla2), hormone-sensitive lipase 
(HSL, Lipe), and monoglyceride lipase (Mgll). Using an in silico screening approach, one 
or more PPAR response elements (PPREs) were identified in each of these genes.  Regula-
tion of Pnpla2, Lipe, and Mgll, which are involved in triglyceride hydrolysis, was studied 
under conditions of elevated hepatic lipids. In wild-type mice fed a high fat diet, the decrease 
in hepatic lipids following treatment with the PPARα agonist Wy14643 was paralleled by 
significant up-regulation of Pnpla2, Lipe, and Mgll, suggesting that induction of triglyceride 
hydrolysis may contribute to the anti-steatotic role of PPARα. Our study illustrates the power 
of transcriptional profiling to uncover novel PPARα-regulated genes and pathways in liver.
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Introduction
The Peroxisome-Proliferator-Activated Receptors (PPARs) play a pivotal role in the regula-
tion of nutrient metabolism. PPARs are ligand-activated transcription factors that belong to 
the superfamily of nuclear hormone receptors [1-3]. They share a common mode of action 
that involves formation of heterodimers with the nuclear receptor RXR, followed by binding 
to specific DNA-response elements in the promoter of target genes. The genomic sequence 
recognized by PPARs, referred to as PPAR response element or PPRE, consists of a direct re-
peat of the consensus hexameric motif AGGTCA interspaced by a single nucleotide. Binding 
of ligands to PPARs leads to recruitment of co-activators and causes chromatin remodeling, 
resulting in initiation of DNA transcription and upregulation of specific PPAR target genes 
[4, 5]. Ligands for PPARs include both endogenous compounds, such as fatty acids and their 
eicosanoid derivatives, and synthetic agonists. Three different PPAR subtypes have been 
identified: PPARα, PPARβ/δ, and PPARγ. The latter isotype, which is most highly expressed 
in adipose tissue, is known to play an important role in adipocyte differentiation and lipid 
storage [6-8]. It is a target for an important class of antidiabetic drugs, the insulin-sensitizing 
thiazolidinediones. Expression of PPARβ/δ is ubiquitous and has been connected to wound 
healing, cholesterol metabolism, and fatty acid oxidation in adipose tissue and muscle [9-12]. 
Finally, PPARα is highly expressed in liver where it stimulates fatty acid uptake and activa-
tion, mitochondrial β–oxidation, peroxisomal fatty acid oxidation, ketogenesis, and fatty acid 
elongation and desaturation. In addition, it has a major role in glucose metabolism [13] and 
the hepatic acute phase response [14, 15]. Importantly, PPARα is the molecular target for the 
hypolipidemic fibrate class of drugs that lower plasma triglycerides and elevate plasma HDL 
(high density lipoprotein) levels. 
In recent years, microarray technology has emerged as a powerful technique to study global 
gene expression. In theory, microarray analysis is a terrific tool to map PPARα-dependent 
genes and further characterize PPARα function. In practice, microarray yields a huge amount 
of data, the analysis and interpretation of which can be very difficult. Numerous studies have 
examined the effect of synthetic PPARα agonists on global gene expression using microar-
rays. While these studies uncovered many possible PPARα target genes, the manner in which 
the data were presented often rendered interpretation difficult. Part of the complexity is due 
to the size of the PPARα-dependent transcriptome in liver, which easily exceeds one thou-
sand genes.
The aim of the present study was two-fold 1) to generate a comprehensive overview of 
PPARα-regulated genes relevant to hepatic lipid metabolism, and 2) to identify possible 
novel target genes and target pathways of PPARα connected with lipid metabolism. To that 
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end we 1) combined microarray data from several independent animal experiments involv-
ing PPARα-null mice. In these experiments, mice were either given Wy14643 or fasted for 
24 hours; 2) focused on up-regulation of genes by PPARα in conformity with the general 
paradigm of transcriptional regulation by nuclear hormone receptors; 3) reduced complexity 
by progressively moving from the complete PPARα-dependent transcriptome towards genes 
relevant to lipid metabolism, and finally to the identification of possible PPARα target genes 
involved in lipid metabolism.
Methods and materials
Materials. Wy14643 was obtained from ChemSyn Laboratories (Lenexa, KS). Recombinant 
human insulin (Actrapid) was from Novo Nordisk (Copenhagen, Denmark). SYBR Green 
was from Eurogentec (Seraing, Belgium). DMEM, fetal calf serum, calf serum, and peni-
cillin/streptomycin/fungizone were from Lonza Bioscience (Verviers, Belgium). Otherwise, 
chemicals were from Sigma (Zwijndrecht, The Netherlands). 
Animals. Male pure-bred Sv129 and PPARα-null mice on a Sv129 background were used at 
3-5 months of age (Jackson Laboratories, Bar Harbor, ME). Animals were fed normal labo-
ratory chow (RMH-B diet, Arie Blok animal feed, Woerden, the Netherlands). Study 1: Fed 
mice were killed at the end of the dark cycle. Fasting was started at the onset of the light cycle 
for 24 hours (n=5 per group). Study 2 and 4: wild-type and PPARα-null mice were fed with 
Wy14643 for 5 days by mixing it in their food (0.1%, n=5 per group). Study 2 and 4 were 
carried out independently and 2 years apart. Study 3: wild-type and PPARα-null mice fasted 
for 4 hours received a single dose of Wy14643 (400 μl of 10 mg/ml Wy14643 dissolved in 
0.5% carboxymethylcellulose) and were killed 6 hours later (n=5 per group). 
Study 5: wild-type and PPARα-null mice at 2-3 months of age were given a high fat diet 
(D12451, Research Diets, New Brunswick, NJ) for 20 weeks (composition available at http://
www.researchdiets.com/pdf/Data%20Sheets/DIO%20Series.pdf). During the last week, half 
of the mice were given Wy14643 for 7 days by mixing it in their food (0.1%, n=5 per group). 
Livers were dissected and immediately frozen in liquid nitrogen. 
All animal experiments were approved by the animal experimentation committee of Wagen-
ingen University and were carried out in conformity with the Public Health Service (PHS) 
Policy on Humane Care and Use of Laboratory Animals.        
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Primary hepatocytes. Rat (Wistar) and mouse (Sv129) hepatocytes were isolated by two-step 
collagenase perfusion as described previously [16]. Cells were plated on collagen-coated 
six-well plates. Viability was determined by Trypan Blue exclusion, and was at least 75%. 
Hepatocytes were suspended in William’s E medium (Lonza Bioscience, Verviers, Belgium) 
supplemented with 10% (v/v) foetal calf serum, 20 m-units/ml insulin, 50 nM dexametha-
sone, 100 U/mL penicillin, 100 μg/mL of streptomycin, 0.25 μg/ml fungizone and 50 μg/ml 
gentamycin. The next day, cells were incubated in fresh medium in the presence or absence 
of Wy14643 (10 µM) dissolved in DMSO for 24 hours, followed by RNA isolation. 
Human hepatocytes and Hepatocyte Culture Medium Bulletkit were purchased from Lonza 
Bioscience (Verviers, Belgium). Human hepatocytes were isolated from a single donor. Cells 
were plated on collagen-coated six-well plates. Upon arrival of the cells, the medium was dis-
carded and was replaced by Hepatocyte Culture Medium. The next day, cells were incubated 
in fresh medium in the presence or absence of Wy14643 (50 µM) dissolved in DMSO for 12 
hours, followed by RNA isolation. 
Affymetrix microarray. Total RNA was prepared from mouse livers and primary hepato-
cytes using TRIzol reagent (Invitrogen, Breda, The Netherlands). RNA was either pooled per 
group or treatment (study 1 and 2, primary hepatocytes), or used individually (study 3 and 
4), and further purified using RNeasy micro columns (Qiagen, Venlo, the Netherlands). RNA 
integrity was checked on an Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam, 
the Netherlands) using 6000 Nano Chips according to the manufacturer’s instructions. RNA 
was judged as suitable for array hybridization only if samples exhibited intact bands corre-
sponding to the 18S and 28S ribosomal RNA subunits, and displayed no chromosomal peaks 
or RNA degradation products (RNA Integrity Number > 8.0). Ten micrograms of RNA were 
used for one cycle cRNA synthesis (Affymetrix, Santa Clara, CA). Hybridization, washing 
and scanning of Affymetrix Genechip MOE430 (study 1 and 2) or mouse genome 430 2.0 
arrays (study 3 and 4) was according to standard Affymetrix protocols. 
Scans of the Affymetrix arrays were processed using packages from the Bioconductor proj-
ect [17]. Expression levels of probe sets were calculated using GCRMA [18], followed by 
identification of differentially expressed probe sets using Limma [19]. Comparison was be-
tween fasted wild-type and fasted PPARα-null mice (study 1) or between Wy14643-treated 
wild-type and Wy14643-treated PPARα-null mice (study 2-4). P-values were corrected for 
multiple testing using a false discovery rate method [20]. Probe sets that satisfied the crite-
rion of FDR < 1% (q-value < 0.01) and fold-change >1.5 were considered to be significantly 
regulated. Functional clustering of the array data was performed by a method based on over-
representation of Gene Ontology (GO) terms [21].
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For the primary hepatocytes, expression levels were calculated applying the multi-chip modi-
fied gamma model for oligonucleotide signal (multi-mgMOS) [22] and a remapped chip 
description file [23].
All microarray datasets were deposited to Gene Expression Omnibus. The GEO series ac-
cession numbers are as follows: study 1: GSE8290, study 2: GSE8291, study 3: GES 8292, 
study 4: GSE8295, primary hepatocytes: GSE8302.
RNA isolation and Q-PCR. Total RNA was extracted from tissues with TRIzol reagent (In-
vitrogen, Breda, the Netherlands). 1 µg of total RNA was reverse-transcribed with iScript 
(Bio-Rad, Veenendaal, the Netherlands). cDNA was PCR-amplified with Platinum Taq DNA 
polymerase (Invitrogen) on a Bio-Rad iCycler or MyIQ PCR machine. Primers were de-
signed to generate a PCR amplification product of 100-200 bp and were taken from Prim-
erbank (http://pga.mgh.harvard.edu/primerbank). Specificity of the amplification was veri-
fied by melt curve analysis and evaluation of efficiency of PCR amplification. The sequence 
of primers used is available upon request. The mRNA expression of all genes reported was 
normalized to 36B4 or cyclophilin gene expression.
In silico screening of putative PPREs using a PPRE classifier. Genomic sequences for 
mouse genes spanning 20 kB centered at the transcriptional start site (TSS) were extracted 
from the Ensembl database (NBCI36) and screened for DR1-type REs with predicted bind-
ing strength of at least 1%. The binding strength prediction was based on a PPRE classifier 
that uses a database of in vitro binding data for PPARs to assign predicted binding strength 
according to a classification scheme [24]. The conservation of the putative PPREs between 
mouse, human, dog and rat were evaluated using the Vertebrate Multiz Alignment and Con-
servation track available from UCSC genome browser (NCBI releases for human and mouse 
genomes, hg18 and mm8, February 2006).
Histological examination of liver. 5µ sections were cut from frozen liver pieces. For Oil Red 
O staining, sections were air dried for 30 minutes, followed by fixation in formal calcium 
(4% formaldehyde, 1% CaCl2). Oil Red O stock solution was prepared by dissolving 0.5 g 
Oil Red O in 500 mL isopropanol. A Oil Red O working solution was prepared by mixing 30 
mL Oil Red O stock with 20 mL dH2O. Sections were immersed on working solution for 10 
minutes followed by extensive washes in H2O. Haematoxylin and Eosin staining of frozen 
liver sections were carried out as described (http://www.ihcworld.com/histology.htm).
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Results
Global analysis of PPARα-dependent gene regulation
We analyzed the data from 4 independent microarray studies to obtain a comprehensive pic-
ture of PPARα-dependent up-regulation of gene expression in mouse liver. In the first study, 
mRNA was compared between livers of 24-hour fasted wild-type and PPARα-null mice. In 
the second study, mRNA was compared between liver of wild-type mice and PPARα-null 
mice fed the PPARα agonist Wy14643 for 5 days. In these two studies, RNA was pooled from 
4-5 mice and hybridized to Affymetrix MOE430A GeneChip arrays. Since no biological rep-
licates were analyzed, only a fold-change threshold criteria could be applied. Using a cut-off 
of 1.5-fold, expression of a total of 1847 probesets was lower in 24-hour fasted PPARα-null 
mice compared with 24-hour fasted wild-type mice (Figure 1A) (http://nutrigene.4t.com/
microarray/ppar2007/). 
Using the same cut-off, 2234 probesets were at least 1.5-fold lower in the livers of PPARα-
null mice fed Wy14643 compared to wild-type mice fed Wy14643 (http://nutrigene.4t.com/
microarray/ppar2007/). The number of probesets that overlapped between the two groups 
was 569. A large proportion of these genes, which are thus under control of PPARα under 
pharmacological and physiological conditions, may represent target genes of PPARα. 
In the third study, mRNA was compared between livers of wild-type mice and PPARα-null 
mice treated with Wy14643 for 6 hours, while in the fourth study mRNA was compared be-
tween livers of wild-type mice and PPARα-null mice fed Wy14643 for 5 days. Study 4 was 
carried out independent of study 2 in a different set of mice. For these two studies, biological 
replicates (4-5 mice per group) were run using Affymetrix mouse genome 430 2.0 GeneChip 
array, enabling statistical analysis of the data which was not possible for study 1 and 2. 
Applying a false discovery rate of 0.01 and a 1.5-fold cut-off, 1679 probesets were lower 
in the livers of PPARα-null mice compared to wild-type mice 6 hours after treatment with 
Wy14643, and 2207 probesets after 5 days of feeding Wy14643 (Figure 1B) 
(http://nutrigene.4t.com/microarray/ppar2007/). While the majority of genes regulated by 
PPARα after 6 hours of Wy14643 treatment were also, and generally more significantly, 
regulated after 5 days of Wy14643 treatment (overlap of 1001 probesets), many genes were 
specifically or more significantly regulated after 6 hours, including the direct PPAR target 
G0S2 and the EL gene, respectively. The complete set of data from study 2 and 4, which 
includes up- and down-regulated genes, has been submitted to the Peroxisome Proliferators 
compendium assembled by Dr. J.C. Corton (US EPA, Research Triangle Park, USA). They 
will be analyzed in conjunction with numerous other microarray experiments involving per-
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oxisome proliferators to obtain the “peroxisome proliferator transcriptome”. In addition, the 
datasets have been submitted to Gene Expression Omnibus.
Figure 1: Microarray analysis of PPARα-dependent gene regulation in mouse liver. A. 
Venn diagram showing the number of differentially expressed probesets between livers of 24-hour 
fasted wild-type and PPARα-null mice, and between wild-type and PPARα-null mice treated with the 
PPARα agonist Wy14643 for 5 days. Pooled RNA was hybridized to Affymetrix MOE430A arrays. 
A fold-change of > 1.5 was used as cut-off. B. Venn diagram showing the number of differentially 
expressed probesets between livers of wild-type and PPARα-null mice treated with the PPARα agonist 
Wy14643 for 6 hours, and between wild-type and PPARα-null mice treated with the PPARα agonist 
Wy14643 for 5 days.  RNA from individual mice was hybridized to mouse 430 2.0 arrays. Probesets 
that satisfied the criteria of fold-change > 1.5 and FDR < 0.01 were considered to be significantly 
regulated. 
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Pathway analysis of PPARα-dependent gene regulation
Functional clustering analysis of the microarray data by Gene Ontology classification indi-
cated that numerous Gene Ontology classes were over-represented among the genes that were 
>1.5-fold up-regulated in 24-hour fasted wild-type compared to 24-hour fasted PPARα-null 
mice. The same was true for the comparison between wild-type and PPARα-null mice treated 
with Wy14643 for 5 days. Among the over-represented Gene Ontology classes we found 
many classes that are known to be governed by PPARα, including fatty acid beta-oxidation, 
acyl-CoA metabolism, leukotriene metabolism and peroxisome organization and biogenesis 
(http://nutrigene.4t.com/microarray/ppar2007/). Interestingly, we also noticed that numerous 
Gene Ontology classes were specifically up-regulated by PPARα under fasting conditions or 
by Wy14643 feeding. The data suggest, for example, that pyruvate metabolism and posttrans-
lational protein targeting to membrane are specifically regulated in a PPARα-dependent man-
ner by Wy14643 but not by fasting. Indeed, it is clear that some genes (for example Acot2 and 
Cd36) are PPARα-dependently regulated by Wy14643 and much less so by fasting, whereas 
others (for example Gpam, Hmgcs2) are PPARα-dependently regulated by fasting and much 
less so by Wy14643. However, it is important to emphasize that the ErmineJ Gene Ontology 
classification, as any functional clustering analysis, needs to be interpreted carefully. 
The Gene Ontology classification analysis of the comparison wild-type vs. PPARα-null mice 
treated with Wy14643 for 6 hours (study 3) was almost identical to the analysis for mice 
treated with Wy14643 for 5 days (study 4), suggesting that most of the gene expression 
changes elicited by Wy14643 treatment are fast transcriptional responses in correspondence 
with direct regulation of gene expression by PPARα. One notable exception was the class 
representing the acute phase response, which was regulated by 5-day but not 6-hour treat-
ment with Wy14643.
Comprehensive list of PPARα-targets involved in lipid metabolism
Using these lists of genes that are up-regulated by PPARα in mouse liver we were able to 
create a comprehensive picture of PPARα-regulated genes connected with lipid metabolism. 
Genes in bold are PPARα-dependently regulated by Wy14643 and during fasting, repre-
senting a conservative list of PPARα targets (Figure 2). Genes in normal font are PPARα-
dependently regulated in any of the four studies included. From this picture it is evident 
that rather than merely regulating the rate limiting enzyme in fatty acid oxidation, PPARα 
appears to regulate virtually every single step in the peroxisomal and mitochondrial fatty acid 
oxidation pathway. Furthermore, many genes involved in fatty acid binding and activation, 
lipid transport, and glycerol metabolism, were controlled by PPARα. What is remarkable is 
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that PPARα also governs the expression of numerous genes involved in the synthesis of fats, 
which runs counter to the idea that PPARα mainly regulates fat catabolism. Several genes 
belonging to the lipogenic pathway have previously been recognized as PPARα targets, in-
cluding Mod1 and Scd1, yet the extent of regulation by PPARα is unexpected [25]. Regula-
tion of lipogenesis by PPARα was mainly observed after Wy14643 treatment, and to a much 
lesser extent after fasting. 
Figure 2: Overview of PPARα-regulated genes involved in hepatic lipid metabolism. 
Genes in bold are PPARα-dependently regulated during fasting and by Wy14643, representing a con-
servative list of PPARα targets. Genes in normal font are PPARα-dependently regulated in any of the 
four studies included. Functional classification is based on a self-made functional annotation system of 
genes involved in lipid metabolism (http://nutrigene.4t.com/microarray/ppar2007). 
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Novel putative targets of PPARα involved in lipid metabolism
In addition to providing an overview of PPARα-dependent gene regulation, we were interested 
in identifying novel PPARα-regulated genes that are implicated in lipid metabolism. To that 
end, we went through the array data from study 1 and 2 on the one hand, and study 3 and 4 on 
the other hand, and selected a number of genes to generate a heat map showing their PPARα-
dependent up-regulation by fasting and/or Wy14643 (Figure 3). To our knowledge none of 
the genes shown, all of which are involved in hepatic lipid metabolism, has yet been reported 
to be regulated by PPARα. This includes phosphatidylcholine transfer protein (lipoprotein 
metabolism), glycerol-3-phosphate acyltransferase (triglyceride synthesis), very low-density 
lipoprotein receptor, choline phosphotransferase (phosphatidylcholine synthesis), and leptin 
receptor. Since all of these genes, except Abcg5, Abcg8 and Lipe, were up-regulated 6 hours 
after Wy14643 treatment, they possibly represent novel direct target genes of PPARα in liver, 
although PPREs have yet to be identified in their respective gene promoters. 
Eight genes (shown in bold, Figure 3) were selected for more detailed investigation of 
PPARα-dependent gene regulation. Three of these genes are expected to be involved in the 
breakdown of hepatic triglycerides towards fatty acids: adipose triglyceride lipase (Pnpla2), 
hormone sensitive lipase (Lipe), and monoglyceride lipase (Mgll). Recent studies suggest 
that this threesome of genes is responsible for adipose tissue lipolysis [26-28]. In addition, we 
selected endothelial lipase (EL, Lipg), a recently identified member of triglyceride lipase gene 
family that is a major determinant of plasma HDL cholesterol [29-31], and electron transfer-
ring flavoprotein dehydrogenase (Etfdh) and electron transferring flavoprotein ß polypeptide 
(Etfb), which are components of the electron transport chain and accept electrons from at 
least nine mitochondrial matrix flavoprotein dehydrogenases [32, 33]. Finally, we selected 
phosphatidylcholine transfer protein (Pctp), which is involved in lipoprotein metabolism, and 
thioredoxin interacting protein (Txnip), which was recently identified as a major regulator 
of the hepatic response to fasting, similar to PPARα. The selection of these genes was based 
entirely on perceived novelty and potential functional importance of the observed regulation. 
Using real-time quantitative PCR (Q-PCR) we confirmed that the expression of all 8 genes in 
liver was increased by Wy14643 feeding in a PPARα-dependent manner (Figure 4A). In ad-
dition, we measured regulation of expression of this set of genes by PPARα during the course 
of fasting (Figure 4B). Expression of all 8 genes went up during fasting which, except for 
Pnpla2, was PPARα-dependent. However, the pattern of expression was remarkably different 
between the various genes, suggesting for each gene a complex and unique interplay between 
several fasting-dependent transcription factors, including PPARα. 
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Figure 3: PPARα-dependent regulation in mouse liver of selected genes involved in lipid 
metabolism as shown by heat map. The (GCRMA normalized) expression data were derived 
from 4 separate microarray studies.  Expression levels in wild-type mice without treatment were set at 
1.  A. Expression data derived from study 1 and 2. B. Expression data derived from study 3 and 4. Genes 
in bold were selected for expression analysis by Q-PCR and in silico screening for putative PPREs.
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Figure 4: PPARα governs expression of selected genes in mouse liver. 
A. Regulation of expression of selected genes by Wy14643-feeding (5 days) in liver of wild-type (+/+) 
and PPARα-null mice (-/-), as determined by Q-PCR. Error bars represent SEM. Differences were eval-
uated statistically using two-way ANOVA. Significance (p-value) of effect of genotype (G), treatment 
(T) and interaction (I) between genotype and treatment is indicated in each figure. B. Regulation of ex-
pression of selected genes by fasting in liver of wild-type (■)  and PPARα-null mice (□), as determined 
by Q-PCR. Error bars represent SEM. Differences in expression between wild-type and PPARα-null 
mice at each time point were evaluated by Student t-test. * p<0.05; ** p<0.01; *** p<0.001.
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PPARα-dependent regulation in primary hepatocytes
To examine whether the PPARα-dependent regulation of the set of genes shown in Figure 
3 was not an indirect consequence of metabolic perturbations elicited by the experimental 
challenge, we studied the effect of PPARα activation in primary mouse, rat and human hepa-
tocytes. Gene expression was first analyzed by microarray (Figure 5A), followed by targeted 
analysis of the selected 8 genes by Q-PCR (Figure 5B). Expression levels were calculated 
by applying a multi-chip modified gamma model for oligonucleotide signal (multi-mgMOS) 
[22] and a remapped chip description file [23] to allow for parallel analysis of the same gene 
within different species. Expression of almost every gene studied was highly up-regulated 
by Wy14643 in mouse and rat hepatocytes, compared to a more modest or no induction in 
human hepatocytes. For reasons that are not completely clear, in human hepatocytes, data 
from Q-PCR and microarray did not always perfectly align. Overall, the data indicate that 
the PPARα-dependent regulation observed in vivo can be reproduced in primary hepatocytes. 
Furthermore, the data suggest that expression of 6 genes is governed by PPARα in human as 
well. 
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Figure 5: Regulation of selected genes involved in lipid metabolism in primary hepa-
tocytes by Wy14643. A. Microarray-based heat map showing relative expression levels of genes 
calculated using a multi-chip modified gamma model for oligonucleotide signal (multi-mgMOS) and a 
remapped chip description file. Expression levels in the absence of ligand were set at 1. B. Relative in-
duction of expression of selected genes in primary hepatocytes by Wy14643, as determined by Q-PCR. 
The primary hepatocytes used for Q-PCR and microarray analysis were from independent experiments. 
Genes were not included when expression was extremely low (Ct>30). Error bars represent SD. The 
effect of Wy14643 on gene expression was evaluated by Student t-test. * p<0.05; ** p<0.01.
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In silico screening of putative PPREs
To evaluate whether the selected eight genes represent possible direct PPAR target genes, the 
(mouse) genes were analyzed for the presence of putative PPREs using an in silico screening 
method (Figure 6). Ten kb up- and downstream of the TSS were examined. For each putative 
PPRE identified, the predicted PPAR subtype specific binding strength was determined. For 
each gene, at least one PPRE was identified that was conserved among rat, dog and human. 
The Etfdh and Txnip genes were characterized by the presence of two very strong putative 
PPREs that were conserved in human. Up to six putative PPREs were identified in the Mgll 
gene, only one of which was conserved in human. A similar picture was found for Pnpla2. 
The putative PPREs located in the EL gene were weak and generally not conserved. Inter-
estingly, a strong putative PPRE was identified in the Pctp gene, which however was not 
conserved in human. Conversely, the human Pctp gene contained several putative PPREs that 
were not conserved in mouse (data not shown). 
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Figure 6: In silico screening for putative PPREs for the selected 8 genes, 10 kb up- and 
downstream of the transcriptional start site were examined for the presence of putative PPREs. For 
each putative PPRE identified, the predicted PPAR subtype specific binding strength was determined, 
as reflected by the height of the bar. The sequence conservation of the PPRE among various species is 
indicated. 
Comprehensive analysis of PPARα-dependent 
regulation of hepatic lipid metabolism by expression profiling
90
PPARα activation prevents hepatic lipid storage after fasting
Our data extend the role of PPARα in hepatic lipid metabolism and suggest that PPARα may 
govern triglyceride hydrolysis. To find out whether activation of the triglyceride hydrolysis 
pathway by PPARα is associated with a decrease in hepatic triglyceride stores, we compared 
wild-type and PPARα-null mice fed a HFD for 20 weeks, followed by treatment for one week 
with Wy14643. Numerous studies, including ours [34], have shown that chronic HFD in-
creases hepatic triglyceride stores. In wild-type mice fed the HFD, treatment with Wy14643 
markedly decreased hepatic lipids (Figure 7A,B), as shown by smaller lipid droplets, which 
was paralleled by significant induction of expression of Pnpla2, Lipe, and Mgll (Figure 7C). 
These data suggest that induction of the triglyceride hydrolysis pathway may contribute to 
the overall reduction in liver triglycerides elicited by PPARα activation.
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Figure 7: Induction of the triglyceride hydrolysis pathway by Wy14643 is paralleled by 
a decrease in hepatic lipid stores.  Hematoxilin and eosin staining (A) and oil red O staining (B) 
of representative liver sections of wild-type and PPARα-null mice treated or not with Wy14643 for 7 
days (magnification 200X). All mice were given a HFD for 20 weeks prior to Wy14643 treatment. (C) 
Hepatic expression of Mgll, Lipe, and Pnpla2 in the 4 experimental groups as determined by Q-PCR. 
Error bars represent SEM. Differences were evaluated statistically using two-way ANOVA. Signifi-
cance (p-value) of effect of genotype (G), treatment (T) and interaction (I) between genotype and treat-
ment is indicated in each figure.
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Discussion 
The aim of our study was two-fold 1) to generate a comprehensive overview of PPARα-
regulated genes relevant to hepatic lipid metabolism, and 2) to identify possible novel target 
genes and target pathways of PPARα connected with lipid metabolism.
It can be argued that to identify possible novel PPARα targets the proper comparison should 
have been between wild-type and wild-type treated with Wy14643, as opposed to wild-type 
treated with Wy14643 and PPARα-null treated with Wy14643, in order to avoid inclusion of 
genes that are differentially expressed between wild-type and PPARα-null mice under basal 
conditions (and could represent genes indirectly regulated by PPARα). The rationale behind 
our decision was that we wanted to be open-minded about the PPARα dependent transcrip-
tome and not exclude genes that are solely regulated by PPARα under basal conditions. For 
example, opting for the comparison wild-type vs. wild-type treated with Wy14643 would 
have led to the exclusion of Etfdh, which according to our data represents a prime candidate 
PPARα target gene in mouse and human. Furthermore, to enable comparison between the 
effects of fasting and Wy14643 it was essential to include the PPARα dependency, since the 
majority of genes regulated by fasting are regulated in a PPARα-independent manner. 
Gene Ontology classification analysis showed that numerous pathways and biological pro-
cesses beyond lipid metabolism were regulated by PPARα. We observed that the expres-
sion of almost 1700 probesets was significantly increased 6 hours after a single oral dose of 
Wy14643. Although not all genes regulated may represent direct PPARα targets, and even 
though the functional consequences of the observed regulation still needs to be demonstrated, 
these data at least suggest a major role for PPARα in hepatic gene expression and overall liver 
homeostasis. 
In agreement with the first aim, we created a comprehensive overview of hepatic PPARα-
regulated genes connected to lipid metabolism (Figure 2). A functional PPRE has been found 
in the promoter of several of these genes, classifying them as direct PPARα target genes, and 
many more genes have been shown to be up-regulated by PPARα without a functional PPRE 
having been identified [25]. It can be presumed that the far majority of genes presented in 
Figure 2 (as well as the other genes that were shown to be regulated by PPARα) are actually 
direct target genes of PPARα, but it is beyond the scope and capacity of the present study to 
address this issue in more detail. Our hope is that by combination of expression arrays with 
global analysis of promoter occupancy by PPARα using chromatin immunoprecipitation and 
tiling or promoter arrays (so called ChIP-on Chip analysis), the complete picture of direct 
PPARα target genes will be available in the future.
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The second aim of our study was to identify possible novel target genes of PPARα represent-
ing specific steps in lipid metabolism unknown to be governed by PPARα. As part of this 
effort, we identified several genes for which a link with PPARα has not yet been reported, 
including VLDL receptor, leptin receptor, and choline phosphotransferase. We focused our 
energy on 8 genes for which regulation by PPARα was deemed most novel and functionally 
interesting. All 8 genes, except for Lipe, were significantly upregulated 6 hours after treat-
ment with Wy14643. 
Using an in silico method to screen for PPREs, for each gene several putative PPREs could 
be located within 10 kb of the transcriptional start site. Within this region, at least one PPRE 
was identified that was conserved among rat, dog and human. The presence of multiple 
strong putative PPREs within the mouse Mgll gene is in correspondence with the marked 
regulation of Mgll expression in mouse liver and isolated hepatocytes. To a lesser extent, this 
is also true for the Pnpla2 and Pctp genes. Furthermore, the predicted presence of 2 strong, 
well conserved putative PPREs in the Etfdh and Txnip genes is in agreement with the high-
est fold-induction of these genes by Wy14643 in primary human hepatocytes. Although in 
silico screening may not be able to substitute for analysis of direct promoter binding by ChIP, 
the predictive power of the method explored has been shown to be remarkably robust [24]. 
Our results also substantiate the developing notion that PPAR-dependent gene regulation is 
generally mediated by multiple PPREs, rather than a single PPRE.
One remarkable outcome of the global analysis of gene regulation by PPARα is that PPARα 
appears to play a major role in governing lipogenesis. While several genes involved in li-
pogenesis were already known as PPARα targets, including ∆5 and ∆6 desaturase (Fads), 
stearoyl-CoA desaturase (Scd), microsomal triglyceride transfer protein (Mttp), and malic en-
zyme (Mod1) [25], the extent of regulation of lipogenesis is somewhat surprising, especially 
since PPARα is generally considered to stimulate fat catabolism rather than fat synthesis. It 
can be speculated that upregulation of fatty acid desaturation and elongation enzymes by 
PPARα might serve to stimulate production of PPARα ligands, and is part of a feed-forward 
action of PPARα that also includes auto-regulation of gene expression.
Although the triglyceride hydrolysis pathway in liver still has to be fully elucidated, it may 
very well be similar to the pathway operating in adipose tissue [28]. Adipose tissue triglyc-
erides are likely hydrolyzed in a three-step process catalyzed by adipose triglyceride lipase 
(Pnpla2), hormone sensitive lipase (Lipe), and monoglyceride lipase (Mgll) [26-28, 35]. Re-
markably, deletion of the Pnpla2 gene in mice not only results in more adipose mass but also 
causes a marked increase in lipid storage in a variety of organs, including liver and heart, sug-
gesting that the triglyceride hydrolysis pathway is conserved between various organs [28]. 
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Disabling the PPARα gene is known to increase hepatic triglyceride accumulation, especially 
under conditions of fasting [34, 36, 37]. Conversely, treatment with PPARα agonists lowers 
hepatic triglyceride levels in various models of hepatic steatosis [38-41]. The anti-steatotic 
effect of PPARα has generally been ascribed to stimulation of fatty acid oxidation, which, 
by decreasing intracellular fatty acid levels, will act as a drain on intracellular triglyceride 
stores. However, our data suggest that PPARα may directly govern the triglyceride hydrolysis 
pathway in liver via up-regulation of lipases Pnpla2, Lipe, Mgll, and possibly Ces1 and Ces3 
(Figure 2). Although it is impossible to provide definite experimental proof that induction of 
the triglyceride hydrolysis pathway by PPARα, or induction of fatty acid oxidation for that 
matter, is necessary and sufficient for its hepatic triglyceride-lowering effect, it likely con-
tributes to the overall reduction in liver triglycerides elicited by PPARα agonists. 
Our data suggest that expression of EL is under control of PPARα. EL, synthesized in en-
dothelial cells, plays an important role in governing plasma lipoprotein concentrations and is 
a major determinant of plasma HDL cholesterol and apoAI concentrations. Indeed, over- ex-
pression of EL in the liver results in a significant decrease in HDL cholesterol and apoAI [29-
31]. EL has been shown to have some triglyceride lipase but mainly phospolipase activity 
[42]. Although in silico screening failed to detect a strong PPREs in this gene, in our study EL 
expression was highly increased by 6 hours Wy14643 treatment and by fasting in a PPARα-
dependent manner, suggesting that EL may be a direct PPARα target gene. As EL expression 
was minimal in primary hepatocytes, EL transcripts likely originated from liver epithelial 
cells rather than liver parenchymal cells. Although further work is necessary, we suspect that 
EL may be a direct PPARα target in endothelial cells.  Considering that, in contrast to EL, 
PPARα agonists raise plasma HDL, the functional importance of regulation of EL by PPARα 
needs to be further validated. 
Another novel PPARα-regulated gene of relevance to lipoprotein metabolism is Pctp. Pctp 
is a steroidogenic acute regulatory-related transfer domain protein that binds phosphatidyl-
cholines with high specificity. Studies with Pctp null mice suggest that it may modulate 
HDL particle size and rates of hepatic clearance [43]. According to our data, expression of 
Pctp increases during fasting, which is abolished in PPARα-null mice. Wy14643 markedly 
up-regulated Pctp mRNA in mouse liver as well as in mouse, rat and human hepatocytes, 
suggesting it may represent a novel PPARα target gene. 
Etfdh and Etfb are essential components of the oxidative phosphorylation pathway. They are 
responsible for the electron transfer from at least 9 mitochondrial flavin-containing dehydro-
genases to the main respiratory chain [32, 33]. According to our data, expression of Etfdh and 
Etfb is governed by PPARα, suggesting that besides the ß-oxidation pathway, PPARα also 
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regulates components of the respiratory chain involved in the transfer of electrons from fatty 
acids and other molecules.
The last gene that we studied in more detail was Txnip, which is also known as Hyplip1. A 
spontaneous mutation within the Txnip gene gives rise to a complex phenotype that resembles 
familial combined hyperlipidemia, including hypercholesterolemia and hypertriglyceridemia 
[44]. Recent studies suggest that Txnip plays an important metabolic role in the fasting-
feeding transition by altering the redox status of the cell, which results in stimulation of the 
tricarboxylic acid cycle at the expense of ketone body or fatty acid synthesis [45]. Indeed, 
Txnip-deficient mice show elevated plasma ketones, elevated free fatty acids, hypercholes-
terolemia and hypertriglyceridemia, yet decreased glucose levels [44, 46]. The phenotype is 
very similar to that of PPARα-null mice, with the exception of the elevated plasma ketones. 
Since hepatic expression of Txnip is decreased in PPARα-null mice, it can be hypothesized 
that part of the effect of PPARα deletion on lipid and glucose metabolism is mediated by 
down-regulation of Txnip in liver, which subsequently might affect redox status. It is unclear 
to what extent Txnip expression is affected by PPARα deletion in tissues other than liver. 
In conclusion, our data indicate that the role of PPARα in hepatic lipid metabolism is much 
more extensive than previously envisioned. By generating a schematic overview of PPARα-
dependent gene regulation in mouse liver, and, for a selected set of genes, by providing 
evidence for direct regulation by PPARα in rodents and human, we have extended the role of 
PPARα in the control of hepatic lipid metabolism. 
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Abstract
Studies in mice have shown that PPARα is an important regulator of hepatic lipid metabolism 
and the acute phase response. However, little information is available on the role of PPARα 
in human liver. Here we set out to compare the function of PPARα in mouse and human he-
patocytes via analysis of target gene regulation.
Primary hepatocytes from 6 human and 6 mouse donors were treated with PPARα agonist 
Wy14643 and gene expression profiling was performed using Affymetrix GeneChips fol-
lowed by a systems biology analysis. Baseline PPARα expression was similar in human 
and mouse hepatocytes. Depending on species and time of exposure, Wy14643 significantly 
induced the expression of 362-672 genes. Surprisingly minor overlap was observed between 
the Wy14643-regulated genes from mouse and human, although more substantial overlap was 
observed at the pathway level. Xenobiotics metabolism and apolipoprotein synthesis were 
specifically regulated by PPARα in human hepatocytes, whereas glycolysis-gluconeogenesis 
was regulated specifically in mouse hepatocytes. Most of the genes commonly regulated in 
mouse and human were involved in lipid metabolism and many represented known PPARα 
targets, including CPT1A, HMGCS2, FABP1, ACSL, and ADFP. Several genes were identi-
fied that were specifically induced by PPARα in human (MBL2, ALAS1, CYP1A1, TSKU) 
or mouse (Fbp2, lgals4, Cd36, Ucp2, Pxmp4). Furthermore, several putative novel PPARα 
targets were identified that were commonly regulated in both species, including CREB3L3, 
KLF10, KLF11 and MAP3K8. 
Our results suggest that PPARα activation has a major impact on gene regulation in human 
hepatocytes. Importantly, the role of PPARα as master regulator of hepatic lipid metabolism 
is generally well-conserved between mouse and human. Overall, however, PPARα regulates 
a mostly divergent set of genes in mouse and human hepatocytes.
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Introduction
The liver plays a major role in the coordination of lipid metabolism. It actively metabolizes 
fatty acids as fuel and is responsible for triglyceride export via synthesis of very low density 
lipoproteins. An imbalance between these pathways may lead to triglyceride accumulation 
and thus hepatic steatosis. Studies in mice have indicated that many aspects of hepatic lipid 
metabolism are under transcriptional control of the Peroxisome Proliferator Activated Re-
ceptor α (PPARα), a transcription factor belonging to the nuclear receptor superfamily. It is 
well established that impaired PPARα function is associated with hepatic lipid accumulation 
[1-3]. Consequently, synthetic agonists for PPARα are explored for the treatment of steatosis 
[4].
Besides PPARα, two other PPARs isotypes are known to exist: PPARβ/δ and PPARγ. The 
PPARs share a common mode of action that involves heterodimerization with the nuclear 
receptor RXR, followed by binding to PPAR response elements (PPREs) in target genes [5]. 
Activation of transcription is induced by binding of ligand, leading to recruitment of specific 
coactivator proteins and dissociation of corepressors. Expression of PPARα and PPARβ/δ is 
relatively ubiquitous, whereas PPARγ is mainly expressed in adipose tissue, macrophages 
and colon [6,7].
PPARα can be ligand-activated by endogenous agonists, which include fatty acids and fatty 
acid derivatives such as eicosanoids and oxidized fatty acids, as well as by various synthetic 
compounds [5,8,9].  The latter group induces proliferation of peroxisomes in rodents and are 
thus referred to as peroxisome proliferators. Peroxisome proliferators encompass a diverse 
group of chemicals ranging from herbicides and insecticides to industrial plasticisers, halo-
genated hydrocarbons, and fibrate drugs [10,11].
Most of the research concerning PPARα has focused on its role in the liver. A wealth of stud-
ies performed almost exclusively in mice has revealed that PPARα serves as a key regula-
tor of hepatic fatty acid catabolism (reviewed in [12]). Using PPARα null mice, it has been 
shown that PPARα is especially important for the adaptive response to fasting by stimulating 
hepatic fatty acid oxidation and ketogenesis [2,13,14]. In addition, PPARα has been shown 
to govern liver inflammation, lipoprotein metabolism, glucose metabolism, and hepatocyte 
proliferation [12,15,16]. The latter response is known to be specific for rodents [17]. The 
species-specific effects of PPARα agonists on hepatocyte proliferation and associated hepa-
tocarcinogenesis were ascribed to a number of factors including properties intrinsic to the 
PPARα protein, conservation and functionality of PPREs in the promoter of target genes, and 
presence or absence of co-regulators depending on the cellular environment [18]. 
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However, apart from the differential effect on hepatocyte and peroxisome proliferation, it is 
not very clear whether PPARα has a similar role in mice and humans and to what extent target 
genes are shared between the two species. Based on the lower expression level of PPARα in 
human liver compared to mouse liver [19], the functionality of PPARα in human liver has 
been questioned [20]. This notion has been further reinforced by the limited impact of PPARα 
agonists on lipid metabolism genes in HepG2 cells [21], which represent the most widely 
used liver cell culture model.
However, a careful and comprehensive comparative analysis of gene regulation by PPARα 
between mouse and human hepatocytes has yet to be performed. To fill this gap we systemati-
cally compared the effect of activation of the transcription factor PPARα in primary mouse 
and human hepatocytes using a whole genome transcriptomics approach. Overall, the results 
reveal that PPARα regulates a mostly divergent set of genes in mouse and human hepatocytes 
and suggest that caution should be exercised when extrapolating the function of a transcrip-
tion factor from mouse to human. 
Materials and methods
Materials.Wy14643 was obtained from ChemSyn Laboratories (Lenexa, KS). Recombinant 
human insulin (Actrapid) was from Novo Nordisk (Copenhagen, Denmark). SYBR Green 
was from Eurogentec (Seraing, Belgium). Fetal calf serum, penicillin/streptomycin/fungi-
zone were from Lonza Bioscience (Verviers, Belgium). Otherwise, chemicals were from 
Sigma (Zwijndrecht, The Netherlands).
Human primary hepatocytes. Human hepatocytes and Hepatocyte Culture Medium Bullet-
kit were purchased from Lonza Bioscience (Verviers, Belgium). Primary hepatocytes were 
isolated from surgical liver biopsies obtained from six individual donors who underwent 
surgery after informed consent was obtained for surgery with subsequent use of samples in 
experiments. Lonza utilizes the hospital’s Institutional Review Board (IRB) to obtain ap-
proval before obtaining these tissues. The characteristics of the donors are presented in Table 
1. Hepatocytes were isolated with two-step collagenase perfusion method and the viability 
of the cells was over 80%.
Cells were plated on collagen-coated six-well plates and filled with maintenance medium. 
Upon arrival of the cells, the medium was discarded and was replaced by Hepatocyte Cul-
ture Medium (HCM) with additives. The additives included Gentamicin sulphate/Amphoter-
cin-B, Bovine serum albumin (Fatty acid free), Transferrin, Ascorbic acid, Insulin, Epidermal 
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growth factor, Hydrocortisone hemisuccinate. The next day, cells were incubated in fresh 
medium in the presence or absence of Wy14643 (50 µM) dissolved in DMSO for 6 and 24 
hours, followed by RNA isolation. 
Mouse primary hepatocytes. Mouse hepatocytes were isolated by two-step collagenase per-
fusion as described previously [51] from 6 different strains of mouse; NMRI, SV129, FVB, 
DBA, BALB/C and C57BL/6J. The characteristics of the mice used are presented in Table 
1.
Cells were plated on collagen-coated six-well plates. Viability was determined by Trypan 
Blue exclusion, and was at least 75%. Hepatocytes were suspended in William’s E medium 
(Lonza Bioscience, Verviers, Belgium) supplemented with 10% (v/v) fetal calf serum, 20 m-
units/mL insulin, 10 nM dexamethasone, 100 U/mL penicillin, 100 μg/mL of streptomycin, 
0.25 μg/mL fungizone and 50 μg/mL gentamycin. After four hours the medium was discarded 
and replaced with fresh medium. The next day, cells were incubated in fresh medium in the 
presence or absence of Wy14643 (10 µM) dissolved in DMSO for 6 and 24 hours, followed 
by RNA isolation. Isolation of mouse primary hepatocytes was approved by the animal ethics 
committee of Wageningen University. A 5-fold lower concentration of Wy14643 was used 
in mouse primary hepatocytes to take into account the higher affinity of Wy14643 for mouse 
PPARα compared to human PPARα [52].
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Table1. Characteristics of human liver donors and mouse different strains.
Affymetrix microarray. Total RNA was prepared from human and mouse primary hepato-
cytes using TRIzol reagent (Invitrogen, Breda, The Netherlands). RNA was used individually 
and further purified using RNeasy micro columns (Qiagen, Venlo, the Netherlands). RNA 
integrity was checked on an Agilent 2100 bioanalyzer (Agilent Technologies, Amsterdam, 
the Netherlands) using 6000 Nano Chips according to the manufacturer’s instructions. RNA 
was judged as suitable for array hybridization only if samples exhibited intact bands corre-
sponding to the 18S and 28S ribosomal RNA subunits, and displayed no chromosomal peaks 
or RNA degradation products (RNA Integrity Number > 8.0). Five hundred nanograms of 
RNA were used for one cycle cRNA synthesis (Affymetrix, Santa Clara, CA). Hybridization, 
washing and scanning of Affymetrix Gene chip mouse genome 430 2.0 arrays (mouse pri-
mary hepatocytes) and human genome U133 2.0 plus was according to standard Affymetrix 
protocols. 
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Scans of the Affymetrix arrays were processed using packages from the Bioconductor project 
[53]. Expression levels of probe sets were calculated using GCRMA, followed by identifi-
cation of differentially expressed probe sets using Limma. Comparison was made between 
treated and untreated (control) human primary hepatocyte, the same was compared for mouse 
primary hepatocyte. Probe sets that satisfied the criterion of Raw P < 0.05 and a mean fold-
change > ±1.1 were considered to be significantly regulated. These selection criteria were 
based on careful inspection of the fold-changes in expression and their statistical significance 
of some known PPARα target genes, including Acadvl, Fatp4, and Acox1, which barely ex-
ceeded these thresholds. Functional analysis of the array data was performed by a method 
based on overrepresentation of Gene Ontology (GO) terms [54-56] and Gene Set Enrichment 
analysis [57]. Orthologs were retrieved via Homologene (NCBI). HomoloGene is a system 
for automated detection of homologs among the annotated genes of several completely se-
quenced eukaryotic genomes.
All Microarray data reported in the manuscript is described in accordance with MIAME 
guidelines.
Q-PCR. 1 µg of total RNA was reverse-transcribed with iScript (Bio-Rad, Veenendaal, the 
Netherlands). cDNA was PCR-amplified with Platinum Taq DNA polymerase (Invitrogen) 
on a Bio-Rad iCycler or MyIQ PCR machine. 
Primers were designed to generate a PCR amplification product of 100-200 bp and were 
taken from Primerbank (http://pga.mgh.harvard.edu/primerbank). Specificity of the amplifi-
cation was verified by melt curve analysis and evaluation of efficiency of PCR amplification. 
The sequence of primers used are provided in Supplementary Table 4. The mRNA expression 
of genes reported was normalized to universal 18S gene expression. To compare PPARα ex-
pression in mouse and human hepatocytes, primers were used that yielded amplicons of equal 
length. A standard curve was included to confirm amplification efficiency of 100%±2 for 
PPARα and for the 18S control gene. PPARα expression was calculated as 1/(2^(CtPPARα 
a-Ct18S)), allowing for direct comparison between the two species.
Human liver RNA was obtained via Ambion and represented a mixture of RNA from 3 in-
dividuals without liver disease. Mouse liver RNA was obtained from 5 male mice on mixed 
genetic background (C57Bl/6-Sv129, fed state).
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Results
PPARα plays an important role in primary human hepatocytes
We first determined PPARα expression in mouse and human liver by quantitative real-time 
PCR. PPARα mRNA was only slightly lower in human liver compared to mouse liver (Fig-
ure 1A). In order to study the effect of PPARα activation on gene expression in human and 
mouse liver, primary human and mouse hepatocytes were incubated with the PPARα ago-
nist Wy14643 for 6 or 24h. To minimize potential statistical bias, the diversity of the six 
human donors was mimicked by performing the equivalent mouse experiment in primary 
hepatocytes from six different mice varying in age, sex and genetic background (Table 1). 
The choice of using Wy14643 as PPARα agonist was based on a pilot experiment in which 
primary human hepatocytes were treated with equal concentrations of either Wy14643 or 
fenofibrate (50 μM). In general, we found that established PPARα target genes were more 
strongly induced by Wy14643 compared to fenofibrate (data not shown).
The expression of PPARα itself was similar between mouse and human hepatocytes (Figure 
1B). While in mouse hepatocytes PPARα mRNA decreased during the course of the incuba-
tion, the opposite was the case in human hepatocytes. Treatment with Wy14643 consistently 
increased the expression of the established PPARα targets Cpt1a and Pdk4 in mouse and hu-
man hepatocytes, indicating activation of PPARα (Figure 1C). 
To study the effect of PPARα activation on global gene expression, microarray analysis was 
performed using Affymetrix GeneChips. We first performed principal component analysis 
(PCA) to sort out the major sources of variation in our microarray data. The PCA plot for 6h 
Wy14643 treatment clearly shows that the principal source of variation is between the spe-
cies (Figure S1). Additionally, the results indicate that: 1) there is large variation between the 
various mice at basal level (untreated cells), whereas the variation between the human donors 
is small; 2) the effect of PPARα activation is more pronounced in mice than in humans; 3) the 
effect of PPARα activation is consistent between the various mice.
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Figure 1. Activation of PPARα in mouse and human hepatocytes. (A) PPARα mRNA ex-
pression levels in human versus mouse liver as expressed relative to universal 18S. (B) PPARα mRNA 
expression levels in human versus mouse primary hepatocytes as expressed relative to universal 18S. 
Expression was determined at 6h (open bars) and 24h (black bars) in control-treated cells (DMSO). (C) 
Relative induction of expression of carnitine palmitoyltransferase 1A (Cpt1a) and pyruvate dehydroge-
nase kinase 4 (Pdk4) was determined in human and mouse primary hepatocytes treated with Wy14643 
for 6h (gray bars) and 24h (black bars). Expression of cells treated with DMSO was set at 1 (white 
bars). Error bars represent SD. *P < 0.05 according to Student’s T-test.
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We found that in human hepatocytes Wy14643 treatment for 6h significantly altered the ex-
pression of 705 genes. A considerably larger number of genes were regulated by Wy14643 
in mouse hepatocytes (Figure 2). More stringent selection dramatically reduced the number 
of significantly regulated genes in human hepatocytes, while it had much less of an effect in 
mouse hepatocytes (data not shown). Surprisingly, more prolonged Wy14643 treatment aug-
mented the number of significantly regulated genes in human hepatocytes, but not in mouse 
hepatocytes. The latter result may be related to the lower expression of PPARα in mouse 
hepatocytes after prolonged incubation (Figure 1B). Overall, these data demonstrate a major 
impact of PPARα activation in human hepatocytes. 
Figure 2. Wy14643 treatment causes major changes in gene expression in human and 
mouse hepatocytes. Bars show number of up- and down-regulated genes in primary human and 
mouse hepatocytes treated with Wy14643 for 6h or 24h. Genes were considered significantly regulated 
if mean fold change (MFC) > 1.1 and P < 0.05. 
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PPARα regulates a mostly divergent set of genes in mouse and human primary hepato-
cytes
We next determined the overlap in genes regulated by Wy14643 in mouse and human he-
patocytes. Data from 6h and 24h Wy14643 treatment were combined to prevent creating a 
bias from possible differences in kinetics of gene regulation between mouse and human and 
separate analyses were carried out for up- and down-regulated genes. A total of 125 genes 
were found to be induced by Wy14643 in both species, many of which were involved in 
various aspects of lipid metabolism (Figure 3A). A smaller number of genes was found to be 
downregulated by Wy14643 in both species (Figure 3B). However, the far majority of genes 
were regulated specifically in one of the species, which would suggest that in general PPARα 
-dependent gene regulation is poorly conserved between mouse and human. A complete list 
of regulated genes in the various categories is available in Supplementary Table 1.
To explore the possible functional impact of PPARα activation in mouse and human hepa-
tocytes, we analyzed for overrepresented Gene Ontology classes in response to Wy14643 
treatment using ErmineJ. Again, data from 6h and 24h Wy14643 treatment were combined. 
Out of 115 GO classes overrepresented after Wy14643-treatment of mouse hepatocytes, 48 
showed overlap with human hepatocytes (Figure 3C). The overlapping GO classes gener-
ally represented various aspects of hepatic fatty acid metabolism including peroxisomal me-
tabolism (Supplementary Table 2). The GO classes specific for the mouse hepatocytes also 
mostly corresponded to lipid metabolic pathways, suggesting that regulation of lipid metabo-
lism is the dominant function of PPARα in mouse hepatocytes. In contrast, the GO classes 
specific for human hepatocytes included alternative metabolic processes including bile acid 
metabolic process, and various aspects of amino acid metabolism. 
A similar type of analysis focusing on upregulated genes was carried out using gene set en-
richment analysis (GSEA). Results from Ingenuity were generally concordant with GSEA 
and will not further be elaborated on here. Out of 33 pathways induced by PPARα activa-
tion in mouse hepatocytes, 20 were also induced in human hepatocytes (Figure 3D), Similar 
to GO analysis, pathways commonly regulated in mouse and human were mostly related 
to lipid metabolism (Supplementary Table 3). Interestingly, the glycolysis-gluconeogenesis 
pathway was specifically upregulated by Wy14643 in mouse (Figure 4A), while xenobiotic 
metabolism was specifically upregulated in human (Figure 4B). Overall, these data show that 
PPARα governs a mostly divergent set of genes in mouse and human hepatocytes, although 
more significant overlap was observed at the pathway level.
 
 
Comparative analysis of gene regulation by 
the transcription factor PPARα between mouse and human
114
Chapter 4
Figure 3. Limited overlap at individual gene level but major overlap at pathway level. 
Venn diagrams showing overlap in significantly upregulated (A) and (B) downregulated genes after 
treatment with Wy14643 in mouse versus human hepatocytes. Genes were included if they were signifi-
cantly regulated by Wy14643 at 6h and/or 24h. Criteria for significance was mean fold-change (MFC) 
> 1.1 and P < 0.05. Genes without orthologs in the other species and/or not present on the array of the 
other species were excluded. (C) Venn diagram showing overlap in overrepresented Gene Ontology 
classes upon Wy14643 treatment in mouse and human hepatocytes based on a functional class score 
method. Data from 6h and 24h Wy14643 treatment were combined in a single analysis. Only GO class-
es containing 8 to 125 genes and FDR < 0.0001 were included in the Venn diagram. (D) Venn diagram 
showing overlap in upregulated processes analyzed by GSEA. Only gene sets having a size between 
15 and 250 genes were included in the analysis. To account for multiple hypothesis tasting, gene sets 
having a FDR < 0.25 were selected. Sources of the gene sets: BIOCARTA, GENMAPP, KEGG, SIG-
NALING ALLIANCE, SIGNALING TRANSDUCTION, GEARRAY and SK manual.
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Figure 4. Heat map illustrating the species-specific regulation of two gene sets originat-
ing from Gene set enrichment analysis (GSEA). (A) Glycolysis-gluconeogenesis as a mouse-
specific upregulated gene set. (B) Xenobiotic metabolism as a human-specific upregulated gene set. 
Genes are ranked based on the mean fold change (MFC). Expression levels in the DMSO-treated cells 
were set at 1. 
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Identification of human and mouse-specific novel putative PPARα target genes
In order to identify additional genes that are specifically regulated by PPARα in one particu-
lar species, we performed scatter plot analysis comparing the effect of 6h PPARα activation 
between mouse and human (Figure 5A). A similar plot was created for 24h PPARα activation 
(Figure 5B). A number of genes could be identified that were induced by Wy14643 specifi-
cally in human (MBL2, CYP1A1, HMOX1 and TSKU) or mouse (FBP2, LGALS4, PXMP4 
and UCP2). To directly compare the effect of Wy14643 on specific genes between mouse 
and human, genes that were upregulated by 6h or 24h Wy14643 in human hepatocytes were 
ranked according to their mean fold-change and the changes in expression compared between 
the individual donors (Figure 6 and Figure S2, respectively). The changes in expression of 
their mouse orthologs are presented in parallel. The picture clearly illustrates the human-
specific induction of MBL2, ALAS1, TSKU, and many other genes. The specific induction of 
TSKU was confirmed by qPCR (Figure S3A). Interestingly, the top 50 of most highly induced 
genes contain a remarkably high number of established PPARα targets, regulation of which 
was conserved in mouse hepatocytes. This includes genes involved in mitochondrial fatty 
acid oxidation and ketogenesis (HMGCS2, CPT1A, CPT2, SLC25A20), peroxisomal/mi-
crosomal fatty acid oxidation (ECH1, CYP4A11), fatty acid binding and activation (FABP1, 
ACSL1, ACSL3), and lipid droplet associated proteins (ADFP). Wy14643 also stimulated 
expression of a number of secreted PPARα targets including FGF21 and ANGPTL4. These 
data support an important role for PPARα in the regulation of lipid metabolism in human 
hepatocytes. Besides numerous known PPARα target genes, several putative novel PPARα 
targets were found to be commonly regulated by Wy14643 in mouse and human, including 
the transcription factors CREB3L3, KLF10 and KLF11, and MAP3K8. Induction of KLF10 
was confirmed by qPCR (Figure S3B).
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Figure 5. Limited similarity in Wy14643-induced gene regulation between mouse and 
human hepatocytes. Scatter plots demonstrating similarities and differences in gene regulation by 
6h (A) and 24h (B) PPARα activation between human and mouse hepatocytes. Graphs show fold-
changes in gene expression after treatment with Wy4643 in human hepatocytes (x-axis) and mouse 
hepatocytes (y-axis). Selected genes that are upregulated specifically by Wy4643 in human or mouse 
are indicated. 
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Figure 6. Partial conservation of Wy14643-induced gene regulation between human and 
mouse hepatocytes. Heat map illustrating the relative induction of the top 50 of upregulated genes 
in response to 6h Wy14643 treatment in human hepatocytes. All genes were significantly changed (P 
< 0.05) and were ranked based on mean fold-change (MFC). Expression levels in the DMSO-treated 
cells were set at 1. Relative changes in expression of the corresponding mouse orthologs in mouse 
hepatocytes are shown in parallel.
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Conversely, the scatter plots and ranking of genes also clearly revealed numerous genes that 
were specifically induced by Wy14643 in mouse, including Fbp2, Lgals4, and Pxmp4, as 
well as known PPARα target genes such as Cd36, Cpt1b and Ucp2 (Figures 5B and 7; Figure 
S4). The mouse specific induction of Fbp2 was confirmed by qPCR (Figure S3C). These 
data suggest that in general the effect of PPARα activation is remarkably dissimilar between 
mouse and human hepatocytes. Nevertheless, many established PPARα targets representing 
key genes in lipid metabolism are commonly regulated in mouse and human. 
The role of PPARα in hepatic lipid metabolism is well conserved between mouse and hu-
man
We showed that a large proportion of the genes commonly regulated by PPARα in mouse and 
human were involved in some aspect of lipid metabolism. To better appreciate the conserva-
tion of PPARα’s role as master regulator of hepatic lipid metabolism, we classified genes 
according to specific lipid metabolic pathways to create a comprehensive picture of PPARα-
dependent gene regulation (Figures 8A,B). The picture reveals that in human hepatocytes 
PPARα activation induces the expression of many genes involved in different aspects of lipid 
metabolism, including fat oxidation, fat synthesis, intracellular TG storage and hydrolysis, 
membrane transport, intracellular activation and trafficking of fatty acids and lipoprotein 
metabolism. Comparison with the corresponding picture for mouse reveals a remarkable con-
servation at the pathway level, indicating that the role of PPARα in hepatic lipid metabolism 
is highly similar between mice and human. The sole exception is lipoprotein metabolism, 
represented by APOA2 and APOA5, which was exclusively regulated in human hepatocytes. 
It is also evident that fewer peroxisomal genes are induced by Wy14643 in human vs. mouse 
hepatocytes. Interestingly, within a particular metabolic pathway the specific genes upregu-
lated by Wy14643 to some extent differ between mouse and human. Taken together, the 
results suggest that in human and mouse hepatocytes PPARα has an equally important role in 
governing lipid metabolism with the exception of lipoprotein metabolism and to a lesser ex-
tent peroxisomal metabolism. However, the specific genes under control of PPARα in mouse 
and human are partially different.
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Figure 7. Partial conservation of Wy14643-induced gene regulation between mouse and 
human hepatocytes. Heat map illustrating the relative induction of the top 50 of upregulated genes 
in response to 6h Wy14643 treatment in mouse hepatocytes. All genes were significantly changed (P 
< 0.05) and were ranked based on mean fold-change (MFC). Expression levels in the DMSO-treated 
cells were set at 1. Relative changes in expression of the corresponding human orthologs in human 
hepatocytes are shown in parallel.
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Figure 8. PPARα serves as a global transcriptional regulator of lipid metabolism in 
mouse and human hepatocytes. Genes significantly upregulated by Wy14643 and that function 
in lipid metabolism were classified into specific metabolic pathways. Separate pictures were created 
for human hepatocytes (A) and mouse hepatocytes (B). Genes significantly upregulated by Wy14643 
at both time points of 6h and 24h are shown in bold. Genes significantly upregulated by Wy14643 in 
human and mouse hepatocytes are shown in red. Genes significantly upregulated by Wy14643 at one 
time point only are shown in normal font. Functional classification is based on a self-made functional 
annotation system of genes involved in lipid metabolism.
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Discussion
Numerous studies have examined the effect of PPARα activation or deletion on hepatic gene 
regulation using transcriptomics. In general, these studies indicate that unlike many other nu-
clear receptors, PPARα governs the expression of a large set of genes, many of which are in-
volved in fatty acid metabolism [22-27].  However, there has been no systematic comparison 
of the whole genome effects of PPARα activation in human versus mouse hepatocytes [28]. 
Accordingly, in the present paper we systematically compared the effect of PPARα activation 
in primary mouse and human hepatocytes using a whole genome transcriptomics approach. 
A number of important general conclusions can be drawn from our work. First, perhaps 
contrary to common conception, our data support a major role for PPARα in human liver, 
as evidenced by the large number of genes altered upon PPARα activation in primary hu-
man hepatocytes. Second, even though the human and mouse hepatocytes were not cultured 
under identical conditions, we feel comfortable to conclude that PPARα regulates a mostly 
divergent set of genes in mouse and human liver. For example, we found that metabolism of 
xenobiotics is specifically regulated by PPARα in human liver. Third, the role of PPARα as 
a master regulator of hepatic lipid metabolism is well conserved between mouse and human. 
However, within each lipid metabolic pathway the specific genes under control of PPARα in 
mouse and human differ to some extent. 
In recent years, the role of PPARα in human liver has been questioned based on RNase 
protection data showing 10-fold lower levels of PPARα mRNA in human liver compared 
with mouse liver [19]. Additionally, human hepatoma HepG2 cells were shown to respond 
poorly to PPARα activation [21]. In contrast, we show by quantitative realtime PCR that in 
liver tissue and primary hepatocytes PPARα expression levels are similar between mouse 
and human. It is inherently difficult to compare hepatic PPARα expression between spe-
cies as PPARα mRNA fluctuations throughout the day [29], is increased by fasting [30], 
and is reduced under conditions of inflammation [31]. Changes in PPARα expression will 
likely influence the transcriptional response to PPARα activation. Our comparative analysis 
of hepatic gene regulation by human PPARα vs. mouse PPARα should thus be considered an 
approximation. Despite the limitations, our analysis represents a major advancement in our 
understanding of PPARα function in human liver.
Consistent with a major role of PPARα in human hepatocytes, the number of genes signifi-
cantly regulated by Wy14643 was very high and was similar to the number in mouse hepa-
tocytes. Although induction of gene expression by Wy14643 was generally less robust in 
human hepatocytes, these cells likely lost some sensitivity due to the extended time between 
isolation and harvesting. We were able to exclude differences in cultured medium as an ex-
planation for the lower fold-inductions in human hepatocytes (data not shown).
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While the number of genes commonly regulated by PPARα in mouse and human hepatocytes 
may seem relatively small, which would suggest minor overlap in PPARα function between 
the two species, the overlap is more impressive when studied at the level of gene ontology. 
Many of the overlapping gene ontology classes represent pathways of lipid metabolism. Sup-
porting these data, many of the 125 genes co-regulated by PPARα in mouse and human are 
involved in various aspects of hepatic lipid handling, including peroxisomal and mitochon-
drial fatty acid oxidation (ACOX1, ECH1), ketogenesis (HMGCS2), fatty acid binding and 
activation (FABP1, ACSL3), and fatty acid uptake (SLC27A2). Our analysis demonstrates 
that in human liver, analogous to the situation in mouse liver [26], PPARα serves as a global 
transcriptional regulator of lipid metabolism.
In addition to numerous established PPARα target genes, several genes were found to be 
co-regulated by Wy14643 in mouse and human that have not yet been linked to PPARα, in-
cluding the liver specific transcription factor CREB3L3. CREB3L3 was recently shown to be 
involved in the hepatic acute phase response, suggesting that it may partially mediate the ef-
fects of PPARα on acute phase response [32]. Other conserved novel putative targets include 
MAP3K8, SGK2, and the transcription factor KLF10 and KLF11. KLF10 and KLF11 encode 
three zinc-finger Krüppel-like transcription factors that binds GCrich/Sp1-like sequences and 
influence cell proliferation [33].
The inability of PPARα agonists to induce peroxisome proliferation in human is well ac-
knowledged, although the precise mechanism remains to be fully elucidated. Using human-
ized PPARα mice, it has been shown that the human PPARα receptor has the ability to induce 
peroxisome proliferation and peroxisomal fatty acid oxidation in the context of a mouse 
liver [34,35]. However, in a previous study using HepG2 cells engineered to express PPARα 
at levels similar to mouse liver, ACOX1 and other peroxisomal genes were not induced by 
PPARα [36]. Similar results were obtained in primary human hepatocytes treated with feno-
fibrate [37].  In contrast, we find that a number of genes involved in peroxisomal fatty acid 
oxidation, including the prototypical PPARα targets ACOX1, ECH1, PEX11A, and ACAA1, 
is commonly induced by PPARα in mouse and human. Simultaneously, we find that induc-
tion by PPARα of numerous other peroxisomal genes, including Ehhadh, Pxmp4, Acot4, and 
Peci, is specific for mouse. Our data argue against a general mechanism and suggest that any 
lack of conservation of PPARα-dependent gene regulation between mouse and human must 
be determined at the level of individual target genes.
Previously, it was shown that APOA1, APOA2 and APOA5 are upregulated by PPARα ago-
nists, which was found to be specific for humans [38-41]. While we confirm the human-spe-
cific upregulation of APO2 and APOA5 by Wy14643, we could not confirm the upregulation 
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of APOA1 by Wy14643. Rather, we found a minor but statistically significant decrease in 
APOA1 expression after 6h of Wy14643 treatment. The reason for this discrepancy is unclear 
but may be related to the type of PPARα agonist used. Overall, our data indicate that regula-
tion of apolipoproteins A by PPARα is specific for humans, which very likely accounts for 
the human specific induction of plasma HDL levels by fibrates [42].
Several individual genes were identified that were also specifically regulated by Wy14643 in 
human hepatocytes. This includes the secreted mannose-binding lectin MBL2, which is an 
important protein of the humoral innate immune system [43], and TSKU, which encodes a 
secreted protein involved in development [44]. Regulation of CYP1A1 by PPARα in human 
hepatocytes has been previously observed [45], and was shown here to be part of a more 
comprehensive regulation of biotransformation enzymes by PPARα  that was specific for 
human hepatocytes. Importantly, while genes belonging to the Cyp4a class are exclusively 
regulated by PPARα in mouse, genes belonging to CYP classes 1-3 are specifically regulated 
by PPARα in human, which confirms previous analyses [46,47].
A number of pathways was found to be specifically induced by Wy14643 in mouse hepato-
cytes, including glycolysis/gluconeogenesis, pentose phosphate pathway, and glycerolipid 
metabolism, as were several specific lipid metabolic pathways. A similar mouse-specific re-
sponse was observed at the level of individual genes. Most notable examples were FBP2 
(fructose-1,6-bisphosphatase 2), LGALS4 (lectin, galactoside-binding, soluble, 4), and sev-
eral ACOTs (Acyl-CoA thioesterases).
Studies in mice have yielded considerable evidence for a direct role of PPARα in hepatic glu-
cose metabolism. Importantly, fasted PPARα -/- mice exhibit markedly reduced plasma glu-
cose levels [30]. Other studies have suggested a direct link between PPARα and hepatic glu-
coneogenesis [48-50]. In contrast, human trials generally do not support an effect of PPARα 
activation on plasma glucose levels. Accordingly, it is tempting to relate these seemingly 
discrepant results to the observed mouse-specific regulation of glucose metabolic pathways.
In conclusion, PPARα activation has a major impact on gene regulation in human liver cells. 
Importantly, the role of PPARα as a master regulator of hepatic lipid metabolism is generally 
well conserved between mouse and human. Overall, however, PPARα regulates a mostly 
divergent set of genes in mouse and human hepatocytes suggesting that caution should be 
exercised when extrapolating the function of a transcription factor from mouse to human. 
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Figure S1  Principal component analysis illustrating the major sources of variation in our  microarray 
dataset. In the first dimension, data separate based on species. The second dimension illustrates the ef-
fect of Wy14643 treatment.
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Figure S2  Heat map illustrating the relative induction of the top 50 of upregulated genes in response 
to 24h Wy14643 treatment in human hepatocytes. All genes were significantly changed (P < 0.05) and 
were ranked based on mean fold-change (MFC). Expression levels in the DMSO-treated cells were set 
at 1. Relative changes in expression of the corresponding mouse orthologs in mouse hepatocytes are 
shown in parallel.
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Figure S3  Species-specific induction of novel putative PPARα genes by Wy14643. (A) Relative in-
duction of Tukushin (TSKU) by Wy14643 in human and mouse hepatocytes. (B) Relative induction of 
Kruppel-like factor 10 (KLF10) by Wy14643 in human and mouse hepatocytes. (C) Relative induction 
of fructose bisphosphatase 2 (Fbp2) by Wy14643 in mouse hepatocytes.  Inductions for 6h (grey bars) 
and 24h (black bars) Wy14643 treatments are shown. Expression of cells treated with DMSO was set at 
1 (white bars). Gene expression was determined by qPCR. Error bars represent SD. *P < 0.05 according 
to Student’s T-test.
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Figure S4  Heat map illustrating the relative induction of the top 50 of upregulated genes in response 
to 24h Wy14643 treatment in mouse hepatocytes. All genes were significantly changed (P < 0.05) and 
were ranked based on mean fold-change (MFC). Expression levels in the DMSO-treated cells were set 
at 1. Relative changes in expression of the corresponding human orthologs in human hepatocytes are 
shown in parallel.
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Additional files can be found online:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729378
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Abstract
PPARα is a major transcriptional regulator of hepatic lipid metabolism. Here, we aimed to 
find novel circulating mediators of PPARα activity in human. Microarray analysis was per-
formed on primary human hepatocytes treated with Wy14643 and data selected for secreted 
proteins. Expression of liver-specific mannose-binding lectin (MBL2), a soluble mediator 
of innate immunity, was markedly upregulated by PPARα activation. Induction of MBL2 
mRNA and protein was confirmed in HepG2 cells but not in mouse hepatocytes. 
In human subjects, fasting increased plasma MBL2 levels. Importantly, in two independent 
clinical trials, treatment with PPARα-agonist fenofibrate markedly increased plasma MBL2 
levels. The relative induction of plasma MBL2 by fenofibrate was not correlated with the 
relative induction of plasma ANGPTL4 or FGF21. These results identify MBL2 as circulat-
ing target of PPARα in humans and suggest that MBL2 may mediate effects of PPARα on 
innate immunity.
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Introduction
The liver is a key organ in the control of lipid metabolism and whole energy homeostasis. 
Although not generally appreciated as an important contributor to endocrine regulation of 
energy metabolism, recent studies point to the liver as a source of secreted factors that have 
profound metabolic effects elsewhere in the body [1, 2]. Studies in mice have demonstrated 
that many aspects of hepatic lipid metabolism are under transcriptional control of the Per-
oxisome Proliferator Activated Receptor α (PPARα), a transcription factor belonging to the 
nuclear receptor superfamily. Lack of PPARα in mice leads to acute energy shortage in liver 
upon fasting and is characterized by defective ketone body formation, hypoglycemia, el-
evated plasma free fatty acids, and severe hepatic steatosis [3, 4]. Recently, it has been shown 
that PPARα also governs the hepatic production of secreted proteins FGF21 and ANGPTL4 
[1, 5]. While FGF21 has been shown to serve as a mediator of the PPARα-induced starvation 
response in mice [6, 7], ANGPTL4 is now well established as a potent regulator of plasma 
triglyceride levels via inhibition of lipoprotein lipase [8]. The present study was undertaken 
to identify potential novel circulating mediators of PPARα activity in human. Our results 
indicate that MBL2, a soluble effector of innate immunity and putative co-receptor for Toll-
like receptors [9], is a circulating target of PPARα in human liver and may mediate effects of 
PPARα on innate immunity.
Materials and methods
Materials. Wy14643 and GW7647 were obtained from ChemSyn Laboratories (Lenexa, KS). 
SYBR Green was from Eurogentec (Seraing, Belgium). Fetal calf serum, penicillin/strepto-
mycin/fungizone were from Lonza Bioscience (Verviers, Belgium). Otherwise, chemicals 
were from Sigma (Zwijndrecht, The Netherlands).
Primary hepatocytes isolation. Primary human hepatocytes from 6 donors were purchased 
from Lonza Bioscience (Verviers, Belgium). Details of isolation and procedure are described 
in a previous publication [10]. Briefly cells were isolated from surgical liver biopsies by two-
step collagenase perfusion method and incubated in the presence or absence of Wy14643 (50 
µM) dissolved in DMSO for 6 and 24 hours, followed by RNA isolation. 
Mouse hepatocytes were isolated as described previously from 6 different strains of mouse: 
NMRI, SV129, FVB, DBA, BALB/C and C57BL/6J [10, 11].
Cells were incubated in fresh medium in the presence or absence of Wy14643 (10 µM) dis-
solved in DMSO for 6 and 24 hours, followed by RNA isolation. Isolation of mouse primary 
hepatocytes was approved by the animal ethics committee of Wageningen University.
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Affymetrix microarray analysis. RNA isolation and subsequent processing for microarray 
were carried out as previously described [10]. Hybridization, washing and scanning of Af-
fymetrix Gene chip human genome U133 2.0 plus and mouse genome 430 2.0 arrays was 
according to standard Affymetrix protocols.  
Analysis of the microarray data was as previously described [10]. Genes encoding secreted 
proteins were selected using Gene Ontology Classification, SignalP and ngLOC (n-gram-
based Bayesian classifier) predicting tools.
Real time quantitative PCR. 1 µg of total RNA was used for reverse-transcription with iScript 
(Bio-Rad, Veenendaal, the Netherlands). PCR was performed with Platinum Taq DNA poly-
merase (Invitrogen) on a Bio-Rad iCycler or MyIQ PCR machine. Specificity of the amplifi-
cation was verified by melt curve analysis and evaluation of efficiency of PCR amplification. 
The mRNA expression reported was normalized to universal 18S gene expression. 
Primer sequences used: hMBL2, forward: GCAAACAGAAATGGCACGTATC, reverse: 
CTGGAACTTGACACACAAGGC; mMbl1, forward: CTGTGGCTATCCCCAGGAAT, 
reverse:TCACGTACATGAACTGCCCTT;mMbl2,forward:TGACAGTGGTTTATGCAGA
GAC,  reverse: CGTCACGTCCATCTTTGCC.
For determination of tissue expression of MBL2, cDNA was prepared from FirstChoice® 
Human Total RNA Survey Panel (Ambion).
HepG2 Cell Culture. Human hepatoma HepG2 cells were grown in DMEM containing 10% 
FCS and 1% penicillin-streptomycin (20,000 units/ml potassium penicillin, 20,000µg/ml 
streptomycin sulfate) at 37ºC/5% CO2. PPARα ligands (Wy14643 10µM, GW7647 10 µM) 
or vehicle (DMSO) was added to the cells for 6h. Cells were harvested using TRIzol (Invit-
rogen, Breda, The Netherlands).
For protein measurement, HepG2 cells were incubated in DMEM without FCS followed by 
addition of GW7647 (10 µM) and Wy14643 (10 µM) for 24h. The medium was collected 
and protein analysis was performed using commercially available MBL2 Oligomer ELISA 
kit (Bioporto Diagnostics, Copenhagen, Denmark).
Human subjects. In the fasting study, blood was taken from 4 healthy young males (age 19-
22). The full details of this study can be found elsewhere [13]. Briefly volunteers received an 
identical meal at 17.00 before the start of a 48h fasting period. During the fasting period, the 
subjects were not allowed to eat or drink anything except water. Blood samples were taken at 
baseline and after 48h of fasting.
For the first fenofibrate study, serum was sampled from eleven obese females with type 2 
diabetes mellitus and serum triglyceride concentrations above 2.0 mmol/l at baseline and 
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after a 3-month treatment with micronized fenofibrate (200 mg/d, Lipanthyl). Full details of 
this study can be found elsewhere [14].
For the second fenofibrate study, fasted blood samples were taken from 19 male and female 
subjects (age 30-70 yrs) with a BMI of at least 27 kg/m2 before and after a 6-week treatment 
with micronized fenofibrate (200 mg/d, Lipanthyl). The full details of this study can be found 
in supplemental text.
All human experiments were approved by the medial ethics committee of Wageningen Uni-
versity or Maastricht University, the Netherlands; or of the First Faculty of Medicine and 
General University Hospital, Prague, Czech Republic. Subjects were informed about the 
design and purpose of the study and provided fully informed written consent. 
Plasma/serum MBL2 analysis. Plasma MBL2 levels were determined using a commercially 
available MBL2 Oligomer Elisa kit (Bioporto Diagnostics, Copenhagen, Denmark) using 
biotinylated monoclonal detection antibody following the instructions of the manufacturer.
Statistical analysis. Statistical significant differences were calculated using Student’s T-test. 
The cut-off for statistical significance was set at a P-value of 0.05 or below. Plasma MBL2 
levels were log-transformed before analysis.
Results
MBL2 expression in liver is regulated by PPARα in human specific manner
The aim of the present paper was to screen for novel circulating mediators of PPARα activ-
ity in human. To that end, we treated primary human hepatocytes with the PPARα agonist 
Wy14643 for 24 hours and performed Affymetrix microarray analysis. Differentially ex-
pressed genes encoding secreted proteins were selected using Gene Ontology Classification. 
In addition to established secreted targets of PPARα such as ANGPTL4 and FGF21, expres-
sion of the gene encoding mannose-binding lectin (MBL2) was significantly upregulated 
by PPARα activation in all donors (Figure 1A). In fact, MBL2 represented the most highly 
induced gene encoding a secreted protein after Wy14643 incubation. MBL2 represents a 
soluble mediator of innate immunity that plays a critical role in innate immune protection 
against pathogens [15]. Other inflammation-related genes encoding secreted proteins that 
were induced by PPARα activation in primary human hepatocytes included CC chemokines 
CCL14, CCL15, and CCL16. Induction of MBL2 was confirmed by PCR and was already 
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observed after 6h of PPARα activation (Figure 1C). In contrast to human hepatocytes, incu-
bation of mouse hepatocytes with Wy14643 did not result in significant induction of MBL2 
(Figure 1B), which was confirmed by qPCR (Figure 1D). It should be emphasized that mouse 
expresses two MBL2 isomers: Mbl1 and Mbl2.
Induction of MBL2 by PPARα activation was reproduced in HepG2 cells. Treatment of the 
cells with Wy14643 and GW7647 significantly increased MBL2 gene expression levels (Fig-
ure 1E) as well secretion into the medium (Figure 1F). To investigate whether MBL2 expres-
sion may be regulated by PPARs in other tissues, we first screened a panel of organs for the 
presence of MBL2 mRNA. MBL2 expression was exclusive to liver among a panel of 20 
human tissues (Figure S1). Overall, these data demonstrate that MBL2 expression and secre-
tion are induced by PPARα in human liver. 
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Figure 1.  PPARα regulates MBL2 expression in human hepatocytes. A) Heat map illustrat-
ing the relative induction of genes encoding secreted proteins in response to 24h Wy14643 treatment 
in human hepatocytes. B) Relative changes in expression of the corresponding mouse orthologs in 
mouse hepatocytes. All genes were significantly changed (P<0.05) and were ranked based on mean 
fold-change (MFC). Expression levels in the DMSO-treated cells were set at 1. C) Relative induction 
of Mannose binding lectin (MBL2) by Wy14643 (50 µM) in human primary hepatocytes. D) Relative 
induction of Mannose binding lectin 1 (Mbl1) and Mannose binding lectin 2 (Mbl2) by Wy14643 (10 
µM) in mouse primary hepatocytes. E) Relative induction of  MBL2 by 6h Wy14643 (10 µM) and 
GW7647 (10 µM) in HepG2 cells. Expression of cells treated with DMSO was set at 1. Error bars 
represent SEM. F) MBL2 protein concentration in the serum free medium of HepG2 cells incubated 
24h in the presence or absence of Wy14643 and GW7647 as assessed by ELISA. Error bars represent 
SEM. ND (Not detected).
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Human MBL2 plasma levels are increased by fenofibrate
Our aim was to find novel circulating mediators of PPARα activity in human. Accordingly, 
we studied the effect of fasting, which leads to activation of hepatic PPARα [3], on plasma 
MBL2 levels. In line with published data, the inter-individual variation in baseline plasma 
MBL2 levels was very high. Although the number of subjects was limited, MBL2 consis-
tently went up upon fasting in all 4 subjects studied (Figure 2A) (P=0.05).
Next, we wanted to study the effect of PPARα activation by synthetic agonists.  To that end, 
we measured serum levels of MBL2 protein in 9 obese females with type 2 diabetes before 
and after three months of treatment with PPARα agonist fenofibrate (200 mg/day). In spite 
of the large inter-individual variation, fenofibrate raised serum MBL2 in all subjects, with a 
mean increase of 86% (P<0.05) (Figure 2B). 
To further substantiate this finding, we measured plasma MBL2 in 19 overweight subjects 
before and after 6 weeks of treatment with the PPARα agonist fenofibrate (200 mg/day). 
Again, fenofibrate raised plasma MBL2 in all subjects (Figure 3). The mean increase in 
plasma MBL2 was identical to the above mentioned study at 86% (P<0.001). The data show 
that circulating MBL2 levels are increased by PPARα activation in human. 
Other circulating targets of PPARα that are produced in liver and that exhibit an increase in 
plasma levels upon fibrate treatment are FGF21 and ANGPTL4 [18-21]. Indeed, we found 
a significant increase in plasma FGF21 (413%, P<0.001) and ANGPTL4 (69%, P<0.01) by 
6 week fenofibrate treatment in the 19 overweight subjects (Figure 3). To examine whether 
some individuals are generally more responsive to PPARα activation regardless of the target 
gene studied, we tested the correlation between the relative increase in plasma MBL2 and 
the relative increase in plasma FGF21 or ANGPTL4 upon fenofibrate treatment. No signifi-
cant correlations were observed (data not shown), arguing against the notion that individu-
als could be classified according to general PPARα responsiveness, at least on the basis of 
changes in plasma levels of PPARα targets. 
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Figure 2. Plasma levels of MBL2 are increased by fasting and fenofibrate treatment. (A) 
48h of fasting increased plasma MBL2 concentrations in 4 healthy males (P=0.05). (B) three months of 
fenofibrate treatment (200 mg/day micronized; Lipanthyl) significantly increased plasma MBL2 con-
centrations in 9 female subjects with type 2 diabetes mellitus (mean increase 86%, P<0.02). 
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Figure 3. Fenofibrate treatment increases plasma levels of MBL2, FGF21 and ANGPTL4. 
Six weeks of fenofibrate treatment (200 mg/day micronized; Lipanthyl) significantly increased plasma 
MBL2 (86%, P<0.001), FGF21 (413%, P<0.001) and ANGPTL4 (69%, P<0.01) concentrations in 19 
overweight subjects.
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Discussion
MBL2 is an important player in complement cascade activation as part of the first line host 
defense. In the present paper we show that: 1) MBL2 is a target gene of PPARα in human he-
patocytes and 2) plasma MBL2 levels are increased by chronic PPARα activation via fibrate 
drugs. MBL2 may thus represent a novel circulating mediator of PPARα action. 
MBL2 recognizes and binds to conserved carbohydrate structures present on the surface 
of microorganisms [9, 15]. MBL2 binding results in activation of the lectin pathway of the 
complement system by the action of MBL2-associated serine proteases (MASPs), which 
associate with circulating MBL2 in their inactive proenzymatic forms [22]. Alternatively, 
MBL2 acts as an opsonin, leading to stimulation of phagocytosis by binding to cell-surface 
receptors present on phagocytic cells. A wealth of data published in the past decade show that 
in addition to being a crucial regulator of hepatic lipid metabolism, PPARα also has a major 
impact on inflammatory pathway [23]. The pronounced induction of MBL2 by PPARα in 
human liver fits within the role of PPARα as important regulator of inflammation and innate 
immunity [24]. 
Currently, little is known about factors controlling plasma MBL2 levels. While MBL2 levels 
in serum are known to be largely determined by polymorphisms in the MBL2 gene, differ-
ences in plasma MBL2 of up to 10-fold can be found between individuals despite identical 
genotypes [25]. Also, little is known about regulation of MBL2 gene expression. The specific 
expression of MBL2 in liver has been suggested to be mediated by HNF3 based on the pres-
ence of specific response element in the MBL2 promoter and its ability to bind HNF3 in vitro 
[26]. However, extensive evidence for regulation of MBL2 by HNF3 is currently lacking. 
Clearly, regulation of MBL2 by PPARα does not exclude regulation by HNF3. 
Recently, evidence was provided that MBL2 may also be expressed in extra-hepatic tissues 
[27]. However, similar to our study, expression was so low that the functional relevance of 
extra-hepatically produced MBL2 may be questioned. 
In our study we surprisingly found that every subject that received fenofibrate exhibited an 
increase in plasma MBL2. Although baseline difference in plasma MBL2 are largely related 
to polymorphisms in the MBL2 gene, our data suggest part of the variation may be due to 
differences in PPARα activity and/or expression level. In this context, it is interesting to note 
that two other secreted proteins that were highly induced by PPARα activation in primary 
human hepatocytes, ANGPTL4 and FGF21, also show large inter-individual variations in 
their plasma level. Similar to MBL2, plasma levels of ANGPTL4 and FGF21 are increased 
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by treatment with PPARα agonist [18-21]. In the present study, no significant correlations 
were found between the relative increase in plasma MBL2 and the relative increase in plasma 
FGF21 or ANGPTL4 upon fenofibrate treatment. The data argue against the notion that indi-
viduals could be classified according to general PPARα responsiveness, at least on the basis 
of changes in plasma levels of PPARα targets. 
Our data indicate that PPARα is unable to induce MBL2 expression in mouse liver. Previ-
ously, several genes have been reported to be specifically regulated by PPARα in human, 
including ApoAI, ApoAII and ApoAIV [28]. For each of these genes the loss of regulation 
in mouse was related to lack of conservation of the functional PPREs. Since the PPRE(s) 
responsible for induction of MBL2 by PPARα remains elusive, it is impossible to determine 
whether a similar mechanism applies here.
MBL2 is known to be under a tight physiological regulatory system, which is evident by its 
stable circulating profiles in healthy individuals, independent of age, gender, time, physical 
exercise [29]. Alterations in MBL2 levels in disease states have been suggested to be partly 
caused by hormonal changes. A limited number of clinical trials have shown an  stimula-
tory effect of growth hormone and thyroid hormones on MBL2 levels [30, 31], which was 
reproduced in hepatocytes cell lines [32]. Preliminary data from our group show that plasma 
MBL2 levels are reduced by insulin in healthy subjects, but not in patients with type 2 diabe-
tes. The inhibitory effect of insulin on plasma MBL2 is in agreement with a previous study 
that reported higher MBL2 levels in patients with insulin-dependent type 1 diabetes [33]. 
Regulation of MBL2 by PPARα and by various metabolically active hormones suggests that 
MBL2 may play a role in regulation of energy metabolism, although additional research is 
needed.
In conclusion, our data point to MBL2 as potential circulating mediator of PPARα activity 
in human. Future studies should investigate a possible role for MBL2 in regulation of energy 
metabolism. 
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Figure S1.  MBL2 is expressed specifically in human liver. mRNA expression of MBL2 was 
determined in human tissues by Q-PCR. Human RNA represented a mix from several individuals (AM-
BION, First choice human total RNA). Expression levels were related to the liver which was the tissue 
showing highest expression.
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Figure S2.  Insulin suppresses MBL2 plasma concentration. 
Changes of MBL2 concentrations before and after 180 minutes of isoglycemic-hyperinsulinemic clamp 
in a group of 6 healthy controls and nine T2DM patients (A). Mean concentration of plasma MB2 levels 
of the controls and patients before and after 180 minutes of isoglycemic-hyperinsulinemic clamp (B). 
Error bars represent SEM. Quantification assessed by using MBL Oligomer ELISA kit.
155
Supplemental methods
Subjects
Subjects with a BMI of at least 27 kg/m2 were recruited via posters in the university and hos-
pital buildings and via advertisements in local newspapers. Subjects came to the university 
for a screening visit. On this visit, fasting blood was sampled for analyses of serum lipids and 
lipoproteins. In addition, height and body weight were determined. Furthermore, subjects 
had to complete a medical and general questionnaire. Exclusion criteria were BMI below 27 
kg/m2, impairment of kidney and liver function, serum total cholesterol above 8 mmol/L, 
serum triglycerides above 4 mmol/L, taking medication that could influence the study out-
come or could interfere with fenofibrate treatment, use of fish oil supplements, consumption 
of plant sterol or stanol-enriched food products, having donated blood within 1 month prior 
to the start of the study, having a diagnosis of any long-term medical condition (e.g. diabetes, 
cardiovascular diseases, epilepsy) or experiencing strong symptoms of allergy. After screen-
ing, twenty-six subjects met all our inclusion criteria and started this study. Subjects received 
oral and written information about the nature and risk of the experimental procedures before 
their written informed consent before the start of the study. The study was approved by the 
Medical Ethical Committee of Maastricht University. 
After inclusion of 26 subjects, 6 subjects dropped out and were not included in the analysis 
(1 man underwent surgery for an aneurism, 1 woman had complained about vapours during 
the placebo period, 1 man and 1 woman did not regularly attend appointments and were 
excluded, 1 man had a work-related reason, and 1 man had personal reasons). Ten men and 
ten women completed the trial. Subjects were 52 ± 12 y (mean ± SD), with a bodyweight of 
98 ± 19 kg for men and 95 ± 20 kg for women, a BMI of 31 ± 5 kg/m2 for men and 34 ± 5 
kg/m2 for women, and a waist circumference of 118 ± 13 cm for men and 116 ± 11 cm for 
women. Serum concentrations of total cholesterol were 6.23 ± 1.18 mmol/L, of LDL cho-
lesterol 3.97 ± 1.09 mmol/L, of HDL cholesterol 1.52 ± 0.44 mmol/L, of triglycerides 1.63 
± 0.59 mmol/L, and of glucose 5.34 ± 0.73 mmol/L. Systolic blood pressure was 131 ± 14 
mmHg and diastolic pressure was 91 ± 8 mmHg. Four subjects smoked. According to the 
National Cholesterol Education Program Adult Treatment Panel III guidelines to diagnose 
the metabolic syndrome, subjects had on average 2.2 ± 1 criteria of the metabolic syndrome 
and 7 out of 20 subjects could be diagnosed as having the metabolic syndrome. 
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Study design
The study had a randomized, double-blind, placebo-controlled, crossover design. Each sub-
ject enrolled in random order in a fish oil, a fenofibrate and a placebo period for 6 weeks with 
a wash-out period of at least 2 weeks between the intervention periods. During the fish oil 
intervention, subjects had to consume 8 fish oil capsules (Marinol C-38™, Lipid Nutrition, 
Wormerveer, the Netherlands), providing approximately 3.7 g/d n-3 LCPUFA (1.7 g/d EPA 
and 1.2 g/d DHA, corresponding to 160-240 g fatty fish/d), together with 2 capsules placebo-
matching fenofibrate (200 mg/d cellulose). During the fenofibrate period, subjects consumed 
2 capsules providing 200 mg/d micronized fenofibrate (Lipanthyl®, Fournier Laboratories, 
Dijon, France), together with 8 placebo-matching fish oil capsules (containing 80% High 
Oleic Sunflower Oil (HOSO)). During the placebo period, subjects received 8 HOSO capsules 
together with 2 cellulose capsules. Subjects were instructed to ingest half of the capsules be-
fore breakfast and the other half before dinner with a glass of water. Subjects were restricted 
in their fish consumption to a maximum of one portion a week. During the study, subjects 
recorded any symptom of illness, visits to physician, medication used, alcohol consumption, 
and any deviations from the protocol in diaries. Body weight was recorded at weeks 0, 5 and 
6 of each intervention period and blood pressure was monitored using a sphygmomanometer 
(Omron M7, CEMEX Medische Techniek BV, Nieuwegein, the Netherlands). At the end of 
the three intervention periods, energy and nutrient intakes were estimated for the previous 4 
weeks using a food frequency questionnaire (FFQ). 
Blood sampling
In week 5 and week 6 of each intervention period, subjects arrived in the morning after an 
overnight fast and after abstinence from drinking alcohol the preceding day. Venous blood
samples were collected in BD vacutainer® tubes (Becton Dickinson Company, NJ, USA). 
Serum was obtained by clotting the blood for 30 minutes, followed by 30 min centrifugation 
at 2000xg. EDTA, NaF and heparin plasma were obtained by centrifugation at 2000xg for 
30 minutes at 4°C, directly after sampling. Serum and plasma aliquots were snap frozen and 
stored at -80 °C until analysis.
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Clinical safety parameters
Serum concentrations of markers of liver and kidney function (total bilirubin, asparagine 
aminotransferase (ASAT), alanine-aminotransferase (ALAT), alkaline phosphatase (ALP), 
γ-glutamyl transpeptidase (γ-GT), ureum, and creatinine) from week 6 of each intervention 
period were determined at the department of Clinical Chemistry, University Hospital Maas-
tricht (Beckman Synchron CX7 Clinical systems, Beckman).
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Abstract
PPARα is an important transcriptional regulator of hepatic lipid metabolism. Most of the 
research on PPARα in liver has been carried out in mice or using hepatocyte cell lines. How-
ever, to what extent results from cell lines properly reflect the function of PPARα remains to 
be established. The aim of the present study was to compare the transcriptional response to 
PPARα activation between HepG2 and primary human hepatocytes, the latter being consid-
ered as the gold standard. Our transcriptomics analysis reveals that the response to PPARα 
agonist is remarkably dissimilar between HepG2 cells and primary human hepatocytes. While 
expression of many established PPARα targets shows significant induction by PPARα activa-
tion in primary hepatocytes, this is much less the case in HepG2 cells which are characterized 
by marginal induction of a limited number of PPARα targets. This set of PPARα targets in-
clude CYP1A1, CPT1A, ADFP, and TRIB3. Instead, PPARα activation in HepG2 cells leads 
to induction of stress response pathways. In conclusion, our results show that HepG2 cells 
relatively poorly reflect the established function of PPARα in lipid metabolism, in contrast to 
primary human hepatocytes. Accordingly, with respect to PPARα function, caution should be 
exercised when extrapolating data from HepG2 cells to human liver.
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Introduction
Peroxisome proliferators activated receptors (PPARs) are ligand inducible nuclear recep-
tors that play a major role in the regulation of cellular energy homeostasis. Three PPARs 
have been identified: PPARα (NR1C1), PPARb/d (NR1C2) and PPARg (NR1C3). PPARs are 
activated by fatty acids and fatty acid derivates, as well as by a diverse group of synthetic 
compounds [1-3]. PPARα is well expressed in liver and other tissues with a high rate of fatty 
acid catabolism such as heart and skeletal muscle [4] and regulates the transcription of nu-
merous genes involved in fatty acid oxidation, fatty acid uptake and transport, ketogenesis, 
gluconeogenesis, amino acid metabolism and inflammation. Compared to PPARα, PPARβ/δ 
is expressed in a broader rage of tissue including brain, small intestine, heart, skeletal muscle, 
adipose and skin tissue [5-7]. Recent studies have linked PPARβ/δ to regulation of glucose 
homeostasis, fatty acid metabolism, wound healing, and inflammation [8-11]. The third iso-
type, PPARγ, is highly expressed in adipose tissue where it is involved in adipose cell dif-
ferentiation and lipid storage [12]. In contrast to the classical steroid receptors, PPARs form 
heterodimers with another nuclear receptor named Retinoid X Receptor (RXR). According 
to the traditional view, target genes of PPARs are characterized by a PPAR responsive ele-
ment (PPRE) in their promoter region that is capable of binding to PPAR/RXR heterodimers. 
However, recent studies suggest that many PPAR binding sites are located distant from the 
transcription start site and that regulation may be conferred by DNA looping [13, 14]. Upon 
ligand binding to PPAR, a conformational change of the receptor results in the dissociation of 
corepressor proteins and the binding of several coactivator proteins which ultimately results 
in initiation of transcription of a target gene [15].  
Because PPARα is expressed at high level in liver, lots of research has been carried out on the 
role of PPARα in the liver. Many of these studies have made use of mouse models due to the 
relative ease to obtain whole liver tissue directly from mice as well as the possibility to per-
form in vivo gene targeting. However the obvious drawback of rodent models are differences 
in the regulation of biological processes between rodents and human. Consequently, extrapo-
lation of data from rodent models to the human situation can be problematic. For example, 
the hepatomegaly and peroxisome proliferation observed in response to PPARα activation 
in mouse and rat is not observed in human cells [16]. However, in contrast to mouse tissue, 
whole human liver tissue and primary human hepatocytes are not widely available and are 
expensive, thereby limiting their use. Instead, much research is performed using liver derived 
and immortalized cell-lines such as the hepatoma derived cell-line HepG2. Several studies 
have used this cell line to investigate the role of PPARα in human liver cells [17-21]. HepG2 
cells are derived from a hepatoma in 15 year old Caucasian male [22]. The advantage of this 
immortalized cell line is the almost unlimited availability and reduced variability compared 
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to donor-derived primary hepatocytes. However, differences in this cell line in comparison 
to primary hepatocytes would be expected due to its transformation from a differentiated and 
low proliferating hepatocyte to a highly proliferating cancer cell line. Previous studies com-
paring the two cell systems have mainly been focused on the difference in responsiveness 
to toxicological stimuli and biotransformation in the two cell types [23-30]. Furthermore, 
previous studies addressed differences in basal gene expression profiles between HepG2 cells 
and primary hepatocytes using microarray technology [31, 32]. These studies show altera-
tions in gene expression in HepG2 cells that are related to its transformation to a cancer cell 
line, which includes genes involved in cell cycle and check-point control as well as genes 
involved in cell death, lipid metabolism, transport and xenobiotic metabolism. Surprisingly, 
Harris et al. also reported loss of gene expression of several genes in primary hepatocytes 
that were actually expressed in whole liver and HepG2 cells, suggesting that is some cases 
HepG2 cells would be a preferred human liver cell model. To date, no systematic effort has 
been performed comparing the transcriptional response to PPARα activation in HepG2 cells 
and human primary hepatocytes. 
 
Material and methods
Cell culture. HepG2 cells were grown in phenol red free Dulbecco’s modified medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), glutamate and antibiotics. Cells 
were kept at 37 °C and 5% CO2. Cells were split the day before experiments. Human hepa-
tocytes and Hepatocyte Culture Medium Bulletkit were purchased from Lonza Bioscience 
(Verviers, Belgium). Primary hepatocytes were isolated from surgical liver biopsies obtained 
from six individual donors who underwent surgery after informed consent was obtained. 
Hepatocytes were isolated with two-step collagenase perfusion method and the viability of 
the cells was over 80%. Cells were plated on collagen-coated six-well plates and filled with 
maintenance medium. Upon arrival of the cells, the medium was discarded and was replaced 
by Hepatocyte Culture Medium (HCM) with additives. Additives included Gentamicin sul-
phate/Amphotercin-B, Bovine serum albumin (Fatty acid free), Transferrin, Ascorbic acid, 
Insulin, Epidermal growth factor, Hydrocortisone hemisuccinate..
Transcriptomics. Total RNA was extracted from either HepG2 cells or primary hepatocytes 
with TRIzol reagent (Invitrogen) and subsequently purified using the SV Total RNA Isola-
tion System (Promega). RNA quality was measured on an Agilent 2100 bioanalyzer (Agi-
lent Technologies) using 6000 Nano Chips according to manufacturer’s instructions. RNA 
was judged as suitable for array hybridization only when samples showed intact bands cor-
responding to the 18S and 28S rRNA subunits, displayed no chromosomal peaks or RNA 
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degradation products and had a RNA integrity number (RIN) above 8.0. Five micrograms 
of RNA were used for one cycle cRNA synthesis (Affymetrix). Hybridization, washing and 
scanning of Affymetrix human genome 133 2.0 plus arrays was carried out according to stan-
dard Affymetrix protocols. Scans of the Affymetrix arrays were processed using packages 
from the R/Bioconductor project. Arrays were normalized with quantile normalization and 
expression levels of probe sets were calculated using the Robust Multichip Average (RMA) 
method. Differentially expressed probe sets were identified using IBMT and genes were con-
sidered to be significantly changed when raw q-values were smaller the 0.05 and fold-change 
was above 1.2 or below -1.2. 
Comparative analysis. To compare the number of genes regulated in HepG2 cells as well as 
the number of cells in primary hepatocytes a venn diagram was created with venny (http://
bioinfogp.cnb.csic.es/tools/venny/index.html). Scatterplots were made by plotting all expres-
sion values of both cell types with the use of the SPSS statistical program. For comparison of 
the top 50 upregulated genes between HepG2 cells and primary hepatocytes, heatmaps were 
created based on fold changes with the use of Microsoft Excel. PCA scores were obtained 
from all expression values taken from the arrays of both HepG2 cells and primary hepato-
cytes with the use of R package FectoMiner.  Obtained PCA scores were plotted using SPSS. 
To define significant difference between cell groups a one-way ANOVA combined with a 
Tukey post hoc analysis  was performed. 
Biological characterization. To characterize genes according to their biological function a 
Gene Set Enrichment Analysis (GSEA) was performed. As a cut off for enriched  gene sets 
the FDR-q value was set at <0.25. Enriched gene sets were ordered according to their normal-
ized enrichment score (NES).  
Results
To compare PPARα induced gene expression in HepG2 cells and primary human hepatocytes, 
cells were treated with PPARα agonist for 6 or 24 hours and changes in gene expression ana-
lyzed by microarray. A  fold-change threshold of 1.2 and a minimal q-value of 0.05 was used. 
The lower-fold change threshold was chosen due to the limited magnitude of gene induction 
by PPARα agonists in human hepatocytes and HepG2 cells. After 6 hours of agonist treat-
ment, 339 genes were upregulated and 282 genes downregulated in HepG2 cells, compared 
to 144 genes upregulated and 73 genes downregulated in primary human hepatocytes (Figure 
1). The difference in number of genes regulated between the two cell systems was even more 
pronounced after 24 hour agonist treatment.
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Figure 1: Expressional changes in HepG2 cells and primary hepatocytes upon PPARα 
activation. Bars indicate total genes regulated at either 6 hours or 24 hours of PPARα agonist treat-
ment with the upper part representing the number of upregulated genes and the bottom part the number 
of downregulated genes. Genes were considered significantly changed when fold changes were >1.2 for 
upregulated genes and <-1.2 for downregulated genes as well as a q-value <0.05.
To further study the response to PPARα activation in HepG2 cells and primary hepatocytes, 
the overlap in gene regulation between the two cell systems was analyzed. As shown in Fig-
ure 2, 20 and 34 genes were commonly upregulated in both cell types after 6 hours and 24 
hour of agonist treatment, respectively. These numbers represent 13.8% and 20.5% of the to-
tal number of genes upregulated in primary hepatocytes, but only 5.9% and 4.6% of the total 
number of genes upregulated in HepG2 cells after 6 hours and 24 hours of PPARα activation, 
respectively. Even less overlap was observed when examining the genes downregulated upon 
agonist treatment.
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Figure 2: Overlap between differential regulated genes in HepG2 cells and primary he-
patocytes. Venn diagrams represent overlap between either the upregulated genes or downregulated 
genes in HepG2 cells and primary hepatocytes. 
To globally compare the gene expression profiles in both cell types, we performed principal 
component analysis (PCA) on the expression values of all genes after 6 or 24 hours agonist 
treatment. As shown in Figure 3, principal component 1 (PC1) explains 79.8% and 78.5% of 
the variation in gene expression at 6 and 24 hours, respectively. PC1 scores for all primary 
hepatocyte samples are not significantly different. Similarly we observed grouping of PC1 
scores for all HepG2 samples without any significant changes between the HepG2 samples. 
However, comparing the PC1 scores of the two cell types shows a significant difference be-
tween the cell types, indicating that PC1 explains significant variation between the general 
expression profiles of the two cell types. Furthermore, we observed significant separation of 
donor 5 and 6 in principal component 2 (PC2), indicating a general expression profile that 
is weakly different from the other four donors explained by PC2. Interestingly, these two 
donors are the two oldest male donors. PC1 and PC2 did not explain any significant variation 
caused by PPARα agonist treatment in either cell type when analyzing all expression data of 
both cell types together.
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Figure 3: Principal component analysis of genes expressed in HepG2 cells and primary 
hepatocytes. Principal component (PC) 1 and 2 represent the variation found between the samples 
after either 6 hours or 24 hours PPARα activation. 
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To further compare changes in gene expression upon PPARα activation between HepG2 cells 
and primary hepatocytes, changes in gene expression for all genes on the array were plotted 
in a scatter diagram (Figure 4). The results show that with the exception of a few genes (e.g. 
KLF10, CYP1A1, ADFP), the majority of genes regulated were regulated specifically in one 
of the cell types. Genes encoding for metallothioneins were specifically regulated in HepG2 
cells. In contrast, many well described PPARα target genes, including PDK4, ANGPTL4 and 
FABP1 [33-36], were regulated specifically in human primary hepatocytes.
To further analyze similarities in gene regulation between the two cell types, we selected 
the top 50 upregulated genes in HepG2 cells and show the corresponding changes in gene 
expression in primary hepatocytes. Conversely, we selected the top 50 upregulated genes in 
primary hepatocytes and show the corresponding changes in gene expression in HepG2 cells 
(Figure 5). The top 50 genes induced in HepG2 cells show a consistent response between the 
three replicates. Among the genes responding most strongly are several genes coding for met-
allothioneins, which do not show any changes in primary hepatocytes. Similar to the scatter 
diagram, the results show that very few genes induced by PPARα agonist treatment in pri-
mary hepatocytes are also regulated in HepG2. Furthermore, the top 50 upregulated genes in 
HepG2 very poorly reflects the known role of PPARα in lipid metabolism and instead points 
towards induction of cellular stress response. In contrast, in primary hepatocytes a large 
number of genes within the top 50 of upregulated genes are involved in lipid metabolism and 
represent established PPARα targets. These include ANGPTL4, FABP1, PCK1, HMGCS2, 
S25A20, ACSL3, CPT2 and several others. These various types of analyses indicate a poor 
match between the effect of PPARα activation between primary hepatocytes and HepG2 
cells. Overall, the observed changes in gene expression in HepG2 very poorly resemble the 
role of PPARα in lipid metabolism, and mostly points towards induction of cellular stress 
response. The set of genes robustly induced in both cell types was limited to VLDLR, ADFP, 
CYP1A1, CPT1A, KLF10 and LOC55908. 
These data suggest that HepG2 cells are an inferior model to study PPARα dependent gene 
regulation, especially in relation to its role in lipid metabolism. 
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Figure 4: Global gene expression comparison in HepG2 cells and primary hepatocytes 
upon PPARα activation. All expression values of all genes were plotted in scatter diagram based on 
fold change after PPARα activation. Selected PPARα target genes are indicated as well as some metal-
lothionins specifically regulated in HepG2 cells.
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Figure 5A: Heatmaps representing top 50 regulated genes in HepG2 cells and primary 
hepatocytes after PPARα agonist treatment. (A) Top 50 significantly upregulated genes in 
HepG2 cells were compared with expressional change of the corresponding gene in primary hepato-
cytes. Genes were considered upregulated when fold change >1.2 and q-value was <0.05.
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Figure 5B: Heatmaps representing top 50 regulated genes in HepG2 cells and primary 
hepatocytes after PPARα agonist treatment. (B) Top 50 genes changed in primary hepatocytes 
were compared to the corresponding gene change in HepG2 cells. Genes were considered upregulated 
when fold change >1.2 and q-value was <0.05.
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Biological classification
The biological classification of genes specifically upregulated or downregulated in either 
HepG2 cells or primary hepatocytes, or commonly regulated in both cell types was inves-
tigated using Gene Set Enrichment Analysis (GSEA). A global comparison of biological 
processes regulated in HepG2 cells and primary hepatocytes showed a rather low number 
of commonly up regulated pathways in the two cell types after 6 hours agonist but slightly a 
better overlap was found after 24 hours agonist (Figure 6A). The biological process enriched 
by PPARα agonist in both cell types belonged to the classical PPARα-dependent pathway 
involved in fatty acid beta oxidation. Additional enrichment of PPARα related pathways was 
found among the biological processes specifically enriched in primary hepatocytes (Figure 
6B). In contrast, pathways exclusively upregulated by PPARα agonist in HepG2 cells were 
related to steroid/sterol metabolism (6 hours). Interestingly, the amino acid degradation path-
way of valine and (iso)leucine was upregulated in both cell types after 24 hours PPARα 
agonist treatment. Previously, amino acid metabolism was shown to be downregulated by 
PPARα in mouse liver [37]. A similar analysis was performed on genes downregulated after 
6 and 24 hours of PPARα stimulation. After 24 hours of agonist treatment no pathways were 
commonly downregulated in both cell types (Figure 6A), which is consistent with the mini-
mal overlap observed at the individual gene level (Figure 2). Consistent with the known sup-
pressive effect of PPARα on inflammation, inflammatory pathways, such as the chemokine 
and interleukine pathways were downregulated by PPARα agonist in both primary hepato-
cytes and HepG2 cells after 6 hours PPARα activation (data not shown).
To further explore differences in gene regulation between HepG2 and primary hepatocytes, 
we compared the expression of several nuclear receptors and co-activator proteins under 
basal condition. As shown in Figure 7, the expression of most nuclear receptors was not very 
different between the two cell types.  However, the nuclear receptors HNF4A, PPARα and 
RXRα were more highly expressed in HepG2 cells compared to primary hepatocytes. These 
data suggest that the minor effect of PPARα agonist in HepG2 cells on established PPARα 
targets and pathways is not related to low PPARα expression. Additionally, we compared 
the expression of several coactivators known to be involved in the PPARα dependent gene 
regulation (Figure 7). Whereas MED1, SRC3 and PRIP were much more highly expressed 
in HepG2 cells, CITED2 and PCAF were much more highly expression in primary hepato-
cytes.  
Comparative microarray analysis of PPARα induced gene expression
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Figure 6: Biological classification of genes regulated in HepG2 cells and primary he-
patocytes upon PPARα induction. (A) Regulated genes in primary hepatocytes and HepG2 cells 
were classified based on biological function using Geneset Enrichment Analysis (GSEA) and com-
pared. Pathways with a FDR-q value below 0.25 were considered enriched. (B) All biological pathways 
enriched after 6 hours PPARα agonist treatment in HepG2 cells and primary hepatocytes. Pathways 
are ordered by normalized enrichment score (NES). Pathways enriched in both cell types are indicated 
(bold).
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Figure 7: Basal expression of selected nuclear receptors and coactivators. 
(A) Basal expression of nuclear receptors in HepG2 cells an primary hepatocytes are compared. (B) 
Expression values of selected coactivators known to be involved in PPARα signaling were compared at 
basal conditions in HepG2 cells and primary hepatocytes.
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Discussion
Most of the research on PPARα in liver has been carried out in mice or using hepatocyte cell 
lines. Previously, we addressed the similarities in response to PPARα activation between 
human and mouse primary hepatocytes [38]. Here, we concentrate our analysis on the most 
widely used liver cell line, which is the hepatocarcinoma-derived cell line HepG2. Since 
cell lines often lose functional properties compared to the tissue from which they were de-
rived from, it is important to investigate the suitability of these cell lines to study PPARα-
dependent gene regulation. Overall, our data indicate that care should be taken in the use of 
HepG2 as a model to study PPARα function in human liver. 
Basal differences in gene expression between HepG2 cells and primary hepatocytes have 
been previously studied using microarrays [31, 32]. It was found that 31% of the genes ex-
pressed in HepG2 cells are specific for this cell type, which included genes involved in path-
ways that are expected to be activated in an immortalized cell line such as cell cycle control, 
oncogenes and tumor suppressor genes. Similarily, Ligoru et al. found 4306 genes to be dif-
ferentially expressed between HepG2 cells and primary hepatocytes under basal conditions. 
Again, several of these genes are involved in cell cycle regulation and checkpoint control. 
Surprisingly, Harris et al. found several genes to be similarly expressed in HepG2 and whole 
liver, but diminished in primary hepatocytes, indicating that primary hepatocytes may not 
always reflect the in vivo situation better compared to HepG2 cells. 
One previous report compared the transcriptional changes upon PPARα stimulation in HepG2 
cells to a rat cell line (FAO) using microarray technology [39]. Very minor overlap in PPARα-
dependent gene regulation was observed between the two cell lines. Furthermore, very few 
genes involved in lipid metabolism were induced by PPARα activation in HepG2 cells. Re-
markably, we could discern little overlap between genes regulated by PPARα in HepG2 cells 
in our study and in the abovementioned report. One possible reason may be differences in the 
properties of the HepG2 cells used as well as differences in culture conditions.  
Our data show that the total number of genes regulated by PPARα agonist in HepG2 cells 
markedly exceeded the number in primary hepatocytes. One likely reason is that HepG2 
cells are a lot more homogenous and consequently the response to PPARα activation is less 
variable and thus more likely to be statistically significant. Indeed, the overall magnitude of 
fold changes in expression were not noticeably different between the two cell types. How-
ever, the changes in gene expression upon PPARα activation in HepG2 cells poorly reflect 
the established function of PPARα in lipid metabolism. In contrast to primary hepatocytes, 
only a limited number of known PPARα targets were induced by PPARα agonist in HepG2 
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cells, which included CPT1A, ADFP, and TRIB3 [40]. Instead, treatment of HepG2 cells 
with PPARα agonist induced the expression of numerous genes involved in stress response 
pathways including various metallothioneins and DDIT4.
Numerous explanations may account for the differential response to PPARα activation be-
tween HepG2 cells and primary hepatocytes. Although HepG2 cells and primary hepatocytes 
were grown in different culture medium, it is unlikely that this would account for the vast 
difference in response to PPARα activation. One possibility is that genome accessibility is 
altered in cancer derived cell lines such as HepG2, resulting in a differential response to 
PPARα activation. Another explanation relates to differences in overall coactivator expres-
sion between the cell types. For instance, expression of  CITED2 and PCAF was significantly 
higher in primary hepatocytes compared to HepG2 cells. Contrary to our expectation, expres-
sion of PPARα itself was higher in HepG2 cells. Finally, individual genes may respond less 
in HepG2 cells because of mutations in the promoter region. For instance, the PPARα target 
gene PDK4 shows decreased basal expression in HepG2 cells because of a mutation in either 
a SP1 or CBF binding site within its promotor [41], which may account for the lack of induc-
tion of PDK4 upon PPARα activation.
With respect to downregulation of gene expression by PPARα, which has been much less 
explored mechanistically but likely accounts for a major portion of PPARα action, we found 
downregulation of several genes involved in acute inflammation pathways in HepG2 cells 
and primary hepatocytes after 6 hours of PPARα activation. Previously, studies in intact 
mouse models have indicated a major role for PPARα in governing hepatic and vascular 
inflammation [4, 42]. 
In conclusion, our results show that HepG2 cells relatively poorly reflect the established 
function of PPARα in lipid metabolism, in contrast to primary human hepatocytes. Accord-
ingly, with respect to PPARα function, caution should be exercised when extrapolating data 
from HepG2 cells to human liver.
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Abstract
The liver is the site of expression of a very dynamic transcriptional regulatory network that 
plays a key role in the regulation of lipid metabolism. One of the important transcription 
factors in liver is PPARα, which has been identified as a master regulator of hepatic lipid 
metabolism. The aim of the present study was to better understand the regulatory role of 
PPARα in liver by identifying potential novel target genes of PPARα. To this aim, we treated 
primary mouse and human hepatocytes with the PPARα agonist Wy14643 and screened the 
top differentially expressed genes for novel PPARα target genes. 
We found KLF11 and KLF10 to be significantly upregulated by PPARα activation in both 
mouse and human hepatocytes, suggesting they may be novel PPARα target genes. We could 
further confirm their PPARα-dependent induction in the liver of mice treated with PPARα 
agonists. Next, we set up a preliminary in vitro transfection study in which we tried to char-
acterize KLF11 and KLF10 target genes in mouse primary hepatocytes. 
Our data suggest that KLF11 overexpression may have an inhibitory effect on PPARα gene 
expression. We also observed the downregulation of genes related to lipogenesis. Despite 
successfully overexpressing KLF11 and KLF10 in mouse liver using hyperdynamic tail vein 
injection of naked plasmids, we did not find any significant effects on PPARα gene expres-
sion level. The data suggest interaction between PPARα, KLF11 and KLF10. Additional 
experiments need to be carried to investigate this interaction in more detail.  
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Introduction
The liver is a central regulator of nutrient homeostasis. This regulatory effect is largely 
achieved via a very dynamic transcriptional regulatory network that modulates genes in-
volved in different biological pathways. Thus, the liver is as an interesting therapeutic target 
for the prevention of chronic diseases such as diabetes and cardiovascular disease. A key 
characterized transcription factor in liver is the peroxisome proliferator activated receptor α 
(PPARα). PPARα belongs to the nuclear hormone receptor superfamily and has been identi-
fied as a master regulator of lipid metabolism in liver [1-4]. Lack of PPARα in mice leads 
to acute energy shortage in liver upon fasting and is characterized by defective ketone body 
formation, hypoglycemia, elevated plasma free fatty acids, and severe hepatic steatosis [5, 6]. 
In addition, PPARα has been shown to govern glucose metabolism, lipoprotein metabolism, 
amino acid metabolism, liver inflammation and hepatocyte proliferation (rodent specific). 
In clinical practice PPARα is the target of hypolipidemic fibrate class of drugs that lower 
plasma triglycerides and elevates plasma HDL (high-density lipoprotein) levels [1, 3, 7-9]. 
Therefore, PPARα target genes has been extensively studied in past years and there is still a 
lot interest in characterizing potential new PPARα-regulated genes. 
Krüppel like factors (KLFs) are another family of transcription factors expressed in liver and 
many other tissues [10-13]. KLFs are members of Sp1-like transcription factor family with 
three conserved DNA binding zinc finger domains in their C-terminal region and variant 
N-terminal domains. KLF proteins bind to GC box or CACCC boxes of genes involved in 
key biological cellular functions including cell proliferation, differentiation and apoptosis. 
KLF10 [14, 15] and KLF11 [16] are characterized by the existence of three repressor do-
mains (R1, R2, R3) [17] as a common structural feature which can interact with corepres-
sors such as SID or SID/R1 [18]. They are alternatively called TIEG1 (KLF10) and TIEG2 
(KLF11) since they are induced early in response to TGF-ß [14]. Studies in pancreas acinar 
cell-specific KLF11 transgenic mice have shown that KLF11 overproduction negatively reg-
ulates exocrine pancreas cell proliferation [19]. The role of KLF11 in endocrine pancreas has 
been established by Neve et al. who showed that KLF11 expression in a pancreatic beta cell 
line is increased in response to high glucose levels and plays a role in insulin secretion [20]. 
Moreover, KLF11 and KLF10 gene variants have been shown to be involved in genetic sus-
ceptibility to type 2 diabetes [20, 21]. Despite their significant expression in liver, not much 
its known about their regulatory mechanisms and metabolic role in liver.
                                                                                                                 
The aim of the present study was to better understand the regulatory role of PPARα in liver 
by identifying its potential novel target genes that can further characterize PPARα function. 
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Here we show that KLF11 and KLF10 are possibly novel PPARα-regulated genes in liver. We 
further tried to characterize their physiological role in liver by utilization of in vitro transfec-
tion assays and in vivo delivery of naked plasmids. Our preliminary in vitro data suggest that 
KLF11 could have inhibitory effect on PPARα expression. We also observed the downregula-
tion of lipogenesis-related genes by KLF11 overexpression. These interesting findings needs 
to be further evaluated in complementary experiments.
Methods and materials
Materials. Wy14643 and Fenofibrate were obtained from ChemSyn Laboratories (Lenexa, 
KS). SYBR Green was from Eurogentec (Seraing, Belgium). 
Fetal calf serum, penicillin/streptomycin/fungizone were from Lonza Bioscience (Verviers, 
Belgium). KLF11 and KLF10 transfection ready full length cDNA clones were obtained 
from Sanbio, BV (Uden, The Netherlands). pEGFP-N2 expression vector was in the stock. 
Effectene® reagents and Maxi Prep kit were from Qiagen (Hilden, Germany). Otherwise, 
chemicals were from Sigma (Zwijndrecht, The Netherlands).     
                                                                         
Primary hepatocytes isolation. Mouse hepatocytes were isolated as described previously 
from 6 different strains of mouse: NMRI, SV129, FVB, DBA, BALB/C and C57BL/6J [22]. 
Cells were incubated in fresh medium in the presence or absence of Wy14643 (10 µM) dis-
solved in DMSO for 6 hours, followed by RNA isolation. Isolation of mouse primary hepato-
cytes was approved by the animal ethics committee of Wageningen University.
Human primary hepatocytes from 6 donors were purchased from Lonza Bioscience (Verviers, 
Belgium). Details of isolation and procedure are described in a previous publication [22]. 
Cells were isolated from surgical liver biopsies by two-step collagenase perfusion method 
and incubated in the presence or absence of Wy14643 (50 µM) dissolved in DMSO for 6 
hours, followed by RNA isolation. 
Affymetrix microarray analysis. RNA isolation and subsequent processing for microarray 
were carried out as previously described [22]. Hybridization, washing and scanning of Af-
fymetrix mouse genome 430 2.0 arrays and Gene chip human genome U133 2.0 plus was ac-
cording to standard Affymetrix protocols. Analysis of the microarray data was as previously 
described [22]. 
Real time quantitative PCR. 1 µg of total RNA was used for reverse-transcription with iScript 
(Bio-Rad, Veenendaal, the Netherlands). PCR was performed with Platinum Taq DNA poly-
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merase (Invitrogen) on a Bio-Rad iCycler or MyIQ PCR machine. Specificity of the amplifi-
cation was verified by melt curve analysis and evaluation of efficiency of PCR amplification. 
The sequence of primers used are listed in table 1. For determination of tissue expression of 
mKLF11 and mKLF10, RNA came from one healthy female adult mouse (strain FVB). Hu-
man RNA represented a mix from several individuals (AMBION, First choice human total 
RNA).
Animal experiments. Male SV129 PPARα-/- mice and corresponding Wt mice (2-6 months 
of age) were purchased at the Jackson Laboratory (Bar Harbor, Maine, USA). The animals 
were switched to a run-in diet consisting of a modified AIN76A diet (corn oil was replaced by 
olive oil) (Research Diet Services, Wijk bij Duurstede, the Netherlands), two weeks before 
start of the experiment. The animals were fasted 4 hours (starting at 5 a.m.) before receiving 
an oral gavage of  WY14643 and Fenofibrate (400 µl of 10 mg/ml WY14643 or Fenofibrate 
dissolved in 0.5% carboxymethylcellulose). Six hours after the gavage, mice (4 to 5 mice 
per group) were sacrificed. For the fasting experiment, animals (3-5 months of age) were 
rather fed a normal laboratory chow diet (RMH-B diet, Arie Blok animal feed, Woerden, the 
Netherlands) or fasted for 24 hours starting at the onset of the light cycle (n = 4-5 per group). 
Livers were removed and directly frozen into liquid nitrogen and stored at -80ºC.  
The animal experiments were approved by the Local Committee for Care and Use of labora-
tory Animals at Wageningen University.
Cell culture and transfections. Primary mouse hepatocytes were isolated from SV129 male 
mice (4-5 mice per group) as described previously [23]. Briefly, after cannulation of the 
portal vein, the liver was perfused with calcium free Hank’s I, calcium containing Hank’s 
II and collagenase (Sigma-Aldrich, Zwijndrecht, the Netherlands) solution respectively. All 
the solutions was pregassed with carbogen (95% O2 and 5% CO2). Next the liver cells are 
released and filtered followed by several washing using Krebs buffer. 
The cell viability was assessed by using trypan blue (Sigma-Aldrich) and was around 80%. 
Hepatocytes were suspended in William’s E medium (Lonza Bioscience, Verviers, Belgium) 
supplemented with 10% (v/v) fetal calf serum, 20 m-units/mL insulin, 10 nM dexametha-
sone, 100 U/mL penicillin, 100 μg/mL of streptomycin, 0.25 μg/mL fungizone and 50 μg/mL 
gentamycin. Cells were plated on collagen (Serva Feinbiochemica, Heidelberg, Germany) 
coated wells with a density of 500,000 cells/ml and seeded at a density of 140,000 cells per 
well in a 12-well plate format. After 2 hours the medium was discarded and replaced with 
fresh medium. After a total 4 hours of incubation, cells were transfected using 1µg DNA 
plasmid per well and Effectene® reagents. Cells were transfected for 7 hours and then the 
medium was replaced by fresh medium without the transfection reagents. 
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The transfection efficiency was evaluated by pEGFP-N2 uptake using fluorescence micros-
copy 24 hours after adding the Effectene® reagents followed by cells harvest and RNA isola-
tion using TRIzol. RNA was purified using RNeasy micro columns (Qiagen, Venlo, the Neth-
erlands) and further was pooled per group. Total RNA (100ng) was labeled using GeneChip® 
whole transcript sense target assay. The corresponding labelled RNA samples were hybrid-
ized on GeneChip Mouse Gene Exon 1.0 ST Arrays, washed, stained and scanned on Af-
fymetrix GeneChip 3000 7G scanner. Scans of the Affymetrix arrays were processed using 
packages from the Bioconductor project [24]. Comparison was made between pEGFP-N2 
transfected primary hepatocytes (control) and KLF11/KLF10 transfected hepatocytes. Genes 
that satisfied the criterion fold-change > ±1.5 were considered to be regulated.
Hydrordynamic tail vein injection. The hydrodynamic tail vein injection of naked plasmid 
DNA is an effective in vivo gene delivery method into the hepatocytes and is an important 
tool to elucidate the function of novel genes in vivo [25]. In this method, a relative large vol-
ume containing the plasmid DNA is rapidly delivered into the tail vein. The tail vein drains 
into the vena cava. A large bolus results in large liquid volume in vena cava which can not 
be handled by heart and goes back (predominantly) in to the liver, resulting in gene transfer 
[26, 27]. Previous studies reported the survival outcome of this method to be 99% and they 
did not observed ill effects [28- 30]. Plasma level of liver enzymes such as alanine 
aminotransaminase (ALT) was increased transiently 24h after the injection and went back to 
normal level after few days. Liver histology showed minimal damage that resolved within a 
week. This method enhance gene transfer to hepatocytes by opening transiently the hepatic 
endothelial barrier. The increased pressure is needed for movement of the DNA out of sinu-
soids and the transfer to the hepatocytes. 
We injected male NMRI mice with PBS or Ringer solution containing 50 µg KLF11 (n = 
4), KLF10 (n = 3) and as control pEGFP-N2 (n = 4) expression vectors (total volume of the 
injection was 10% of the total body weight). The injection time was less than 10 seconds. A 
3ml syringe with a 27G 0.5 needle was used. Mice were under anesthesia with isoflurane dur-
ing the injections. 24h after the injection time mice were sacrificed and different livers lobes 
were removed and directly frozen into liquid nitrogen (stored at -80ºC) or fixed by immersion 
in 4% PBS-buffered formaldehyde, processed in an automatic tissue processor, embedded in 
paraffin and sectioned at 5µM for GFP fluorescence microscopy.       
                                                                         
Immunostaining of GFP protein was performed on paraffin-embedded liver sections using a 
primary antibody against yellow fluorescent protein (YFP) and a secondary anti rabbit poly-
clonal antibody. Sections were dewaxed in xylene and rehydrated in a series of graded alco-
hols. Antigen retrieval was performed by placing the slides in citrate buffer and heat them in a 
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microwave oven 10 min (70% power) without lid and 30 min (50% power) with lid. Sections 
were incubated one hour with the primary antibody diluted 1: 500 in PBS (24ºC) followed 
by one hour incubation with secondary antibody diluted 1:100 in PBS. Visualization of the 
complex was done using AEC Substrate Chromogen for 10 minutes at room temperature. Af-
ter counterstaining with Meyer’s hematoxylin sections were mounted with Imsol or Kaiser’s. 
Negative controls were used omitting 
The animal experiments were approved by the animal experimentation committee of Wagen-
ingen University.
Statistical analysis. Statistical significant differences were calculated using Student’s T-test. 
The cut-off for statistical significance was set at a P-value of 0.05 or below. 
Results 
KLF11 and KLF10  expression in mouse and human liver is regulated by PPARα 
In order to find novel putative PPARα-regulated genes in liver, we treated primary mouse 
and human hepatocytes with the PPARα agonist Wy14643 for 6 hours and performed Af-
fymetrix microarray analysis. Top differentially expressed genes were identified. In addition 
to well-known PPARα target genes such as PDK4, FABP1, ADFP and ANGPTL4, we found 
KLF11 and KLF10 to be significantly upregulated by PPARα activation in both mouse and 
human hepatocytes, suggesting they may be putative novel PPARα target genes. Induction of 
KLF11 and KLF10 was confirmed by PCR (Figure 1A). In addition, a comparison between liver 
RNA from Wt and PPARα-/- mice treated or not with the synthetic PPARα ligands Wy14643 
and fenofibrate for 6 hours revealed significant PPARα-dependent induction of KLF11 and 
KLF10 (Figure 1B). To assess if physiological activation of PPARα can also regulate KLFs, 
we compared liver RNA from Wt and PPARα-/- mice subjected to 24h fasting (Figure 1C). 
Baseline KLF10 and KLF11 expression were significantly decreased in PPARα-/- mice com-
pared to the corresponding wildtype mice. Interestingly, fasting did not affect KLF10 and 
KLF11 expression in Wt mice, whereas expression went up significantly in PPARα-/- mice. 
Overall, these data suggest that KLF11 and KLF10 may be novel PPARα target genes in 
mouse and human liver.
We identified the ubiquitous expression of KLFs mRNA in a panel of mouse and human 
tissues, data shown only for KLF11 (Figure 2). This suggests that KLF11 and KLF10 ex-
pression may be also regulated by PPARα in other tissues. The mRNA levels of KLF11 and 
KLF10 were slightly higher in primary hepatocytes compared to total liver (Figure S1).
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Figure 1. KLF10 and KLF11 are putative novel PPARα target in mouse and human 
liver. (A) Human and mouse primary hepatocytes were treated with Wy14643 (50µM and 10µM re-
spectively) or DMSO as control for 6h. Relative induction of  KLF11 and KLF10 by Wy14643 was 
determined by qPCR. Expression levels in the DMSO-treated cells were set at 1. Error bars represent 
SEM. *P < 0.05 according to Student’s T-test. (B) Microarray gene expression of KLF11 and KLF10 
in livers of wildtype and PPARα-/- mice 6 hours after receiving an oral gavage of  the PPARα agonists 
Wy14643 or fenofibrate (4mg) (n= 4-5 mice per group). Gene expression levels from wildtype animals 
that received only vehicle were set at 1. Error bars represent SEM. (C) Microarray gene expression of 
KLF11 and KLF10 in livers of fed and 24 hour fasted wildtype and PPARα-/- mice (n = 4-5 mice per 
group). Gene expression levels from wildtype fed animals were set at 1. Error bars represent SEM.
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Identifying KLF11 and KLF10  target genes in liver 
In order to identify the physiological role of KLF11 and KLF10 in liver, we started with a 
preliminary in vitro study in which we transfected primary mouse hepatocytes with KLF11 
and KLF10 plasmids using Effectene® transfection reagents. We managed to overexpress 
KLF11 and KLF10 genes by approximately 30 and 40-fold (Figure S2). The effect of KLF11 
and KLF10 overexpression on whole genome gene expression was explored using microar-
ray.
Figure 2. KLF11 is expressed ubiquitously in human and mouse tissues. mRNA expression 
of KLF11 was determined in human and mouse tissues by Q-PCR. Human RNA represented a mix from 
several individuals (AMBION, First choice human total RNA). Mouse RNA was obtained from one 
healthy female adult mouse (strain FVB). Expression levels were relative to the tissue with the highest 
expression. BAT: Brown adipose tissue; WAT: White adipose tissue.
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Overexpression of KLF11 altered expression of 702 genes with more genes being upregu-
lated compared to downregulated. In comparison, KLF10 overexpression had a much smaller 
effect on gene regulation with 53 genes upregulated and 48 genes downregulated (Figure 
3A). Next we determined the overlap in genes regulated by the KLF11 or KLF10 with known 
PPARα target genes originating from our previous publication [22]. Separate analysis was 
carried out for up- and down-regulated genes (Figure 3B).
Only a total of 41 and 42 genes were found to be up- and down-regulated by both KLF11 
overexpression and PPARα activity, respectively. However, the majority of the regulated 
genes were regulated rather specifically by KLF11 or PPARα. KLF10 regulated genes did 
not overlap with PPARα target genes except for one upregulated gene (Tmem171) and one 
downregulated gene (Gnpnat1). KLF10 and KLF11 showed also a minor overlap. The con-
siderable overlap between KLF11 regulated genes and known targets of PPARα became the 
focus of the rest of the study. A complete list of regulated genes in the various parts of the 
Venn diagrams is available in Supplementary table 1.
In order to zoom in and identify the top up- or down-regulated genes upon KLF11 overex-
pression, we created a array based heat map representing genes which are ranked according 
to their fold change compared to the control (Figure 3C). The changes in the expression of 
the same genes upon KLF10 overexpression are presented in parallel. The top upregulated 
genes by KLF11 mainly represent inflammation related genes such as immune related gene 1 
(IRG1) and chemokines (CXCL11, CCL5). Interestingly, the list of top downregulated genes 
included PPARα and its well-known target gene HMGCS2, which was specific for KLF11. 
To further explore the possible functional impact of KLF11 overexpression in hepatocytes, 
ingenuity pathway analysis was performed with the focus on downregulated processes. Re-
markably, the top downregulated metabolic pathway by KLF11 overexpression was lipid 
metabolism. Some other top downregulated pathways included molecular transport, small 
molecule biochemistry and cellular development (data not shown). So from these prelimi-
nary data we speculated that KLF11 activity could have a functional impact on lipid metabo-
lism possibly via the inhibitory effect on PPARα expression.
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Figure 3. KLF11 and KLF10 overexpression can mediate hepatic gene regulation with 
minor overlap with PPARα target genes. (A) Mouse primary hepatocytes were transfected with 
expression vectors for KLF11 and KLF10 using Effectene® reagents. 24 hours after transfection, RNA 
was isolated and hybridized to GeneChip Mouse Exon 1.0 ST Arrays. Bars show number of up- and 
down-regulated genes. Genes were considered regulated if  fold change > ±1.5. (B) Venn diagrams 
showing overlap in upregulated and downregulated genes by KLF11, KLF10 and PPARα in mouse 
primary hepatocytes. PPARα target genes were recruited from our previous publication [22]. (C) Heat 
maps illustrating the relative up- and down regulation of the top regulated genes in response to KLF11 
overexpression in mouse hepatocytes. Genes were ranked based on their fold-change. Expression levels 
in the pEGFP-N2 transfected cells were set at 1. Relative changes in response to KLF10 overexpression 
are shown in parallel.
KLF11 overexpression significantly downregulates PPARα
In order to evaluate the reproducibility of the negative regulatory effect of KLF11 activity on 
PPARα gene expression, we repeated the in vitro transfection of KLF11 and KLF10 expres-
sion vectors in primary mouse hepatocytes isolated from four SV129 male mice. Q-PCR data 
confirmed the significant downreguation of PPARα mRNA by KLF11 overexpression. The 
inhibitory effect on PPARα mRNA expression was specific for KLF11 overexpression and 
was not observed for KLF10 (Figure 4A).
Next we checked the expression of a number of genes related to different biological processes 
(Figure 4B). KLF11 overexpression reduced the expression of genes involved in lipogenesis 
(SCD1 and SCD2). We also observed a trend towards a reduction for a ketogenesis related 
gene (HMGCS2). On the other hand, KLF11 overexpression stimulated the expression of 
CXCL10, which is an inflammatory chemokine. No effect was detected on CPT1a and bile 
and cholesterol transporter related genes ABCB11 and ABCG5. 
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Figure 4. KLF11 overexpression downregulates hepatic PPARα gene expression and 
influences SCD1, SCD2 and CXCL10. (A) PPARα expression in mouse primary hepatocytes 
(n=4-5 per group) transfected with KLF11, KLF10 and pEGFP-N2 DNA plasmids. (B) mRNA expres-
sion of a few selected genes in KLF11 transfected mouse primary hepatocytes was determined by qPCR 
(n=4 per group). Expression levels in the pEGFP-N2 transfected cells were set at 1. Error bars represent 
SEM. *P < 0.05 according to Student’s T-test.
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In vivo effect of KLF11 and KLF10 overexpression on PPARα gene expression
In order to evaluate the inhibitory effect of KLF11 activity on PPARα gene expression in 
vivo, we performed hydro-dynamic tail vein injection (HTV) using expression vectors for 
KLF11 and KLF10. As control we injected mice with pEGFP-N2 expression vectors. Firstly, 
to evaluate the efficiency of HTV method we detected the presence of green fluorescent 
protein (GFP) by fluorescence microscopy in different liver lobes. We could observe clear 
fluorescence in all different liver lobes. The highest uptake was mainly observed in the cells 
surrounding hepatic portal and central veins (Figure 5A). Staining of the liver tissue with an 
antibody against green fluorescent protein confirmed the microscopy findings (Figure 5A). 
As identified by q-PCR analysis, we could successfully overexpress KLF11 (16 fold) and 
KLF10 (35 fold) genes by HTV method (Figure 5B). In contrast to our expectation, no differ-
ence in PPARα gene expression, could be detected upon KLF11 nor KLF10 overexpression 
(Figure 5C). There was also a large variation in PPARα gene expression levels among differ-
ent mice within each group and thus creating large standard error bars.
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Figure 5. KLF11-KLF10 overexpression in liver via hydrodynamic tail vein injection 
does not influence PPARα gene expression. (A) 10x magnification image of mouse left lobe of 
liver tissue by fluorescence microscopy (left). Liver was fixed in formaldehyde for GFP fluorescence 
microscopy. 10x magnification image of mouse left lobe of liver tissue stained with an antibody against 
GFP (middle), or negative control. (B) KLF11 and KLF10 gene expression in the liver of mice injected 
with DNA plasmids (n=3-4 per group) determined by qPCR. (C) PPARα gene expression in the liver 
of mice injected with DNA plasmids (n=3-4 per group) determined by qPCR. Expression levels in the 
pEGFP-N2 injected mice were set at 1.Error bars represent SEM. 
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Discussion
PPARα controls many aspects of hepatic lipid metabolism by modulating the expression of 
numerous genes [4, 31]. PPARα deletion has been linked to triglyceride storage in liver [5, 
32, 33], while its activation has been shown to reverse hepatic steatosis [34]. Thus, character-
izing novel PPARα target genes has gained a lot importance to further identify its regulatory 
role and mechanism of action.  
Besides PPARα, liver is also a site of expression for other transcription factors including 
Krüppel-like factors. Members of this protein family have been previously implicated in the 
regulation of metabolism in liver [35], skeletal muscle [36] and adipocytes [37]. However not 
much is known about the metabolic role of KLF11 and KLF10 in liver and factors controlling 
their regulation.
In the present study, we identify transcription factors KLF11 and KLF10 as putative nov-
el PPARα target genes. Few lines of evidence suggest a link between KLF10-KLF11 and 
PPARα. As it was recently shown by Guillaumond et al. both PPARα and KLF10 are cir-
cadian clock controlled metabolic sensors and more interestingly they share a few clock 
controlled target genes suggesting the coordinated action of these regulators [38]. Here we 
show that activation of PPARα by synthetic ligands significantly upregulates KLF10 and 
KLF11 gene expression in mouse liver, which was conserved in primary human hepatocytes. 
PPARα-independent regulation of KLFs by fasting suggests the involvement of another tran-
scription factor in their regulation. Previously, we have characterized PPARß/δ as a free fatty 
acid sensor in liver [39]. By knowing that PPARα-/- mice have increased flux of plasma free 
fatty acids, it is tempting to speculate the involvement of PPARß in the hepatic regulation of 
KLF10-KLF11 in fasted state.
An interaction between PPARß and another KLF protein family member (KLF5) has been 
demonstrated by Oishi et al. They showed that under basal condition, SUMOylated KLF5 is 
in a transcriptionally repressive regulatory complex containing unliganded PPARß. A ligand 
dependent activation of PPARß caused deSUMOylation of KLF5 which promotes its interac-
tion with PPARß, recruitment of coregulators and PPARß activity followed by regulation of 
metabolic genes [36].
Interestingly, our in vitro preliminary data suggests that KLF11 overexpression can downreg-
ulate PPARα gene expression and also suppress lipid metabolism related genes. This suggests 
a potential negative feedback mechanism whereby KLF11 down-regulates its regulator. The 
need for this feedback inhibition could be related to the known KLF11 effects of mediating 
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TGF-ß signaling and inflammation in liver, which may implies that its levels must be tightly 
controlled. Clearly, additional research is needed.
Although transfection of primary hepatocytes is a challenging task, we could optimize a 
protocol to obtain reasonably high transfection efficiencies and could successfully overex-
press the targeted genes in vitro as measured by Q-PCR and evaluated by GFP fluorescence 
microscopy. However, confirmation of the changes at the protein level will be worthwhile.
In order to evaluate the in vivo effect of KLF10 or KLF11 overexpression on PPARα gene 
expression, we utilized the method of hydro-dynamic tail vein injection. By the means of this 
method, we managed to significantly overexpress KLF10 and KLF11 in liver. Unfortunately, 
we observed a large variation in PPARα gene expression levels between the mice within 
each injection group. The large variation may be related to a number of issues:  site of DNA 
overexpression, paranchymal cells versus non- paranchymal cells, the variable amount of en-
doplasmic reticulum (ER) stress caused by enhanced protein metabolism and inflammatory 
consequences, the involvement of other regulatory factors in the interaction between KLF11 
and PPARα in vivo. Efficient uptake of the DNA plasmids by liver paranchymal cells has 
been previously reported for smaller plasmid structures [26]. The size of the DNA plasmid 
can influence its transport from sinusoids to hepatocytes. The KLF10 and KLF11 expression 
plasmids used in our study were approximately 9kb, which may have impacted their trans-
port. Moreover, we do not know if this variation only applies to PPARα gene expression or 
if it is more general phenomenon observed with hydro-dynamic tail vein injections. Hydro-
dynamic tail vein injection have been previously used in order to overexpress genes encod-
ing liver secreted proteins. However, to our knowledge it has not been used to overexpress 
transcription factors and study target gene regulation. 
Despite the limitations of the present study, which needs follow up experiments, we could 
optimize hydro-dynamic tail vein injections, which is rather a simple way of DNA delivery 
to the liver and is less labor intensive compared to other transduction methods using viral 
vectors. Our primary findings suggest KLF10 and KLF11 are PPARα target genes in liver 
and point at a possible interaction between KLF11 and PPARα. Considering the importance 
of PPARα signaling in fatty acid metabolism, we can speculate about a role of  KLF11 in 
hepatic lipid metabolism.
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Figure S1. KLF11 and KLF10 gene expression in mouse liver and primary hepatocytes. 
mRNA expression of KLF11 and KLF10 was determined by qPCR in mouse liver and primary hepato-
cytes isolated from two C57BJ6 mice. Expression level in the liver is set at 100.
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Figure S2. KLF11-KLF10 overexpression in mouse primary hepatocytes transfected 
with DNA plasmids. KLF11 and KLF10 mRNA expression determined by qPCR in mouse 
primary hepatocytes isolated from a Sv129 mouse, and transfected with pEGFP-N2 (control), KLF11 
and KLF10 DNA plasmids. The expression of the cells transfected with pEGFP-N2 is set at one. Error 
bars represent SEM (top). 10x magnification image of pEGFP-N2 transfected primary hepatocytes under 
fluorescence microscope (bottom). 
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Additional files can be found online:
http://nutrigene.4t.com/data/MRphd/index.html
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Since the discovery of PPARα in 1990 [1], a wealth of studies have been performed to expand 
our knowledge about its role in nutrient and energy metabolism. Synthetic agonists of PPARα 
lower plasma triglycerides and raise plasma high-density lipoprotein (HDL) levels and are 
thus used clinically for the treatment of dyslipidemia linked with obesity, diabetes, and car-
diovascular diseases [2-6]. Since the biological function of a transcription factor is mainly 
coupled to the function of its target genes, many PPARα-regulated genes and processes have 
been so far screened by applying microarray techniques combined with other functional ge-
nomics tools such as adenoviral gene delivery and siRNA-mediated gene silencing. How-
ever, the large size of the PPARα-dependent transcriptome, which is especially true in liver, 
makes this approach challenging. Furthermore, microarray technology yields a huge amount 
of data, which makes the analysis and interpretation of the findings very difficult. Thus, there 
is still of great interest to make sense out of the large PPARα-dependent transcriptome and to 
identify novel PPARα controlled genes and processes.
Therefore, the first objective of the research presented in this thesis was to better characterize 
and understand PPARα function in liver by identifying PPARα-regulated genes and meta-
bolic pathways. To this aim we applied a comprehensive genome analysis using microarray 
technology combined with knockout mouse models. We analyzed the data from independent 
microarray studies in which comparisons were made between mRNA from livers of 24-hour 
fasted wild-type and PPARα-null mice or mRNA from livers of wild-type mice and PPARα-
null mice fed PPARα agonist Wy14643 for 6 hours and for 5 days. This comprehensive ap-
proach enabled us to generate a schematic overview of PPARα-regulated genes relevant to 
hepatic lipid metabolism. Compared to previously gained knowledge, our data indicate the 
extensive role of PPARα in hepatic lipid metabolism, identifying a large number of PPARα 
target genes involved in different aspects of lipid metabolism, starting from genes involved 
in fatty acid uptake through membranes, followed by genes linked to fatty acid activation, 
intracellular fatty acid trafficking, mitochondrial, peroxisomal and microsomal fatty acid oxi-
dation, fatty acid synthesis and storage, and glycerol metabolism.    
                                  
Remarkably, while a few genes involved in lipogenesis were already known as PPARα tar-
gets including ∆5 and ∆6 desaturases (Fads), stearoyl-CoA desaturase (Scd), microsomal 
triglyceride transfer protein (Mttp), and malic enzyme (Mod1) [7], we found many other 
PPARα-regulated genes to be implicated in lipogenesis, suggesting a major role of PPARα 
in governing hepatic lipogenesis. The involvement of PPARα in upregulation of fatty acid 
desaturation and elongation enzymes might be part of a feed-forward action that includes 
auto-regulation of gene expression by stimulating the production of PPARα ligands.                                 
Interestingly, the observed regulation of many lipogenic genes by PPARα was not conserved 
in primary hepatocytes treated with PPARα agonist Wy14643 as shown in chapter 4. This 
Chapter 8
211
observation suggests that PPARα mostly regulates lipogenesis via indirect mechanisms. One 
of the candidates for mediation of this indirect effect is Srebf1, an essential transcriptional 
regulator of fatty acid synthesis in liver. Consistent with this notion, induction of lipogenic 
genes by chronic PPARα activation was completely abolished in Srebf1-/- mice [8]. A cross-
talk between PPARα and Srebf signaling has been suggested via direct physical interaction 
with Srebf. Thus, an alternative mechanism may be that PPARα is recruited to promoters of 
Srebf targets and stimulates Srebf activity [9]. Our data showed upregulation of Srebf1 gene 
expression by PPARα activation in liver and mouse primary hepatocytes. Possibly, this effect 
occurred via PPARα-induced Srebf1 proteolytic cleavage and Srebf1 activation, thereby gen-
erating an autoloop regulatory circuit that may also lead to increased Srebf1 mRNA [10, 11]. 
The relatively modest induction of Srebf1 mRNA level by PPARα in primary hepatocytes 
may have been too insignificant to cause appreciable induction of lipogenic genes. Moreover, 
there is a possibility for the involvement of other coregulatory factors. The transcriptional 
activity of Srebfs often requires cooperation with other DNA binding transcription factors 
such as Sp1 and Creb as well as coactivators [12].
Our comprehensive analysis also led to the identification of novel PPARα target genes in-
cluding Etfdh, Etfb, El,  Pctp, Txnip, Pnpla2, Lipe, Mgll. The last three genes are known to be 
involved in the 3 steps of  triglyceride hydrolysis in adipose tissue [13-16].  Their regulation 
by PPARα suggests that the anti-steatotic effect of PPARα activity, which has been mainly 
ascribed to induction of fatty acid oxidation, may also be directly mediated via induction of 
the triglyceride hydrolysis pathway. Although the triglyceride hydrolysis pathway in liver has 
yet to be fully elucidated, there is a possible similarity to the pathway operating in adipose 
tissue [15]. 
To provide evidence for the direct regulation of a few novel putative target genes of PPARα, 
we took advantage of in silico screening of the potential PPREs. However, it should be noted 
that more recent studies reveal relatively poor overlap between the detection of a PPRE in 
the 1-2 kb region upstream of the transcriptional start site of a gene and actual binding of the 
transcription factor and gene regulation [9, 17, 18]. However, we tried to limit the list of puta-
tive PPARα target genes by employing a conservative set of criteria that takes into account 
the role of PPARα during fasting, by zooming in on upregulated genes rather than down-
regulated genes, and by addressing the timing of gene induction upon PPARα activation. 
Nevertheless, more detailed evaluation of direct regulation of each gene by PPARα demands 
complementary assays that include examination of DNA binding and identifying functional 
PPREs, which was beyond the scope and aim of the research presented in this thesis. 
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Most of the research on the role of PPARα in liver has been performed in mice, revealing 
that  PPARα serves as a key regulator of hepatic lipid metabolism [7]. Interestingly, the role 
of PPARα in human liver has been questioned based on its detected lower expression levels 
compared to mouse liver [19]. Furthermore, PPARα has clear species-specific effects: for 
example, PPARα agonists cause hepatocyte proliferation and hepatocarcinogenesis only in 
rodents [20]. Another example is the effect of PPARα activity on lipoprotein metabolism 
and the human specific upregulation of Apoa1, Apoa2 and Apoa5 by PPARα, leading to the 
observed human specific induction of plasma HDL levels by fibrates [21].           
The species specific function of PPARα has been ascribed to a number of molecular mech-
anisms including intrinsic properties of PPARα protein, conservation and functionality of 
PPREs, and the cellular environment in relation to the presence and absence of co-regulators 
[22]. Apart from the differential effects on hepatocytes proliferation, hepatocarcinogenesis 
and lipoprotein metabolism, it is not clear whether PPARα has a similar role in mice and 
human and to what extent target genes can be classified as species-specific or commonly 
regulated genes.                                   
                                                                                                       
Accordingly, in our second aim we set out to perform a comprehensive comparative analysis 
of gene regulation by PPARα between mouse and human hepatocytes. Contrary to common 
conception, we found similar PPARα expression levels in liver tissue and primary hepato-
cytes between mouse and human. Our data identified a large number of genes regulated by 
PPARα activation in human primary hepatocytes, identifying a major role for PPARα in hu-
man liver.  
                                      
The reason for the discrepancy with the previous study showing an approximately 10-fold 
lower PPARα expression in human liver compared to mouse liver may be related to the 
methodology applied to measure gene expression (RNAse protection versus qPCR) [19]. 
Ideally, it would be of great interest to measure basal PPARα expression in freshly isolated 
liver tissue from the donors but this is practically impossible since we don’t have access 
to these donors. Instead we measured PPARα in human liver RNA obtained via Ambion, 
which represents a mixture of RNA from 3 individuals without liver disease, as well as in 
mouse liver RNA obtained from 5 mice on mixed genetic background (fed state). The results 
showed that expression of PPARα in human liver is only slightly lower compared to mouse 
liver, supporting our data obtained in primary hepatocytes. In general, comparative analyses 
of PPARα gene expression are complicated by the observation that PPARα in mouse liver 
fluctuates throughout the day [23], is increased by fasting [24], and is reduced under condi-
tions of inflammation [25]. Recently, we were also able to confirm the latter observation in 
liver sections obtained from human subjects with steatohepatitis (our unpublished data).                  
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Besides genes involved in mitochondrial and microsomal fatty acid oxidation, we also found 
a considerable number of genes involved in peroxisomal fatty acid oxidation to be induced 
by PPARα in human primary hepatocytes. Our finding argues against the common notion that 
PPARα does not regulate fatty acid oxidation in human liver. It is well acknowledged that 
PPARα agonists do not induce peroxisome proliferation in human although the molecular 
basis of this species difference is not known.    
                                                  
It was suggested that in human, decreased expression levels or the activity of PPARα con-
tributes to the resistance to peroxisome proliferation upon treatment with fibrate drugs. To 
examine the mechanism behind these species differences, several approaches have been ap-
plied. In this regard, overexpression of human PPARα in HepG2 cells did not lead to induc-
tion of Acox1 and other peroxisomal genes [26]. Data obtained with primary cultures of 
human hepatocytes yielded similar results [27]. A different approach to study the role of 
human PPARα is by using so called PPARα-humanized mice. Upon fenofibrate treatment, 
these mice exhibited decreased serum triglycerides and marked increases in known PPARα 
target genes encoding peroxisomal, mitochondrial, and microsomal fatty acid oxidation en-
zymes, indicating that human PPARα is a functional receptor. Strikingly, despite the induced 
peroxisome proliferation and peroxisomal fatty acid oxidation genes within the context of 
mouse liver, unlike wild-type mice, the PPARα-humanized mice did not display increases in 
carcinogenic responses [28, 29]. In line with the humanized PPARα mice findings, our data 
also identified the conserved induction of many PPARα target genes specifically related to 
fatty acid oxidation in mouse and human. We also found the induction of a few peroxisomal 
genes by PPARα in both species. It should be mentioned, however, that numerous other per-
oxisomal genes showed mouse specific regulation.
Interestingly, we found that at the individual gene level PPARα mostly governs different set 
of genes in mouse and human liver, which was evident by the relative small number of genes 
commonly regulated by PPARα in mouse and human hepatocytes. In contrast, the overlap 
became more impressive when studied at the level of gene ontology. Many of the overlap-
ping gene ontology classes represented pathways of lipid metabolism and accordingly, we 
could define a conserved role of PPARα as a master regulator of lipid metabolism between 
two species.
One of the strong points of this research is the use of human primary hepatocytes rather than 
the most widely used liver cell line, HepG2. As discussed in chapter 6, the HepG2 cell line 
poorly reflects the established PPARα target genes and function, specifically with regards to 
lipid metabolism. It can be argued that human primary hepatocytes are isolated from liver 
biopsies of patients undergoing surgery, so it is not clear to what extent their basal transcrip-
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tome can reflect the gene expression profile of a healthy hepatocyte. Knowing that a more 
ideal experimental setup is practically and ethically unfeasible, and is unlikely to yield vastly 
different results, we believe that we utilized the most suitable model for studying PPARα 
function in human liver. Despite the limitations, our analysis represents a major advancement 
in our understanding of PPARα function in human liver.
Interestingly, our study also identified novel human and/or mouse PPARα target genes, in-
cluding Klf10, Klf11 (commonly regulated), CYP classes 1-3 (human specifically regulated), 
and Fbp2 (mouse specifically regulated) which provides further clues towards the function of 
PPARα in mouse and human liver. One major concern related to species specific target genes 
is that cultured hepatocytes are extremely sensitive to culture conditions. Since these condi-
tions were not exactly the same for mouse and human hepatocytes with respect to the culture 
medium and its ingredients, the question arises if the detected target genes are really species 
specific. We tested this aspect by culturing mouse hepatocytes in both types of medium and 
addressed, by qPCR, the response to Wy14643 for few selected target genes, including those 
which were species specific. We obtained marked induction of Cpt1a and Fbp2 by Wy14643 
in mouse hepatocytes cultured in the medium for human hepatocytes and we did not observe 
any induction of Tsku, one of the identified human specific PPARα target genes, in mouse he-
patocytes regardless of which medium was used. Our data also did not reveal a systematically 
lower induction of PPARα targets by Wy14643 in mouse hepatocytes cultured in medium for 
human hepatocytes. Thus, we believe that the species specific regulation of identified target 
genes is not due to the differences in culturing medium.
We also found a number of pathways to be specifically induced by PPARα in mouse or hu-
man hepatocytes. An example is mouse specific regulation of glucose metabolic pathways 
by PPARα. This finding is relevant to the studies in mice showing a direct role of PPARα in 
hepatic glucose metabolism and gluconeogenesis [24, 30-32], while human trials generally 
do not support an effect of PPARα activation on plasma glucose levels [33]. Our analysis also 
pointed towards human-specific regulation of certain xenobiotic-metabolizing enzymes by 
PPARα, which confirms previous analyses showing genes belonging to Cyp classes 1-3 are 
specifically regulated by PPARα in human [34].   
                                                     
The comprehensive analysis of PPARα-regulated genes in human primary hepatocytes also 
led us to identify a novel PPARα target gene, called Mbl2, with human specific regulation. 
MBL2 is mainly known to play a role in innate immunity. Considering the role of Mbl2 in 
immune system and knowing that PPARα mainly downregulates immune-related genes [35, 
36], makes it interesting to speculate about a metabolic function for Mbl2 besides its immune 
related effects, which is of great interest for future research.           
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A precedent for a linkage between a component of the complement pathway and lipid me-
tabolism is set by a protein called acylation stimulating protein (ASP).                                        
Upon Mbl binding to pathogens followed by conformational changes in the Mbl multimer, 
the lectin complement pathway is initiated. Activation of the lectin pathway is followed by 
an enzymatic cascade generating C3 convertase, which in turn produces C3b and C3a [37]. 
Arginine removal from activated C3 (C3a) by carboxypeptidase results in C3a-desArg, also 
known as ASP. Thus, Mbl2 might lead to ASP production. ASP is a circulating adipokine 
which acts as an anabolic stimulator of TG storage in adipocytes. Different studies have 
demonstrated that ASP influences fat storage by stimulating diacylglycerol acyltransferase 
(Dgat) activity, the rate limiting step in triglyceride (TG) synthesis [38], increases glucose 
transporter Glut4 translocation [39], indirectly stimulates LPL activity in adipose tissue [40], 
and inhibits lipolysis [41]. This effects are mediated via the ASP receptor, C5L2, a seven 
transmembrane G protein coupled receptor [42, 43]. Since both the ASP precursor, and its 
receptor C5L2 are also expressed in liver, unidentified effects mediated by ASP on liver 
metabolism are expected [44]. Additional experiments need to be carried to investigate this 
hypothesis in more detail.
Remarkably, we could also detect changes at plasma Mbl2 levels in patients received fenofi-
brate treatment or in healthy subjects upon fasting. These findings suggest Mbl2 as a putative 
novel mediator of hepatic PPARα activity. Compared to other liver secreted proteins includ-
ing Angptl4 and Fgf21, which are also expressed in other tissues than liver, Mbl2 exclusive 
expression in liver makes it an interesting tissue specific biomarker. Thus, measurement of 
Mbl2 plasma levels may be an indicator of hepatic PPARα activity as far as it is measured 
within the same individual before and after a challenge such as fenofibrate treatment. How-
ever, the Mbl2 gene harbors polymorphisms in its promoter region and it is yet not known if 
these polymorphisms could influence the PPARα binding properties. Despite the possibility 
of existing mutations, we observed that fenofibrate treatment increased Mbl2 plasma levels 
in all subjects irrespective of variant basal plasma Mbl2 levels. The question remains if in-
dividuals can be classified into different categories of PPARα responsiveness based on the 
magnitude of observed changes in plasma levels of specific PPARα target genes. We could 
not find a correlation between the relative increase in plasma levels of several PPARα secret-
ed target genes upon fenofibrate treatment, including Mbl2, Angptl4 and Fgf21, suggesting 
that individuals cannot easily be classified based on PPARα responsiveness.                          
                                                                           
The human specific regulation of Mbl2 by PPARα can involve a number of different mecha-
nisms. One is the loss of functional PPREs, which has been previously found for other hu-
man specific PPARα target genes including those encoding apolipoproteins [45]. In case of 
Mbl2, the functional PPREs that mediate regulation by PPARα remain to be elucidated, and 
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thus it is unclear whether the functional PPRE is conserved between species. Other possible 
mechanisms are the intrinsic properties of human PPARα protein, and the cellular context, 
including presence of specific co-activators. 
Previously, many studies have been performed to identify genes regulated by PPARα. In 
general, these studies indicate that unlike many other nuclear receptors, PPARα governs the 
expression of a large set of genes, many of which are involved in fatty acid metabolism. A 
brief overview of some of the studies that applied microarray technology and that were aimed 
at identifying hepatic PPARα target genes clearly shows some major limitations and gaps in 
the analysis and findings which we tried to remedy in our research.
One of the first studies using microarray technology discovered that PPARα influences amino 
acid metabolism and urea synthesis. The integrated strategy was the activation of PPARα by 
synthetic agonist Wy14643 combined with using PPARα knockout mouse model [46]. In an-
other study aiming at finding novel PPARα target genes, mice were treated with the PPARα 
agonists Wy14643 and fenofibrate for 2-3 days. The authors could confirm the previously 
reported PPARα target genes in ß-oxidation and lipid metabolism plus discovering a few 
novel PPARα regulated genes [47]. In another similar study, using cDNA arrays, changes in 
hepatic gene expression in mice exposed to Wy14643 for two weeks were measured. Besides 
finding increased expression of genes involved in lipid and glucose metabolism and genes 
associated with peroxisome biogenesis, a large number of genes were found to be repressed, 
which were not studied further by the authors [48]. In most of the studies evaluating the ef-
fect of PPARα agonists on liver gene expression profiles, a long term activation of PPARα is 
targeted and not always a knock out model is applied [49, 50]. As a consequence, it is unclear 
whether the observed changes in gene expression reflect direct gene regulation or are due to 
indirect mechanisms.
There are also examples of in vitro studies applying microarray technique for a large scale 
profiling of gene expression changes elicited by PPARα activation. In one study, mouse pri-
mary hepatocytes were exposed to multiple concentrations of several PPARα agonists for 
24h hours followed by global genes expression profiling. The aim of the study was to under-
stand the molecular mechanisms responsible for the pleiotropic effects of PPARα agonists. 
The authors found regulation of many genes in lipid metabolism plus a few genes involved 
in oxidative reactions [51]. In the only study aimed at comparing expressional responses to 
PPARα activation in human and rodents, primary human, rat and mouse hepatocytes were 
exposed to PPARα synthetic agonist for 72 hours and gene expression analysis performed 
using Affymetrix GeneChips. The authors categorized the differentially expressed genes into 
three main groups: fatty acid transport and metabolism, xenobiotic metabolism and cell pro-
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liferation and death. They found genes in the peroxisomal pathway that were specifically 
regulated in mice, while specific target genes in the xenobiotic pathway were only regulated 
in human. Genes involved in fatty acid metabolism and transport were regulated across all 
the species [52].
Considering the importance of PPARα as a lipid sensor, which can become activated by 
dietary fatty acids [53-55], it is of great importance to study the effect of natural PPARα 
ligands on hepatic gene expression profile. Therefore, it was recently shown that the effects 
of dietary unsaturated fatty acids on hepatic gene expression are almost exclusively medi-
ated by PPARα and mimic the effect of synthetic PPARα agonists [56]. The considerable 
large overlap between the genes regulated by fatty acids and by the PPARα agonist Wy14643 
demonstrates the usefulness of transcriptomics studies using synthetic PPARα agonists to 
augment understanding of nutrient mediated gene regulation.
In the research presented in this thesis, we have mainly studied the PPARα mediated gene 
regulation by synthetic agonists, due to the lack of transcriptional changes in primary he-
patocytes in response to fatty acids. The reason behind this lack of responsiveness is not 
clear, but several possible mechanisms can be proposed. One could be the low expression of 
intracellular fatty acid binding proteins, which have been proposed to transport fatty acids to 
the nucleus. We could detect a significant decline in Fabp1 and Fabp2 gene expression levels 
upon culturing hepatocytes. This was also the case for PPARα expression itself. Fabp1 has 
been shown to interact with PPARα [57] and therefore appears to be needed for shuttling of 
fatty acids to PPARα [58-60]. Fabp2 is also able to bind fatty acids [61-64] and may interact 
with PPARs. Accordingly, we tried to overcome these unfavorable changes by transfecting 
mouse primary hepatocytes with Fabp1, Fabp2, PPARα and PPARß DNA plasmids. Although 
we successfully overexpressed these genes, we could still not restore the in vivo observed 
effects of fatty acids on PPARα activation. It could be argued that the lack of response to 
fatty acids in hepatocytes may be related to the form in which fatty acids are delivered to the 
cells [65], the mechanisms of internalization, and presence of distinct fatty acid pools within 
hepatocytes [66, 67]. We also tried to augment the response of HepG2 cell line to fatty acids 
by using histone deacetylase inhibitors including butyrate [68, 69] and Trichostatin A [70, 71] 
in order to make the chromatin less dense and increase accessibility for transcription [72-74], 
but this methods also failed to cause PPARα activation by fatty acids.
Compared with other microarray studies published, the strength of the research approach pre-
sented in this thesis is multi-fold; first, activation of PPARα by specific agonist Wy14632 for 
both shorter and longer duration of exposure. Second, a systematic comprehensive approach 
involving whole mouse and human genome analysis combined with using proper pathway 
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analysis tools in order to visualize the changes at the pathway level. Third, application of 
knockout mouse models to find PPARα dependent regulations. Fourth, combination of physi-
ological and pharmacological PPARα stimuli, and in vivo versus in vitro approaches.
Nevertheless, transcriptomics studies carry several limitations; one is that besides the ability 
to screen for the changes at the expression level of a very large number of genes and thus 
generating gene expression profile pictures, they do not provide information on the precise 
molecular mechanisms that underlie the observed regulations. They also do not provide us 
with information on protein-DNA interactions which can be assessed by other strategies such 
as ChIP-on-chip or ChIP-Seq techniques. Another critical issue is the statistical approach 
used to identify differences in gene expression. Statistical significance is not necessarily rep-
resenting biological significance and often statistical criteria preclude the detection of small 
changes in gene expression as observed in nutrients mediated signaling or human studies. In 
such cases, applying a improper statistical tool can result in a major loss of information. The 
best approach to fully understand the functional relevance and mechanisms of PPAR depen-
dent gene regulation is to combine transcriptomics methods with other functional genomics 
tools that cause alterations in the expression of potential molecular mediators, such as siRNA 
based gene silencing or  knock-out technology.
Overall this thesis represents a good example of the combination of microarray technology 
with a knockout mouse model in order to characterize the functional role of a transcription 
factor in gene regulation via identifation of its target genes and pathways. This research has 
truly extended our understanding of PPARα-regulated genes and function in liver, and has 
specifically high-lightened a major role of PPARα in human hepatocytes. This research has 
also given birth to a possible biomarker of hepatic PPARα activity which is of great interest 
for upcoming studies. Considering  the need for proper biomarkers in the field of nutrigenom-
ics and beyond, further evaluation of Mbl2 as a biomarker is of huge importance. The identi-
fication of other novel putative PPARα target genes offers ample opportunities for continued 
research. 
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Summary
Metabolic syndrome is defined by a number of metabolic disorders including visceral obe-
sity, insulin resistance, hypertension and dyslipidemia and it is associated longitudinally with 
increased risk for cardiovascular disease and diabetes. The number of people with metabolic 
syndrome is increasing and the prevalence of type 2 diabetes shows an upward trend. Nutrig-
enomics can contribute to the prevention of numerous chronic diseases including the meta-
bolic s yndrome by pr oviding a  s olid m echanistic f ramework f or e vidence ba sed nut rition.           
Nutrigenomics investigates the interaction between nutrients and genes at the molecular level 
by using genomics tools and is mainly focused on disease prevention rather than disease 
cures. Within the field of nutrigenomics, dietary nutrients and their metabolites are consid-
ered as signaling molecules that target cellular sensing systems. Members of the nuclear re-
ceptor superfamily play a major role in sensing nutrients and mediating their effects on gene 
expression. One important group of these nuclear receptors are PPARs, which encompass 
PPARα, PPARß/δ and PPARγ.
PPARα is a ligand activated transcription factor that plays a major role in nutrient homeo-
stasis. At the functional level, PPARα is known as the master regulator of lipid metabolism 
in liver. Clinically, it serves as the molecular target of the fibrate class of drugs which lower 
fasting plasma triglycerides and raise plasma HDL levels and are thus prescribed for 
the treatment of dyslipidemia. Thus, there is large interest to identify PPARα novel controlled 
genes and processes.      
The first aim of the research presented in this thesis was to better characterize and under-
stand PPARα function in liver by identifying PPARα-regulated genes and metabolic path-
ways. With the help of independent microarray studies we generated a schematic overview of 
PPARα-regulated genes relevant to hepatic lipid metabolism, leading to the identification of 
a large number of PPARα target genes involved in different aspects of lipid metabolism. Fur-
thermore, we identified novel PPARα target genes and characterized a major role of PPARα 
in lipogenesis.                                                                               
Since the role of PPARα in liver has mostly been studied in mice, as a second aim we set 
out to perform a comprehensive comparative analysis of gene regulation by PPARα between 
mouse and human hepatocytes. We were able to find a large number of genes regulated by 
PPARα activation in human primary hepatocytes, identifying a major role for PPARα in 
human liver. While we found minor overlap at the individual gene level, PPARα mostly 
governed many overlapping gene ontology classes representing pathways of lipid metabo-
lism. Most of the genes commonly regulated in mouse and human were involved in lipid 
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metabolism and many represented known PPARα targets. Accordingly, the role of PPARα as 
master regulator of hepatic lipid metabolism is well conserved between mouse and human. 
One of the strong points of this research was the use of primary human hepatocytes rather 
than the most widely used liver cell line, HepG2. As discussed in this thesis, the HepG2 cell 
line poorly reflects the established PPARα target genes and function, specifically in relation 
to lipid metabolism.    
                                                                                        
One of the additional aims of this research was to identify novel PPARα target genes and the 
comprehensive analysis of PPARα-regulated genes in human primary hepatocytes led to the 
characterization of a novel PPARα target gene, called mannose binding lectin (Mbl2), with 
human specific regulation. Regulation of Mbl2 by PPARα suggests that it may play a role 
in regulation of energy metabolism, although additional research is needed. We could also 
detect changes in plasma Mbl2 levels in subjects receiving fenofibrate treatment or upon 
fasting. These findings suggest Mbl2 as a potential circulating mediator of hepatic PPARα 
activity in human. 
Finally, we found transcription factors Klf11 and Klf10 to be significantly upregulated by 
PPARα activation in both mouse and human hepatocytes, suggesting they may be novel 
PPARα target genes. We could further confirm their PPARα dependent induction in the liver 
of mice treated with PPARα agonist. Interestingly, our preliminary in vitro data suggest that 
Klf11 overexpression in primary hepatocytes can downregulate PPARα gene expression. We 
utilized the method of hydro-dynamic tail vein injection of naked plasmid to study the in vivo 
effects of Klf11 and Klf10 overexpression in liver. Although we could successfully induce 
hepatic Klf11 and Klf10 gene expression, we failed to reproduce the in vitro data. Overall, 
the data suggest interaction between PPARα, Klf11 and Klf10. Additional experiments need 
to be  carried to investigate this interaction in more de tail.                                                                                                 
In this thesis, microarray technology and transcriptomics are applied to characterize the role 
of PPARα via identification of its target genes and pathways. This research has truly extended 
our understanding of PPARα-regulated genes and function in liver, and has specifically high-
lighted a major role of PPARα in human hepatocytes. This research has also given birth to a 
possible biomarker of hepatic PPARα activity which is of great interest for upcoming stud-
ies. The identification of novel putative PPARα target genes offers ample opportunities for 
continued research.
227
Samenvatting (Summary in Dutch)
Metabool syndroom wordt gedefinieerd door de aanwezigheid van een aantal metabole af-
wijkingen waaronder viscerale obesitas, insuline resistentie, hypertensie en dyslipidemie, 
en gaat gepaard met een verhoogd risico voor hart en vaatziekten en diabetes. Het aantal 
mensen met metabool syndroom is stijgende waardoor ook de prevalentie van type 2 diabetes 
een opwaartse tendens laat zien. Nutrigenomics kan bijdragen aan de preventie van talrijke 
chronische ziekten waaronder het metabool syndroom door mechanistische inzichten aan te 
reiken die de basis vormen voor zgn. evidence-based nutrition.
Binnen het gebied van nutrigenomics bestudeert men de interactie tussen voedingsstoffen 
en genen op moleculair niveau door gebruik te maken van genomics technieken. Het onder-
zoek richt zich vooral op de preventie van ziekten en beschouwt voedingsstoffen en daarvan 
afgeleide metabolieten als signaal stoffen die inwerken op cellulaire sensor systemen. Een 
belangrijk voorbeeld van zo’n sensor systeem vormen de nucleaire receptoren. Nucleaire 
receptoren, waaronder de zogenaamde PPARs, zijn als groep verantwoordelijk voor de regu-
latie van gentranscriptie door voedingsstoffen.
PPARα is een door ligand geactiveerde transcriptiefactor die een belangrijke rol speelt bij 
nutrient homeostase en vooral bekend staat als algemene regulator van de vetstofwisseling in 
de lever. De receptor fungeert als moleculaire target voor een specifieke groep medicijnen, 
de zogenaamde fibraten, die gebruikt worden bij de behandeling van dyslipidemie en het 
plasma triglyceriden en HDL gehalte respectievelijk verlagen en verhogen. Er is om die re-
den grote interesse om een beter beeld te krijgen van de door PPARα gereguleerde processen 
en genen. 
Het eerste doel van het in dit proefschrift beschreven onderzoek was om de functie van 
PPARα in lever beter in kaart te brengen door het identificeren van door PPARα-gereguleerde 
genen en metabole paden. Door middel van diverse microarray studies is een uitgebreid 
schematisch overzicht geconstrueerd van door PPARα gereguleerde genen die betrokken zijn 
bij het vetmetabolisme. Daarnaast zijn nieuwe PPARα target gene geïdentificeerd en is een 
betrokkenheid van PPARα in lipogenese aangetoond.
Een tweede doel van het onderzoek was om een uitgebreide vergelijking te maken tussen 
levercellen van muis en mens met betrekking tot de effecten van PPARα op genexpressie. 
Hiervoor werkt gekozen omdat de kennis over PPARα vooral afkomstig is uit studies in 
muizen en er relatief weinig bekend is over de rol van PPARα in de mens. Een groot aantal 
genen werd door PPARα gereguleerd in primaire hepatocyten van de mens, waarbij er op 
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het niveau van individuele genen relatief weinig overlap was met door PPARα gereguleerde 
genen in primaire hepatocyten van de muis. Daarentegen was er relatief wel veel overlap op 
het niveau van gen ontologie klassen die specifieke paden in het vetmetabolisme vertegen-
woordigen. Het merendeel van de genen die door PPARα werd gereguleerd in zowel muis en 
mens was betrokken bij het vetmetabolisme. De rol van PPARα als algemene regulator van 
het vetmetabolisme is aldus goed geconserveerd tussen muis en mens. In het onderzoek is 
gebruik gemaakt van primaire levercellen van de mens in plaats van de veel gebruikte HepG2 
cellen. Zoals in dit proefschrift beschreven geven HepG2 een zeer beperkte weergave van de 
rol van PPARα in het vetmetabolisme. 
Een verder doel van het proefschrift was het identificeren van nieuwe target genen van PPARα. 
Een uitgebreide analyse van door PPARα gereguleerde genen in primaire hepatocyten van de 
mens leidde tot de vondst van een nieuw humaan specifiek PPARα target gen met als naam 
mannose binding lectin (Mbl2). Regulatie van Mbl2 door PPARα impliceert een mogelijke 
rol in het vetmetabolisme en werd ondersteund door de effecten van fibraten en vasten op het 
plasma Mbl2 gehalte, al is verder onderzoek noodzakelijk. De bevindingen wijzen op een 
mogelijke rol van Mbl2 als circulerende effector van PPARα activiteit in de lever.
Naast Mbl2 werden ook de transcriptie factoren Klf10 en Klf11 geinduceerd door PPARα 
activatie in hepatocyten van zowel muis als mens, daarmee suggererend dat Klf10 en Klf11 
mogelijke nieuwe target genen van PPARα zijn. Regulatie door PPARα in de lever kon 
worden bevestigd in muizen behandeld met PPARα agonist. Een opvallende bevinding was 
dat overexpressie van Klf11 in levercellen de expressie van PPARα onderdrukte. Met behulp 
van een speciale techniek waarbij plasmiden in de staart van de muis geïnjecteerd worden is 
geprobeerd deze resultaten te bevestigen. Alhoewel significante overexpressie van Klf10 en 
Klf11 bereikt werd, konden de in vitro data niet worden gereproduceerd. De data wijzen op 
een interactie tussen PPARα en Klf10 en KLF11 maar verder onderzoek is noodzakelijk om 
deze interactie beter uit te werken.
In dit proefschrift werden microarray en transcriptomics technieken toegepast om de rol van 
PPARα beter in kaart te brengen door middel van het identificeren van nieuwe target genen 
en pathways. Het onderzoek heeft geleid tot een beter inzicht in de functie van PPARα bij 
regulatie van genexpressie in de lever en heeft vooral het belang van PPARα in de lever bij 
de mens blootgelegd. Het onderzoek heeft ook een mogelijk nieuwe biomarker opgeleverd 
die interessant is voor toekomstige studies. Tevens geeft de identificatie van talloze nieuwe 
mogelijke PPARα target genen voldoende aanleiding voor verder onderzoek.
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